Programme ectrims2015

Scientific Programme

Wednesday, 07 October 2015

Teaching Courses, Hall C08:30 - 10:00 Teaching Course 1 How do I choose the correct disease-modifying

treatment?

ChairsB. Kieseier (Düsseldorf, Germany)R.J. Fox (Cleveland, United States)

Teaching Courses, Hall D08:30 - 10:00 Teaching Course 2 Neuroimmunology in relation to MS

pathophysiology and immunotherapy

ChairsR. Liblau (Toulouse, France)J. Goverman (Seattle, United States)

Activation of the pathogenic T-cell response in the periphery R. Liblau (Toulouse, France)

The role of different effector T cells in CNS autoimmunity J. Goverman (Seattle, United States)

What have we learned from failed and successful immunotherapy trials in MS patients H. Wiendl (Münster, Germany)

Teaching Courses, Hall E08:30 - 10:00 Teaching Course 3 MAGNIMS MRI in monitoring disease activity and

progression

ChairsC. Enzinger (Graz, Austria)N. De Stefano (Siena, Italy)

Chances and challenges in monitoring disease activity and progression in MS C. Enzinger (Graz, Austria)

MRI as a tool to identify inadequate treatment response in MS in clinical practice N. De Stefano (Siena, Italy)

MRI in the detection of opportunistic infections and paradoxical reactions T. Yousry (London, United Kingdom)

Page 1 / 114


Teaching Courses, Hall F08:30 - 10:00 Teaching Course 4 Management during pregnancy and postpartum

ChairsK. Hellwig (Bochum, Germany)M. Houtchens (Brookline, United States)

Multiple sclerosis and pregnancy: family panning, contraception, conception andrelapse management

M. Houtchens (Brookline, United States)

Multiple sclerosis and pregnancy: immunological considerations I. Elovaara (Tampere, Finland)

Multiple sclerosis and pregnancy: medications and lactation K. Hellwig (Bochum, Germany)

Teaching Courses, Hall G08:30 - 10:00 Teaching Course 5 IMSCOGS NEDA controversy: cognition and

fatigue are irrelevant for guiding treatment decisions as they arenot measurable in an objective and time-saving fashion

ChairsF. Paul (Berlin, Germany)I. Penner (Düsseldorf, Germany)

Yes F. Paul (Berlin, Germany)

No B. Brochet (Bordeaux Cedex, France)

Teaching Courses, Hall C10:30 - 12:00 Teaching Course 8 Differential diagnoses and diagnostic dilemmas

ChairsS. Fredrikson (Stockholm, Sweden)A. Siva (Istanbul, Turkey)

Diagnostic and differential diagnostic aspects in MS S. Fredrikson (Stockholm, Sweden)

MRI - possibilities and pitfalls in diagnosis of MS A. Siva (Istanbul, Turkey)

Heterogeneity of idiopathic inflammatory demyelinating disease S. Vukusic (Bron, France)

Page 2 / 114


Teaching Courses, Hall D10:30 - 12:00 Teaching Course 9 Current controversy in management: interactive

case discussion

ChairsA.E. Miller (New York, United States)X. Montalban (Barcelona, Spain)

Case 1 A.E. Miller (New York, United States)

Case 2 X. Montalban (Barcelona, Spain)

Teaching Courses, Hall E10:30 - 12:00 Teaching Course 10 Paediatric MS

ChairsB. Banwell (Philadelphia, United States)C. Hemingway (London, United Kingdom)

New clinical diagnostic criteria C. Hemingway (London, United Kingdom)

MRI advances B. Banwell (Philadelphia, United States)

Genetic and environmental determinants of risk R. Hintzen (Rotterdam, Netherlands)

Teaching Courses, Hall F10:30 - 12:00 Teaching Course 11 MAGNIMS Quantitative MR imaging in the

management of multiple sclerosis

ChairsA. Rovira (Barcelona, Spain)H. Vrenken (Amsterdam, Netherlands)

Focal lesion load quantitative MR measures H. Vrenken (Amsterdam, Netherlands)

Brain and spinal cord volume measurements A. Rovira (Barcelona, Spain)

Advanced quantitative brain MR measures M. Filippi (Milano, Italy)

Page 3 / 114


Teaching Courses, Hall G10:30 - 12:00 Teaching Course 12 Neuromyelitis Optica Spectrum Disorders

ChairsJ. Palace (Oxford, United Kingdom)B. Weinshenker (Rochester, United States)

Pathophysiology K. Fujihara (Sendai, Japan)

Diagnosis B. Weinshenker (Rochester, United States)

Treatment J. Palace (Oxford, United Kingdom)

Satellite Symposia, Hall B12:30 - 13:30 Satellite Symposium: Axoglial interaction and pathophysiology of

progressive MS

European Charcot Foundation

ChairsG. Comi (Milan, Italy)X. Montalban (Barcelona, Spain)

12:30 - 12:50 Myelin Repair process: Insight from Experimental Models A.B. Evercoren (Paris, France)

12:50 - 13:10 Axonal Signals in remyelination C. Taveggia (Milan, Italy)

13:10 - 13:30 Role of gut Microbiota on Microglia activation in MS M. Prinz (Freiburg, Germany)

Teaching Courses, Hall D12:30 - 14:00 Teaching Course 6 Symptomatic therapy of gait disturbances,

spasticity, bladder dysfunction, pain and fatique

ChairsT. Berger (Innsbruck, Austria)J. de Seze (Strasbourg, France)

Symptomatic treatment of gait disturbances and spasticity T. Berger (Innsbruck, Austria)

Symptomatic treatment of bladder dysfunction J. de Seze (Strasbourg, France)

Page 4 / 114


Symptomatic treatment of pain and fatigue C. Solaro (Genova, Italy)

Teaching Courses, Hall E12:30 - 14:00 Teaching Course 7 Comorbidity and multiple sclerosis: clinical and

research issues

ChairsH. Tremlett (Vancouver, Canada)R.A. Marrie (Winnipeg, Canada)

Comorbidity in multiple sclerosis: What do we know and what do we need to know? R.A. Marrie (Winnipeg, Canada)

Comorbidity: insights from administrative data H. Tremlett (Vancouver, Canada)

Comorbidity: insights from registries and related databases M. Magyari (Copenhagen, Denmark)

Teaching Courses, Hall F12:30 - 14:00 Teaching Course 13 Myelin regeneration and neuroprotection in

multiple sclerosis: from cellular mechanisms to clinical trials

ChairsC. Lubetzki (Paris, France)B. Stankoff (Paris, France)

Experimental approaches to investigate the mechanisms of remyelination in the CNS C. Lubetzki (Paris, France)

Neuronal damage and perspectives of neuroprotection in MS D. Mahad (Edinburgh, United Kingdom)

Imaging tools for clinical trials of remyelination and neuroprotection B. Stankoff (Paris, France)

Teaching Courses, Hall G12:30 - 14:00 Teaching Course 14 Using social-media to manage and research MS

ChairsA. Thomson (London, United Kingdom)D. Baker (London, United Kingdom)

What is social-media and how to use it? A. Thomson (London, United Kingdom)

Page 5 / 114


How to use social-media to manage and research multiple sclerosis? D. Baker (London, United Kingdom)

How patients use social-media? J. Stachowiak (London, United Kingdom)

Young Scientific Investigators' Sessions, Hall B14:00 - 15:30 Young Scientific Investigators I

ChairsA. Rodríguez-Antigüedad (Bilbao, Spain)B. Kieseier (Düsseldorf, Germany)

14:00 - 14:15 The TH17-associated cytokine interleukin-26 regulates barrier function duringneuroinflammation

B. Broux (Diepenbeek, Belgium)

14:15 - 14:30 Atrophy of the retinal nerve fiber layer and ganglion cell-inner plexiform layer isassociated with cognitive impairment in multiple sclerosis

D. Coric (Amsterdam, Netherlands)

14:30 - 14:45 Melatonin contributes to the seasonality of multiple sclerosis relapses M.F. Farez (Buenos Aires, Argentina)

14:45 - 15:00 Immunomodulatory effects of fingolimod on B cell phenotype and functional profileduring treatment of patients with multiple sclerosis

S. Blumenfeld (Haifa, Israel)

15:00 - 15:15 Neurite orientation dispersion and density imaging (NODDI) in RRMS L. Kipp (London, United Kingdom)

Nurses Sessions, Hall C14:15 - 15:30 Nurses' Session I: Living with Multiple Sclerosis; Challenges for

Patients (and nurses)

ChairsA. Krakau (Copenhagen, Denmark)B. Porter (London, United Kingdom)

14:15 - 14:30 Management of psychosocial adjustment among people with MS S. Sevilla (Barcelona, Spain)

14:30 - 14:45 Sexuality in patients with Multiple Sclerosis M.C. Petersen (Copenhagen, Denmark)

14:45 - 15:00 MS Compliance, how to motivated patient R. Haugstad (Bergen, Norway)

Page 6 / 114


Young Scientific Investigators' Sessions, Hall B16:00 - 17:15 Young Scientific Investigators II

ChairsB.A. Cree (San Francisco, United States)C. Oreja-Guevara (Madrid, Spain)

16:00 - 16:15 The impact of 2015 criteria for Neuromyelitis optica spectrum disorders (NMOSD) onthe diagnostic rates of NMOSD

S.H.M. Hamid (Liverpool, United Kingdom)

16:15 - 16:30 Functional connectivity impairment shows distinct sensory and cognitive patterns inrelapsing remitting multiple sclerosis with different disease duration

G. Castellazzi (Pavia, Italy)

16:30 - 16:45 Central role of Th2 and Tc2 lymphocytes in multiple sclerosis pattern II demyelinatinglesions

R. Planas (Zurich, Switzerland)

16:45 - 17:00 Assessment of perilesional pathology in cortical and leukocortical lesions in MS byultra high resolution quantitative 7T MRI

C. Louapre (Charlestown MA, United States)

17:00 - 17:15 Extending natalizumab treatment up to eight weeks shown safe and effective inpatients with multiple sclerosis: updated analysis from an ongoing multicenter study

L. Zhovtis Ryerson (New York, United States)

Nurses Sessions, Hall C16:00 - 17:15 Nurses' Session II: Patient Involvement

ChairsA. Krakau (Copenhagen, Denmark)B. Porter (London, United Kingdom)

16:00 - 16:15 Understanding Patient activation H. Gilburt (London, United Kingdom)

16:15 - 16:30 Co-design of services F. Yauner (London, United Kingdom)

16:30 - 16:45 How technology can help improve MS care B. Porter (London, United Kingdom)

Satellite Symposia, Hall B17:15 - 18:15 Satellite Symposium: Looking beyond the surface

Novartis Pharma AG

ChairsJ. Sastre-Garriga (Barcelona, Spain)

Page 7 / 114


17:15 - 17:20 Opening and welcome J. Sastre-Garriga (Barcelona, Spain)

17:20 - 17:35 Breaking the ice

17:35 - 17:50 What lies beneath? T. Sprenger (Basel, Switzerland)

17:50 - 18:05 Revealing hidden depths F. Piehl (Stockholm, Sweden)

18:05 - 18:15 Summary and close J. Sastre-Garriga (Barcelona, Spain)

Satellite Symposia, Hall A18:30 - 19:30 Satellite Symposium

Page 8 / 114


Thursday, 08 October 2015


Plenary Sessions, Hall A09:00 - 10:15 Plenary Session 1 Welcome Address and ECTRIMS Lecture

ChairsX. Montalban (Barcelona, Spain)

09:00 - 09:10 Welcome to Barcelona



09:30 - 10:15 ECTRIMS lecture: Progressive MS - how do we meet the therapeutic challenge? A.J. Thompson (London, United Kingdom)

Parallel Sessions, Hall A10:45 - 12:15 Parallel Session 1 Safety concerns and risk management

ChairsR. Gold (Bochum, Germany)E. Havrdová (Prague, Czech Republic)

10:45 - 11:05 Risk minimization strategies P. Soelberg Sørensen (Copenhagen, Denmark)

11:05 - 11:25 Patient perceived risk and acceptance C. Heesen (Hamburg, Germany)

11:25 - 11:37 PML risk stratification during natalizumab therapy using anti-JCV antibody index andL-selectin

N. Schwab (Muenster, Germany)

11:37 - 11:49 Time course of α4-integrin receptor desaturation and disease activity return afternatalizumab cessation: a prospective assessment from the TOFINGO study

T. Derfuss (Basel, Switzerland)

11:49 - 12:01 Are stable MS patients who stop their disease-modifying therapy (DMT) at increasedrisk for relapses and disability progression compared to patients who continue onDMTs? A propensity-score matched analysis of the MSBase registrants

I. Kister (New York, United States)

Page 9 / 114


12:01 - 12:13 MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluatelymphocyte reduction in fingolimod treatment over time, demographic predictors oflymphopenia and association with reported safety events

J. Haartsen (Melbourne, Australia)

Parallel Sessions, Hall B10:45 - 12:15 Parallel Session 2 New challenges in clinical trial design

ChairsF. Fazekas (Graz, Austria)L. Kappos (Basel, Switzerland)

10:45 - 11:05 Assessing repair: clinical and MRI outcomes O. Ciccarelli (London, United Kingdom)

11:05 - 11:25 Modern designs G. Cutter (Birmingham, United States)

11:25 - 11:37 Single-question patient-reported disability strongly correlates with ExpandedDisability Status Scale

K.S. Pandey (Livingston, United States)

11:37 - 11:49 EDSS mixture in MS clinical trials affects the overall outcome and power A.R. Salter (Birmingham, United States)

11:49 - 12:01 Neurostatus e-Scoring (NESC): first experience in a phase 3 clinical trial withsiponimod (BAF312) in secondary progressive multiple sclerosis (EXPAND)

M. D'Souza (Basel, Switzerland)

12:01 - 12:13 Effect of daclizumab HYP versus intramuscular interferon beta-1a on no evidence ofdisease activity in patients with relapsing-remitting multiple sclerosis: analysis of theDECIDE study

L. Kappos (Basel, Switzerland)

Parallel Sessions, Hall C10:45 - 12:15 Parallel Session 3 Society and MS

ChairsM. Clanet (Toulouse, France)C. Thalheim (Brussels, Belgium)

10:45 - 11:05 The increasing differences in MS care in the EU A. Winslow (Dublin, Ireland)

11:05 - 11:25 Economic aspects of innovative treatments B. Uitdehaag (Amsterdam, Netherlands)

Page 10 / 114


11:25 - 11:37 Earnings among multiple sclerosis patients compared to individuals without MS, intotal and for different educational levels and types of occupations - a longitudinalpopulation-based cohort study

M. Wiberg (Stockholm, Sweden)

11:37 - 11:49 Burden and depression in caregivers and patients with multiple sclerosis. MS-feelingstudy

J. Meca-Lallana (Murcia, Spain)

11:49 - 12:01 Multiple sclerosis, employment & cognitive testing: comparison of the predictabilityof SDMT and computerized cognitive testing

M. Gudesblatt (Patchogue, United States)

12:01 - 12:13 Determinants of mental health disorders in children of parents with parental multiplesclerosis

N. Razaz (Vancouver, Canada)

Parallel Sessions, Hall D10:45 - 12:15 IMSCOGS Parallel Session 1 MRI and cognition

ChairsS. Fredrikson (Stockholm, Sweden)L. Krupp (Stony Brook, United States)

10:45 - 10:55 The atrophy story J. DeLuca (New Orange, United States)

10:55 - 11:05 The network story C. Enzinger (Graz, Austria)

11:05 - 11:17 Comorbid depression in multiple sclerosis: cognitive and hippocampal impacts N.L. Sicotte (Los Angeles, United States)

11:17 - 11:29 Relationship between rehabilitation and functional reorganisation of the memorynetwork in MS

A. Eshaghi (London, United Kingdom)

11:29 - 11:41 Hippocampal-related memory network in multiple sclerosis: a structural connectivityanalysis

S. Llufriu (Barcelona, Spain)

11:41 - 11:53 Impact of sleep on functional connectivity and cognition in multiple sclerosis Q. van Geest (Amsterdam, Netherlands)

Page 11 / 114


Satellite Symposia, Hall A13:00 - 14:00 Satellite Symposium: Get it right first time: Long-term therapy in

modern MS

Merck Serono

ChairsD. Bates (Newcastle upon Tyne, United Kingdom)O. Fernández (Málaga, Spain)

13:00 - 13:11 Welcome and introduction D. Bates (Newcastle upon Tyne, United Kingdom) O. Fernández (Málaga, Spain)

13:11 - 13:33 Long-term disability prevention: the ultimate goal M.S. Freedman (Ottawa, Canada)

13:33 - 13:55 Long-term benefits versus potential risks: the balancing act A. Prat (Montreal, Canada)

13:55 - 14:00 Summary and close D. Bates (Newcastle upon Tyne, United Kingdom)

Parallel Sessions, Hall A14:15 - 15:45 Parallel Session 4 MRI as primary endpoint of clinical trials

ChairsJ.A. Cohen (Cleveland, United States)G. Comi (Milan, Italy)

14:15 - 14:35 Should MRI be the PEP of phase III trials in MS? YES M.P. Sormani (Genoa, Italy)

14:35 - 14:55 Should MRI be the Primary Endpoint of phase III trials in MS? NO B. Weinshenker (Rochester, United States)

14:55 - 15:07 Different MRI measures predict clinical deterioration and cognitive impairment in MS:a 5 year longitudinal study

P. Preziosa (Milano, Italy)

15:07 - 15:19 11C-PBR28 MR-PET imaging detects in vivo diffuse inflammation in cortex, deep grayand normal appearing white matter associated with neurodegeneration and clinicaldisability

E. Herranz (Charlestown, United States)

15:19 - 15:31 Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis:results from a placebo-controlled phase III trial (INFORMS)

Ö. Yaldizli (London, United Kingdom)

15:31 - 15:43 Grey matter sodium accumulation better explains cognitive deficits in multiplesclerosis than atrophy

A. Maarouf (Marseille, France)

Page 12 / 114


Parallel Sessions, Hall B14:15 - 15:45 Parallel Session 5 Personalized therapy

ChairsA. Rovira (Barcelona, Spain)C. Teunissen (Amsterdam, Netherlands)

14:15 - 14:35 Clinical and MRI predictors L. Prosperini (Rome, Italy)

14:35 - 14:55 Molecular biomarkers M. Comabella (Barcelona, Spain)

14:55 - 15:07 Early MRI and clinical predictors of disability progression over 6 years in patientsafter first clinical event suggestive of multiple sclerosis

T. Uher (Prague, Czech Republic)

15:07 - 15:19 Dynamic model for predicting prognosis in CIS patients M. Tintoré (Barcelona, Spain)

15:19 - 15:31 Predictive value of NEDA for disease outcomes over 6 years in patients with RRMS L. Kappos (Basel, Switzerland)

15:31 - 15:43 Pregnancy does not prevent disease re-activation after natalizumab suspension inpatients with multiple sclerosis

E. Portaccio (Florence, Italy)

Parallel Sessions, Hall C14:15 - 15:45 Parallel Session 6 Genetics and environment

ChairsA. García-Merino (Madrid, Spain)H.F. Harbo (Oslo, Norway)

14:15 - 14:35 Functional consequences of risk genes L. Fugger (Oxford, United Kingdom)

14:35 - 14:55 Genes and environment interactions T. Olsson (Stockholm, Sweden)

14:55 - 15:07 Smoking, organic solvents and MS susceptibility; interaction with HLA genotype L. Alfredsson (Stockholm, Sweden)

15:07 - 15:19 MS susceptibility networks: 4 gene modules are preferentially targeted by MSvariants

P. De Jager (Boston, United States)

15:19 - 15:31 Cell type specific deep RNA-seq finds candidate genes for multiple sclerosis loci in T-cells

S. Sawcer (Cambridge, United Kingdom)

15:31 - 15:43 Sun exposure over the life-course and associations with multiple sclerosis H. Tremlett (Vancouver, Canada)

Page 13 / 114


Parallel Sessions, Hall D14:15 - 15:45 IMSCOGS Parallel Session 2 Cognitive assessment

<font face="Times New Roman" size="3"> </font>

ChairsP. Hämäläinen (Masku, Finland)M. Falautano (Milano, Italy)

14:15 - 14:25 BICAMS D. Langdon (Egham, United Kingdom)

14:25 - 14:35 Relevance of cognitive assessment in clinical trials R.H.B. Benedict (Buffalo, United States)

14:35 - 14:47 Could information processing speed be assessed using computerized speed cognitivetest during only 30 seconds?

A. Ruet (Bordeaux, France)

14:47 - 14:59 Computerized assessement of cognitive performance in patients with multiplesclerosis: relationship to working ability

G. Adler (Mannheim, Germany)

14:59 - 15:11 The impact of different concurrent tasks on the magnitude of cognitive-motorinterference phenomenon in multiple sclerosis

L. Prosperini (Rome, Italy)

15:11 - 15:23 Effect of vitamin D replacement on cognition in multiple sclerosis (MS) patients H. Darwish (Beirut, Lebanon)

Poster Sessions, Poster Exhibition15:45 - 17:00 Poster Session 1

NMDA receptor antibodies are a rare condition in inflammatory demyelinatingdiseases

M. Reindl (Innsbruck, Austria)

Diagnostic value of enhancing lesions on post-contrast T1-weighted magneticresonance images in clinically isolated syndromes

M. Díaz-Sánchez (Sevilla, Spain)

Understanding the characteristics of secondary progressive multiple sclerosis tofacilitate early identification

D. Simsek (Basel, Switzerland)

Corpus callosum lesions in patients with a clinical isolated syndrome N.A. Cerdá-Fuertes (Sevilla, Spain)

Property of neuromyelitis optica spectrum disorder S. Svilpe (Riga, Latvia)

Page 14 / 114


Efficacy of rituximab in refractory neuromyelitis optica N. Collongues (Strasbourg, France)

Autologous hematopoietic stem cell transplant in patients with neuromyelitis optica -four year update

J.M. Burton (Calgary, Canada)

Genetic variation within miR-146a predicts disease onset & relapse in multiplesclerosis

Y. Zhou (Hobart, Australia)

Variation within myelin basic protein gene predicts disease course in multiplesclerosis

Y. Zhou (Hobart, Australia)

Short myelitis as a first manifestation of neuromyelitis optica spectrum disorder S.-Y. Huh (Busan, Korea, Republic of)

Age and gender effects on neuromyelitis optica spectrum disorder phenotypes D.K. Sato (Sao Paulo, Brazil)

Clinical phenotypes of pediatric and adult patients with anti-MOG antibodies D.K. Sato (Sao Paulo, Brazil)

Longitudinal analysis of autoantibodies, IFN-gamma, and IL-17 in the serum ofpatients with concomitant NMO and SLE

Z. Illes (Odense, Denmark)

Do vaccinations trigger relapses in neuromyelitis optica? M. Levy (Baltimore, United States)

Neuromyelitis optica in Spain: a multicenter study of 178 patients M. Sepúlveda (Barcelona, Spain)

Decision-making in multiple sclerosis: a neuroeconomics approach M. Sepúlveda (Barcelona, Spain)

Comorbid conditions and medication utilization among pediatric-onset multiplesclerosis patients in the United States

M. Wenten (Cambridge, United States)

Evidence of an association between multiple sclerosis and renal disease M. Wenten (Cambridge, United States)

Acquisition of early developmental milestones and need for special educationservices in paediatric-onset multiple sclerosis

G.S. Aaen (Loma Linda, United States)

Interferon beta-1b in treatment-naïve paediatric patients with relapsing-remittingMS: 1-year results from the BETAPAEDIC study

J. Gärtner (Göttingen, Germany)

Assessing motivations and perspectives of children and youth in pediatric multiplesclerosis studies

C. Phan (Toronto, Canada)

Page 15 / 114


Investigation of DNA methylation and pediatric multiple sclerosis risk H.E. Hanwell (Toronto, Canada)

The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis L. Pasto (Forence, Italy)

Relapsing central nervous system demyelination in children with myelinoligodendrocyte glycoprotein (MOG) antibodies

Y. Hacohen (London, United Kingdom)

Effect of obesity and puberty on risk and age at onset of pediatric MS T. Chitnis (Boston, United States)

Prospective observational data on 30 patients starting fingolimod before the age of21 years

Y.D. Fragoso (Santos, Brazil)

Dimethyl fumarate in children with multiple sclerosis: a dual-center experience N. Makhani (New Haven, United States)

Association of dietary salt intake and relapse rate in pediatric multiple sclerosis B. Nourbakhsh (San Francisco, United States)

Defining the overlapping period of relapsing-remitting and progressive phases ofmultiple sclerosis for continuing disease modifying treatments

M. Novotna (Rochester, United States)

Multiple sclerosis in the treatment era: long-term evolution of neurologicalimpairments and low rates of secondary progression

B.A. Cree (San Francisco, United States)

Long-term effects of fingolimod on NEDA by year of treatment B.A. Cree (San Francisco, United States)

The effect of age on the disease phenotype before the onset of progressive MS A. Scalfari (London, United Kingdom)

No evidence of disease activity in treated patients after first clinical event suggestiveof multiple sclerosis - follow-up study

T. Uher (Prague, Czech Republic)

Clinical course of childhood-onset multiple sclerosis: results from the Swedishmultiple sclerosis register

A. Manouchehrinia (Stockholm, Sweden)

The topographical model of MS: translation into quantified clinical metrics S. Krieger (New York, United States)

Exploring causes associated with MS-related deaths on death certificates: apopulation-based study in British Columbia, Canada

M.D. Alotaibi (Vancouver, Canada)

Incidence of multiple sclerosis in Puerto Rico: a multicenter initiative A. Chinea (Guaynabo, Puerto Rico)

Page 16 / 114


Multiple sclerosis epidemiology in middle east and north Africa: a systematic reviewand meta-analysis

P. Heydarpour (Tehran, Iran, Islamic Republic of)

Prevalence of depression and anxiety among patients with multiple sclerosisattending the MS clinic at Sheikh Khalifa Medical City, UAE: cross sectional study

A. Mudhafar (Abu Dhabi, United Arab Emirates)

Demographic and clinical profile of PEDIATRIC patients with multiple sclerosis:descriptive analysis of a prospective monitored, population-based cohort study in theBasque Country (Spain)

M. Mendibe (Baracaldo, Spain)

Generalized increase in the burden of psychiatric comorbidity in multiple sclerosis ascompared to the general population: a population-based Canadian study

R.A. Marrie (Winnipeg, Canada)

A retrospective review to identify real-world hospitalization rates and steroid use dueto relapse

D. Davidson (Mississauga, Canada)

Relationship of headache and vitamin D supplementation in MS patients G. Vorobeychik (Burnaby, Canada)

Prevalence of multiple sclerosis in Iranian emigrants: review of the evidence Z. Nasr (Isfahan, Iran, Islamic Republic of)

Children of chronically ill parents: relationship between parental multiple sclerosisand childhood developmental health

N. Razaz (Vancouver, Canada)

Vitamin D, race/ethnicity and the risk of multiple sclerosis A.M. Langer-Gould (Pasadena, United States)

10-year progression predictors after first treatment initiation in a relapsing-remittingMS cohort

V.G. Jokubaitis (Parkville, Australia)

Risk of self-harm and suicide in people admitted to hospital with multiple sclerosis:record-linkage study

S. Ramagopalan (London, United Kingdom)

Month-of-birth-effect in multiple sclerosis in Austria H. Rauschka (Vienna, Austria)

Medication adherence and the impact of oral medications: a study from the pacificnorthwest multiple sclerosis registry

T. Stuchiner (Portland, United States)

Best practices for assessing environmental tobacco smoke exposure in children usingquestionnaires: a systematic review of measurement properties

S. Magalhaes (Montreal, Canada)

Page 17 / 114


Cigarette smoking does not influence disability accumulation in primary progressivemultiple sclerosis

O. Javizian (Calgary, Canada)

Time to relapse and disability progression in a long-term cohort of people withclinically isolated syndrome and relapse-onset multiple sclerosis treated with disease-modifying drugs: a prospective nationwide survey in Switzerland

C. Lienert (Bruderholz, Switzerland)

Association of lifestyle factors with health outcomes in a large international sampleof people with MS

C. Marck (Melbourne, Australia)

Hazards of cerebrovascular, cardiovascular and lung comorbidities in multiplesclerosis - a nationwide study in Denmark using multiple data sources

A. Thormann (Copenhagen, Denmark)

ReMuS - Czech national registry of multiple sclerosis patients - 2 years experience D. Horakova (Prague, Czech Republic)

On-going increase in incidence and prevalence of multiple sclerosis in Newcastle,Australia: a 50-year study

K. Ribbons (Newcastle, Australia)

Anxiety levels are a predictor of cognitive performance in an Australian MS patientcohort

K. Ribbons (Newcastle, Australia)

2D MR spectroscopy can identify molecules differentiating MS from healthy controls K. Ribbons (Newcastle, Australia)

Prognostic indicators of secondary progression in a pediatric-onset multiple sclerosiscohort

R. Alroughani (Kuwait, Kuwait)

Seroprevalence and risk of seroconversion against JC virus among multiple sclerosispatients in Eastern Mediterranean region: a multi-national study

R. Alroughani (Kuwait, Kuwait)

Clinical features and updated epidemiology data of multiple sclerosis andneuromyelitis optica from the Hong Kong Multiple Sclerosis Registry

A. Lau (Hong Kong, Hong Kong)

Course of disease and treatment decisions in patients with relapsing-remittingmultiple sclerosis after two years of first-line disease modifying treatment: aretrospective observational study

C. Winterstein (Ismaning, Germany)

Clinical manifestations of multiple sclerosis are determined by both latitude and HLAclass II allele in Japanese

Y. Nakamura (Fukuoka, Japan)

Childlessness and pregnancy issues in multiple sclerosis patients: a multicenterretrospective prevalence study

D. Ferraro (Modena, Italy)

Page 18 / 114


Modulation of tregs and invariant natural killer T cells by fingolimod in relapsing-remitting multiple sclerosis patients


A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgGband: preliminary results


Post-partum MRI activity in patients with multiple sclerosis M. Houtchens (Brookline, United States)

Gender identity disorders and multiple sclerosis risk: a national record-linkage study J. Pakpoor (Oxford, United Kingdom)

Differential effects of sex steroid hormones on the chronic and acute phases ofexperimental autoimmune encephalomyelitis

M.G. Massa (Bochum, Germany)

“Injectables” during pregnancy in women with multiple sclerosis K. Hellwig (Bochum, Germany)

Managing complex MS symptoms: international challenges experienced by community-based neurologists

P. Ng (Brossard, Canada)

Association between sleep disturbance and perceived cognitive dysfunction over 12months in individuals living with multiple sclerosis

A.J. Hughes (Seattle, United States)

Potentially modifiable prognostic factors for disability progression in multiplesclerosis: the symptom triad of fatigue, depression and bladder dysfunction

K.V. Turpin (Edmonton, Canada)

Characterizing the phenotype of depression in multiple sclerosis: relativecontribution of somatic symptoms as a moderator of depression severity

H. Hasselmann (Berlin, Germany)

Long-term stability of pain type and severity among people with multiple sclerosis S. Shahrbanian (Montreal, Quebec, Canada, Canada)

Impact of a maximal endurance test on perceived symptoms and walking capacity inpersons with multiple sclerosis

P. Feys (Hasselt, Belgium)

Multiple sclerosis, fatigue & sleep disorders: exploration of sleep latency, REMlatency and total REM in a community cohort of people with multiple sclerosisreporting fatigue


Multiple sclerosis and EDSS: a walking scale with no legs M. Gudesblatt (Patchogue, United States)

Page 19 / 114


Multiple sclerosis: computerized objective gait analysis of the impact of a 6-Minutetimed walk on selected gait characteristics in people with multiple sclerosis - puttinglong legs on the walking scale


Multiple sclerosis, cognitive function profile, & EDSS: a walking scale with cognitiveproblems and premature unemployment


Sexual functioning in multiple sclerosis C.A. Young (Liverpool, United Kingdom)

The role of positive coping and hopefulness in predicting quality of life in multiplesclerosis

C.A. Young (Liverpool, United Kingdom)

Fatigue and quality of life in multiple sclerosis: the mediating effect of activitylimitation and the moderating effect of gender and disease type

C.A. Young (Liverpool, United Kingdom)

Exploring the association between fatigue and autonomic dysfunction in multiplesclerosis

O. Tolson (Newcastle Upon Tyne, United Kingdom)

Empirical evidence supporting the validity of the Neuro-QOL Scales in a large clinicalsample of persons with MS

D.M. Miller (Cleveland, United States)

Easy EDSS Score: simplified EDSS rating using a smartphone application M. Cohen (Nice, France)

Real-life outcomes in Rebif-treated MS patients I. Rouleau (Montréal, Canada)

Prospective memory in MS: impact of cue salience and contribution of executivefunctioning

I. Rouleau (Montréal, Canada)

Efficacy and safety of a three-times weekly dosing regimen of glatiramer acetate inrelapsing-remitting multiple sclerosis patients: 3-year results of the glatirameracetate low-frequency administration (GALA) open-label extension study

O. Khan (Detroit, United States)

Characterization of baseline cognitive profiles of RRMS and SPMS patients ininternational multiple sclerosis clinical trials utilizing MS-COG

M. Mellion (Cambridge, United States)

Development of a short version of the MSQOL-54 using factor analysis and itemresponse theory

A. Solari (Milan, Italy)

Home-based palliative approach for people with severe multiple sclerosis and theircarers (PeNSAMI): ongoing study

A. Solari (Milan, Italy)

Page 20 / 114


Baseline cognitive function predicts clinical disability progression in an integratedRRMS clinical trial database

K. Raghupathi (Cambridge, United States)

Development and validation of employment-specific assessment instruments inGerman MS patients

P. Flachenecker (Bad Wildbad, Germany)

Long-term follow-up of laquinimod in patients with relapsing-remitting multiplesclerosis

G. Comi (Milan, Italy)

Tablet-based waiting room cognitive screening in a multiple sclerosis clinic H.N. Beadnall (Camperdown, Australia)

The WHOQOL-Bref in MS: impact and satisfaction? I. Pomeroy (Liverpool, United Kingdom)

Multiple sclerosis performance test: longitudinal validation in fingolimod-treated MSpatients and healthy controls

S. Rao (Cleveland, United States)

Processing speed test vs. symbol digit modalities test: test-retest reliability, practiceeffects, sensitivity, and convergent validity


The self-administered, iPad®-based processing speed test: impact of technicianpresence on task performance


Clinically meaningful change of walking assessments in patients with multiplesclerosis treated with PR-fampridine

N. Sola-Valls (Barcelona, Spain)

Test-retest reliability and concurrent validity of a Dutch version of the 8-itemactionable screening questionnaire for bladder overactivity in multiple sclerosis

P.J. Jongen (Nijmegen, Netherlands)

Video-based paired-comparison ranking: a validation tool for fine-grainedmeasurements of motor dysfunction in multiple sclerosis

J. Burggraaff (Amsterdam, Netherlands)

Validation of the German version of the multiple sclerosis work difficultiesquestionnaire (MSWDQ)

D. Ellenberger (Goettingen, Germany)

Multiple sclerosis relapse in US patients: a population-based analysis of healthcareresource use, productivity and costs in the 30 days post-event

J. Lotya (Dublin, Ireland)

Association between time to treatment initiation of delayed-release dimethylfumarate following MS diagnosis and medical costs in a real-world setting

R. Iyer (Cambridge, United States)

Page 21 / 114


Costs of illness of multiple sclerosis in Sweden - a population-based register study H. Gyllensten (Stockholm, Sweden)

Budget impact model (BIM) in multiple sclerosis: experience of Italian centres E. Baldi (Cona Ferrara, Italy)

Antibodies to MOG and AQP4 in a patient with a fulminant demyelinatingencephalomyelitis, clinical course and neuropathological examination: a case report

F. Di Pauli (Innsbruck, Austria)

Peptide identification and mapping on MS tissue by MALDI IMAGING S. Nischwitz (München, Germany)

Mitochondrial dynamics dysfunction in multiple sclerosis A.N. Carvalho (Amsterdam, Netherlands)

Axonal damage and loss in multiple sclerosis and neuromyelitis optica E. Bahn (Göttingen, Germany)

Cytotoxic effects of antibodies on glial-neuronal networks in neuromyelitis optica andmultiple sclerosis

D.E. Harlow (Aurora, United States)

CSF oxidative stress profiles in multiple sclerosis R.T. Ibitoye (Bristol, United Kingdom)

Astrocyte and myelin injury in neuroinflammatory disorders with myelinoligodendrocyte glycoprotein or aquaporin-4 antibody positive cerebrospinal fluid

K. Kaneko (Sendai, Japan)

Th1 cells inhibit the expression of connexins in astrocytes M. Watanabe (Fukuoka, Japan)

Chronic lymphotoxin-alpha expression in the meninges produces sub-pial corticalpathology in the rat

E. Browne (London, United Kingdom)

The effect of MRI inflammatory activity and age on the association of brain volumeloss with disability progression: per-quartile subgroup analysis

D. Jeffery (Mooresville, United States)

RGC-32 regulates TGF-β extracellular matrix expression in astrocytes A. Tatomir (Baltimore, United States)

Indicators of enterocyte damage and small intestinal permeability in multiplesclerosis: a pilot study

I. Stetkarova (Prague, Czech Republic)

A novel and refined primate EAE model induced with recombinant human MOG inincomplete Freund's adjuvant

A. Jagessar (Rijswijk, Netherlands)

Enhanced cortical activity in remission is due to compensatory neuronal TNFαproduction

E. Ellwardt (Mainz, Germany)

Page 22 / 114


Treatment with relaxin reduces the severity, decreases chemokines, chemokinereceptors and pro-inflammatory cytokines in experimental autoimmuneencephalomyelitis in C57BL/6 mice

R. Garvin (Glasgow, United Kingdom)

Oligodendrocyte damage triggers immune-cell recruitment into the forebrain M. Kipp (München, Germany)

Multi-dimensional analysis in two different types of murine experimental autoimmuneencephalomyelitis

K. Yamamura (Tokushima, Japan)

DMF treatment in a B-cell dependent EAE model S. Traffehn (Göttingen, Germany)

Following anti-CD20 treatment, repletion kinetic and immune-competence ofreappearing B-cells depends on peripheral stimulation

L. Feldmann (Göttingen, Germany)

Novel mechanism of autoimmune demyelination regulation via miR-155-3p and heatshock protein 40

M. Cichalewska (Lodz, Poland)

Biodistribution of teriflunomide in naïve rats vs rats with experimental autoimmuneencephalomyelitis

J. Kaplan (Framingham, United States)

MOG-induced EAE in rats triggers anti-neurofascin antibodies facilitated by non-MHCgenes

S. Flytzani (Stockholm, Sweden)

Angiotensin 1-7 ameliorates disease in a mouse model of multiple sclerosis R. Stone (Los Angeles, United States)

In vivo modeling of the nascent multiple sclerosis lesion: epsilon toxin treated micedevelop focal demyelinating lesions

J.R. Linden (New York, United States)

A new animal model of cortical neuroinflammation induces neurodegeneration andcognitive impairment as an approach to the progressive forms of multiple sclerosis

B.A. Silva (Buenos Aires, Argentina)

Peptidylarginine deiminases as regulators of the epigenetic state of oligodendrocyteprecursor cells

A. Falcao (Stockholm, Sweden)

Genome-wide association analysis in a German multiple sclerosis cohort T.F.M. Andlauer (Munich, Germany)

Genes and environment in multiple sclerosis: an integrated study of multiple sclerosisrisk factors in first-degree relatives

Z. Xia (Boston, United States)

Page 23 / 114


MicroRNA sequencing identifies down-regulated microRNA in CD4+ T-cells ofsecondary progressive multiple sclerosis patients

K.A. Sanders (Gold Coast, Australia)

Relapse-related miRNA signature regulates general metabolism processes inleucocytes and a different underexpressed miRNA subset in remission is involved inthe regulation of innate immunity

M. Muñoz-Culla (San Sebastian, Spain)

TARDBP Ala382Thr mutation and C9orf72 expansion in a Sardinian MS population L. Lorefice (Cagliari, Italy)

The burden of multiple sclerosis and patients' cooping strategies L. Lorefice (Cagliari, Italy)

CD86 genetic risk in multiple sclerosis B. Fiddes (Cambridge, United Kingdom)

Influence of the multiple sclerosis-associated IL2RA SNP rs2104286 on geneexpression in healthy individuals and multiple sclerosis patients

S. Buhelt (Copenhagen, Denmark)

Whole exome and transcriptome sequencing identifies NR1H3 (LXRA) p.Arg415Gln infamilial progressive multiple sclerosis

C. Vilarino-Guell (Vancouver, Canada)

DNA methylation profiling of vitamin D pathway genes in T-cells from RRMS patientscompared to healthy controls

P. Aznar (Pamplona, Spain)

Interleukine 17 is detected in CSF in radiologically and clinically isolated syndromes C. Lebrun (Nice, France)

Interleukin 18, chemokines CXCL10 and CXCL13 in the serum and cerebrospinal fluidof patients with relapsing-remitting and primary progressive multiple sclerosis

P. Iwanowski (Poznan, Poland)

Different pathophysiological relevance of branched fatty acid metabolism in mice andmen: alpha-methylacyl-CoA racemase regulates the T cell response only inexperimental autoimmune encephalomyelitis but not in multiple sclerosis

C.A. Mayer (Frankfurt, Germany)

Ceramide synthase6 / C16-ceramides mediate anti-inflammatory effects during thedevelopment of EAE and MS possibly by suppressing the migration and bydeactivation of neutrophils: a new target for anti-inflammatory therapy in MS?

C.A. Mayer (Frankfurt, Germany)

Endogenous soluble TACI is elevated in multiple sclerosis patients and sharesfunctional properties with atacicept

F.S. Hoffmann (Munich, Germany)

Casein kinase 2 controls encephalitogenicity of Th17 cells in experimentalautoimmune encephalomyelitis

E. Witsch (Mainz, Germany)

Page 24 / 114


Polyfunctionality of peripheral blood iNKT cells as an immunological marker ofdifferent forms of multiple sclerosis and following different immunomodulatorytreatments

A.M. Simone (Modena, Italy)

IL-35 is a critical regulator of immunity during helminth infections associated withmultiple sclerosis

J. Correale (Buenos Aires, Argentina)

Decreased concentration of Klotho in the cerebrospinal fluid of patients withrelapsing-remitting multiple sclerosis

M.H. Harirchian (Tehran, Iran, Islamic Republic of)

Serum chitinase 3-like 1 levels in patients with multiple sclerosis and neuromyelitisoptica

D. Kaya (Izmir, Turkey)

Differential expression and putative pathogenic role of intracellular K2P channels inmultiple sclerosis

T. Ruck (Münster, Germany)

Natalizumab-induced alterations in circulating B-cells of multiple sclerosis patients -special reference to chemokine receptors

M. Saraste (Turku, Finland)

CNS migration of regulatory B cells in EAE is dependent on VLA-4 K. Lehmann-Horn (San Francisco, United States)

Therapeutic potential of a novel NMDA receptor subunit 2B antagonist in a mousemodel of autoimmune neuroinflammation

S. Glumm (Muenster, Germany)

Molecular analyses of the multiple sclerosis susceptibility gene CLEC16A in T cells I.S. Leikfoss (Oslo, Norway)

The role of MS susceptibility gene PLEK in neuroinflammation C. Larochelle (Montreal, Canada)

Fatal rebound MS activity following natalizumab withdrawal: ante and post-mortemimmunological characterization of CNS-infiltrating cells

C. Larochelle (Montreal, Canada)

The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitaminD in CD4+ T cells

T. Berge (Oslo, Norway)

Nonfunctional natural killer regulatory cells in multiple sclerosis A. Laroni (Genova, Italy)

T/B lymphocyte subset analysis of NMOSD with MOG autoantibody and AQP4autoantibody

S. Tanaka (Kawagoe, Japan)

Complexity of the brain-infiltrating T-cell repertoire in Rasmussen encephalitis F. Al Nimer (Zurich, Switzerland)

Page 25 / 114


Myelin-reactive antibodies initiate T-cell-mediated CNS autoimmunity by opsonisationof auto-antigen

S. Kinzel (Göttingen, Germany)

Impact and fate of distinct T-cell subsets in the course of autoimmuneneuroinflammation

R. Gollan (Mainz, Germany)

CD20 expressing T-cells: phenotype, cytokine profile and response toimmunomodulatory treatments in MS

E. Schuh (Munich, Germany)

CXCL13, but not BAFF and APRIL, intrathecal synthesis associates with a decreasedcortical thickness in multiple sclerosis at clinical onset

M. Puthenparampil (Padua, Italy)

High CCR5 expression in natalizumab-associated progressive multifocalleukoencephalopathy immune reconstitution inflammatory syndrome supports antiCCR5 therapy

L. Stork (Göttingen, Germany)

Toxoplasma gondii infection as a protective factor against multiple sclerosis risk A. Koskderelioglu (Izmir, Turkey)

Pilot baseline versus treatment clinical trial of the HIV drug raltegravir in patientswith active relapsing remitting multiple sclerosis: the INSPIRE study

J. Gold (London, United Kingdom)

Vitamin D and Epstein-Barr virus antibody levels in a prospective cohort of MSpatients

S. Wergeland (Bergen, Norway)

Antibody response to individual Epstein-Barr virus proteins in multiple sclerosis J. Lindsey (Houston, United States)

Beneficial effect of smoking cessation on multiple sclerosis prognosis R. Ramanujam (Stockholm, Sweden)

Vitamin D status does not influence disability progression of multiple sclerosispatients over three years follow-up

A.-H. Muris (Maastricht, Netherlands)

1α, 25-dihydroxy-vitamin D3 effects selectively activation and pro-inflammatoryphenotype of different antigen-presenting cells

L. Neubeck (Dresden, Germany)

Dietary fatty acids directly affect immune response in CNS autoimmunity via thesmall intestine

A. Duscha (Bochum, Germany)

Body mass index influence disease activity and interferon-beta treatment response inmultiple sclerosis

S.A. Stokke Kvistad (Bergen, Norway)

Page 26 / 114


Oral succinate contained as a food additive exacerbates experimental autoimmuneencephalomyelitis via increased IL-1β production

K. Takata (Osaka, Japan)

Interaction between smoking and HLA genotype in multiple sclerosis development T. Olsson (Stockholm, Sweden)

Alterations of the human gut microbiome in multiple sclerosis S. Jangi (Boston, United States)

c-Fos reporter reveals temporal, spatial and transcriptional astrocytic activity inexperimental autoimmune encephalomyelitis (EAE), correlated with disease severityand modulated by S1P-signaling

J. Chun (La Jolla, United States)

K2P channels: novel regulators of oligodendroglial cell functions S. Korr (Münster, Germany)

Are axon initial segments affected in multiple sclerosis ? A. Dilsizoglu Senol (Paris, France)

Neurodegenerative gene profiling in the central nervous system during experimentalautoimmune encephalomyelitis

N. Fissolo (Barcelona, Spain)

NG2, expressed by immune and neural cells, displays multiple roles in development ofexperimental autoimmune encephalomyelitis

G. Ferrara (Genoa, Italy)

Glia-axonal ribosome transfer in peripheral and central demyelination: a novelmechanism for axonal survival?

G.J. Schenk (Amsterdam, Netherlands)

Deficiency in the LINGO-1 signalling pathway enhances optic nerve regeneration in aknock out mouse optic nerve crush model

S. Mi (Cambridge, United States)

Inhibition of neurogenesis in a Marburg´s variant of multiple sclerosis C. Oreja-Guevara (Madrid, Spain)

Depression and fatigue improve after mindfulness training C. Oreja-Guevara (Madrid, Spain)

Abnormalities of the main cortical and subcortical functional networks in MS patients M. Filippi (Milano, Italy)

Cognitive correlates of the brain functional connectome abnormalities in pediatricpatients with multiple sclerosis

M. Filippi (Milano, Italy)

Fampridine modulates thalamic resting state functional connectivity and amelioratesfatigue in multiple sclerosis patients

M. Filippi (Milano, Italy)

Page 27 / 114


Effects of action observation therapy on rehabilitation of motor deficits of thedominant right upper limb in patients with MS: an exploratory study with structuraland functional MRI

M. Rocca (Milan, Italy)

Differential contribution of cerebellar resting state functional connectivityabnormalities to cognitive impairment in pediatric and adult patients with multiplesclerosis


FMRI correlates of sustained attention in pediatric multiple sclerosis M. Rocca (Milan, Italy)

Microstructural thalamic and cortico-thalamic correlates of cognitive impairment inpediatric multiple sclerosis


Contribution of MRI lesions in late onset multiple sclerosis Y. Beckmann (Izmir, Turkey)

Cannabis induced alterations in brain activation during a test of informationprocessing speed in patients with MS

B. Pavisian (Toronto, Canada)

Changes in connectivity of cognitive networks and thalamic volume in RRMS: anfMRI/DTI study

M. Cerghet (Detroit, United States)

Evaluating the sensitivity of subtraction imaging for the detection of new T2 multiplesclerosis lesions when using visual analysis, semiautomatic and automaticapproaches

M. Cabezas (Barcelona, Spain)

A pipeline for detecting new multiple sclerosis lesions on longitudinal brain magneticresonance imaging

M. Cabezas (Barcelona, Spain)

Elevated brain temperature is associated with worse fatigue in multiple sclerosispatients

V.M. Leavitt (New York, United States)

N-acetylaspartate and creatine decrease with myelin damage in relapsing multiplesclerosis

E.L. MacMillan (Vancouver, Canada)

Consistency of grey matter volume measurement in multiple sclerosis:comparison ofFSL, FreeSurfer and SPM

V. Popescu (Amsterdam, Netherlands)

Evaluation of two automated lesion segmentation and filling pipelines for brain tissuesegmentation of multiple sclerosis patients

X. Llado (Girona, Spain)

Manual segmentation of MS cortical lesions using MRI: a comparison of three MRIreading protocols

J. Maranzano (Montreal, Canada)

Page 28 / 114


T2 and T2* relaxometry as a detector of USPIO enhancement in CIS patients A. Kerbrat (Rennes, France)

Differentiating neuromyelitis optica from other causes of longitudinally extensivetransverse myelitis on spinal magnetic resonance imaging

I. Izbudak (Baltimore, United States)

Periventricular lesion burden in multiple sclerosis correlates with cortical thinning M. Jehna (Graz, Austria)

Grey/white matter ratio at diagnosis, and the risk of 10-year multiple sclerosisprogression

M. Moccia (Napoli, Italy)

A serial 10-year follow-up study of early relapsing-remitting MS patients: exploringlong-term value of different MRI brain volumetric outcomes in predicting disabilityprogression

R. Zivadinov (Buffalo, United States)

Cerebral microbleeds in multiple sclerosis. A case-control study R. Zivadinov (Buffalo, United States)

A prospective optical coherence tomography study evaluating the effect of glatirameracetate on changes in retinal nerve fiber layer thickness in patients with relapsing-remitting multiple sclerosis over 24 months


Patterns of decreased cortical surface-based magnetization transfer ratio in multiplesclerosis

D.A. Rudko (Montreal, Canada)

Magnetic resonance spectroscopy of the hippocampus is not correlated with memoryperformance in early and late stages of multiple sclerosis

W. Köhler (Wermsdorf, Germany)

Visualizing and characterizing cortical gray matter lesions in MS with 7T MRI L. Jonkman (Amsterdam, Netherlands)

Gray matter correlates of cognitive performance differ between relapsing-remittingand primary-progressive multiple sclerosis

L. Jonkman (Amsterdam, Netherlands)

Periventricular venous density is normal in neuromyelitis optica - preliminary datafrom a 7T MRI study

S. Schumacher (Berlin, Germany)

Accurate and reliable atrophy measurement on clinical quality FLAIR scans M.G. Dwyer (Buffalo, United States)

MR frequency shifts in new MS lesions of CIS patients over 2 years A. Rauscher (Vancouver, Canada)

Differential neurodegenerative mechanisms in thalamus throughout multiple sclerosisstages: a multimodal quantitative 3 T and 7 T MRI study

C. Louapre (Charlestown MA, United States)

Page 29 / 114


A longitudinal study of spinal cord lesion load in progressive multiple sclerosis D. Plantone (London, United Kingdom)

Changes in cervical cord MRI metrics in a one-year follow-up study in early primaryprogressive multiple sclerosis

N. Cawley (London, United Kingdom)

Spinal cord atrophy as a primary outcome measure in primary progressive multiplesclerosis neuroprotective trials

N. Cawley (London, United Kingdom)

Evidence of progressive demyelination and neurodegeneration in chronic MS lesions:DTI study

A. Klistorner (Sydney, Australia)

An Argentinian cohort of individuals with radiologically isolated syndrome M.I. Gaitán (Buenos Aires, Argentina)

Volume estimation of subcortical grey matter structures in multiple sclerosis:comparison between NeuroQuant® and FIRST

D. Pareto (Barcelona, Spain)

Patterns of regional gray matter and white matter atrophy progression contributingto clinical deterioration in MS: a 5-year tensor-based morphometry study


The effects of natalizumab and fingolimod on clinical, neuropsychological and MRImeasures in relapsing remitting multiple sclerosis: a one-year comparative study


A method for segmentation of multiple sclerosis lesions on magnetic resonanceimages

L. Storelli (Milano, Italy)

MSmetrix: accurate untrained method for longitudinal lesion segmentation A. Maertens (Leuven, Belgium)

Assessing intra- and interscanner variability of automated brain volumetry usingSPM12, SIENA, and SIENAX

R. Opfer (Hamburg, Germany)

Functional network imbalance underlies severity of cognitive impairment in multiplesclerosis

M.M. Schoonheim (Amsterdam, Netherlands)

Evaluation of [18F]GE-180 PET imaging in relapsing-remitting multiple sclerosispatients: a first-in-human study

W. Trigg (Amersham, United Kingdom)

Use of cortical thickness to detect localized damage in the somatomotor cortex in MS:relation with clinical disability

M. Tonietto (Verona, Italy)

Abnormal cerebral venous haemodynamics in patients with MS S. Kolbe (Parkville, Australia)

Page 30 / 114


Hippocampal-DMN disconnectivity in MS is related to WM lesions and contributes toclinical symptoms

L. Vacchi (Milano, Italy)

Functional cognitive control load in multiple sclerosis L. Vacchi (Milano, Italy)

Phase-sensitive inversion recovery improves the detection of cerebellar corticallesions and discloses their correlation with disability in multiple sclerosis

A. Favaretto (Padova, Italy)

The role of spinal cord MRI as an adjunct to brain MRI at 3T in defining “no evidenceof disease activity” in patients with multiple sclerosis

S. Tummala (Boston, United States)

Prediction of conversion to secondary progression phase in multiple sclerosis M. Castellaro (Padova, Italy)

7T MP2RAGE for detection of cortical lesions V.V. Sethi (Bethesda, United States)

Improved framework for tractography reconstruction of the optic radiation E. Martinez-Heras (Barcelona, Spain)

White and grey matter network evolution in patients with early relapsing-remittingmultiple sclerosis

V. Fleischer (Mainz, Germany)

23Na-MRI reveals sodium accumulation in skin of patients with relapsing-remittingmultiple sclerosis

K. Huhn (Erlangen, Germany)

Sodium (23Na) MRI of acute and chronic tissue changes in multiple sclerosis P. Eisele (Mannheim, Germany)

Topography of metabolic abnormalities over the entire brain using voxel-wisestatistical mapping of fast 3D-MRSI Proof of concept on multiple sclerosis

M. Donadieu (Marseille, France)

Regional microstructural white matter damage is proportional to fatigue in multiplesclerosis

A. Bisecco (Napoli, Italy)

Quantitative histological validation of NODDI MRI indices of neurite morphology inmultiple sclerosis spinal cord

F. Grussu (London, United Kingdom)

MRI anisotropy improves with remyelination in a mouse model of MS Y. Zhang (Calgary, Canada)

The yearly rate of relative thalamic atrophy (2D- and 3D-yrRTA) differentiates CISfrom controls

M. Menéndez González (Oviedo, Spain)

Page 31 / 114


Leptomeningeal enhancement on delayed acquisition, post-contrast 7 Tesla MRI inmultiple sclerosis

D.M. Harrison (Baltimore, United States)

Changes in the normal appearing white matter in neuromyelitis optica measured byMRI at 7T field strength

I.-J. Chou (Nottingham, United Kingdom)

Intensity of initial demyelinating event associated with lower subsequent MWF in newMS lesions

S.A. Gauthier (New York, United States)

Disrupted blood flow modulation in functional brain networks in multiple sclerosismeasured with hypercapnia MRI

Y. Ge (New York City, United States)

Longitudinal study of venous oxygenation in multiple sclerosis with advanced MRI Y. Ge (New York City, United States)

Quality assurance of advanced imaging in a multicenter trial of ibudilast therapy forprogressive multiple sclerosis

X. Zhou (Cleveland, United States)

Prediction of executive functions in multiple sclerosis based on structural andfunctional MRI - insights from a multicentre study

M. Loitfelder (Graz, Austria)

Signal abnormalities on susceptibility-weighted MR imaging in patients with clinicallyisolated syndromes and in subjects with incidental focal white matter lesions

A. Rovira (Barcelona, Spain)

Efficiency of FLAIR* at 1.5T, 3T, and 7T for detecting perivenular lesions in multiplesclerosis (MS)

L. Vuolo (Florence, Italy)

Leptomeningeal enhancement analysis in diagnostic clinical setting L. Vuolo (Florence, Italy)

Cortical lesions in pediatric-onset multiple sclerosis: a preliminary 7 tesla view R. Datta (Philadelphia, United States)

MTR-derived pial and subpial abnormalities in the spinal cord of RRMS patients: a two-year follow-up study

F. De Angelis (London, United Kingdom)

Local increases in metabolite levels predict lesion formation and lesion severity inrelapsing-remitting multiple sclerosis

A.J. Eijlers (Amsterdam, Netherlands)

Neuroplastic cerebral grey and white matter changes following constraint-inducedmovement therapy for chronic hemiparetic MS: randomised controlled trial

V.W. Mark (Birmingham, United States)

Page 32 / 114


Early structural changes in relapsing remitting multiple sclerosis patients withdepression

J.I. Rojas (Buenos Aires, Argentina)

Anti-viral antibodies levels are not associated with OCT measures B. Weinstock-Guttman (Buffalo, United States)

Longitudinal reduction of total macular volume in relapsing and remitting multiplesclerosis: indicative of ongoing neurodegeneration

A.S. Loughran-fjeldstad (Salt Lake City, United States)

Microcystic macula edema in myelin oligodendrocyte glycoprotein (MOG-) antibody-associated relapsing optic neuritis

J. Havla (Munich, Germany)

Evaluation of choroidal vascular changes in patients with multiple sclerosis usingenhanced depth imaging optical coherence tomography

M. Demirkiran (Adana, Turkey)

Optical coherence tomography in multiple sclerosis patients: correlation with MRspectroscopy

M. Siger (Lodz, Poland)

Relationships between brain atrophy and structure of optic nerves in multiplesclerosis

S. Sivertseva (Tyumen, Russian Federation)

A comprehensive analysis of the optic pathway, from retina to cortex, discloses nocorrelation between white matter inflammation and neurodegeneration in very earlymultiple sclerosis

L. Federle (Padova, Italy)

Prospective study of retinal nerve fibre layer thickness in alemtuzumab treatedmultiple sclerosis patients

A.-L. Nguyen (Vancouver, Canada)

Leber;s hereditary optic neuropathy & untreated remitting relapsing MS sharemulticolor OCT findings: potential biomarker for mitochondrial flavoproteinbiosynthesis and for electron transport chain activation

R.C. Sergott (Philadelphia, United States)

Patterns of OCT changes in optic neuritis C. Maggiore (London, United Kingdom)

OCT characteristics at baseline in the SPRINT-MS/NN 102 phase II trial of ibudilast inprogressive MS

R.A. Bermel (Cleveland, United States)

Reduced corneal nerve fiber and dendritic cell density in patients with multiplesclerosis

J. Mikolajczak (Berlin, Germany)

Asymptomatic subjects differ less from their twin siblings with multiple sclerosis,than from healthy controls in cognition. A Finnish twin cohort study

H. Kuusisto (Hämeenlinna, Finland)

Page 33 / 114


Differences between oVEMP and cVEMP in the correlation with the brainstem andcervical spinal cord MRI in multiple sclerosis

M. Krbot Skoric (Zagreb, Croatia)

Analysis of upper limb movement in multiple sclerosis subjects during common dailyactions

A. Tacchino (Genova, Italy)

THC:CBD oromucosal spray effect on spasticity assessed with stretch reflex inmultiple sclerosis

L. Marinelli (Genova, Italy)

Evaluating optic neuritis with visual evoked potentials, which one is more sensitiveblack white pattern or red-white and red-black pattern stimuli?

A. Soysal (Istanbul, Turkey)

Intracortical inhibition in multiple sclerosis: relation to clinical subtype, motordisability, and cortical damage

J.C. Nantes (Montreal, Canada)

Step initiation under dual-tasking in patients with clinically isolated syndrome (opticneuritis) suggestive of multiple sclerosis

G. Brecl Jakob (Ljubljana, Slovenia)

Emotional valence improve retrieval of autobiographical memory in multiple sclerosis N. Derache (Caen, France)

The prevalence of bipolar disorders and impact on quality of life in a cohort ofpatients with multiple sclerosis

I. Berrios Morales (Worcester, United States)

Evidence of attentional impairment using virtual driving simulation in multiplesclerosis

A. Mondou (Caen, France)

Mood and multiple sclerosis M. Ponzio (Genoa, Italy)

Characteristics of verbal fluency in patients with relapsing-remitting multiplesclerosis

E. Tyburski (Szczecin, Poland)

Relationships among subjective trait and state measures of fatigue and cognitivefatigue on an attention task

A.K. Roth (Lawrence, United States)

Level of stress and coping strategies in the multiple sclerosis patients with milddisability

A. Pokryszko-Dragan (Wrocław, Poland)

Survey-based assessment of the relationship between cognitive impairment andmentally stimulating activity in multiple sclerosis

B. Prager (Cleveland, United States)

Page 34 / 114


Immunosuppressive therapy improves cognitive function in secondary progressivemultiple sclerosis patients

M. Kinner (Bochum, Germany)

Cognitive behavioural therapy in multiple sclerosis: effectiveness in reducingdepressive symptoms and cognitive impairments

T. Olivares (La Laguna, Spain)

Integrative group-based cognitive rehabilitation efficacy in multiple sclerosis O. Rilo (Bilbao, Spain)

Switching from branded to generic glatiramer acetate: two-year MRI data from theGATE trial demonstrates continuous efficacy

F. Barkhof (Amsterdam, Netherlands)

MRI results in patients with CIS treated with interferon beta-1b: 11-year follow up inBENEFIT (BENEFIT 11)


Daclizumab high-yield process (DAC HYP) vs. intramuscular interferon beta-1a insubgroups predictive of active disease: results from the DECIDE study

H. Wiendl (Münster, Germany)

Lymphocyte counts in patients receiving daclizumab HYP in DECIDE H. Wiendl (Münster, Germany)

No evidence of disease activity achieved in patients with active relapsing-remittingmultiple sclerosis who switched to alemtuzumab from subcutaneous interferonbeta-1a: CARE-MS I and II extension studies


IL-17 neutralization by subcutaneous CJM112, a fully human anti IL-17A monoclonalantibody for the treatment of relapsing-remitting multiple sclerosis: study design of aphase 2 trial


Effects of daclizumab HYP on accumulation of disability exclusive of acute relapse inmoderate/severe relapsing-remitting multiple sclerosis patients: a compositedisability outcome from the DECIDE study

J.L. Bennett (Aurora, United States)

Blockade of CD127 exerts a variable clinical effect in the marmoset EAE model Y.S. Kap (Rijswijk, Netherlands)

EAE in the marmoset as a preclinical model for B-cell targeting therapies Y.S. Kap (Rijswijk, Netherlands)

Immune response to seasonal influenza vaccine in patients with relapsing-remittingmultiple sclerosis on long-term daclizumab HYP treatment

L. Mehta (Cambridge, United States)

Safety and tolerability of MEDI-551 in patients with relapsing forms of multiplesclerosis: results from a phase 1 randomised, placebo-controlled, escalatingintravenous and subcutaneous dose study

M. Agius (Sacramento, United States)

Page 35 / 114


High persistence with fingolimod in Canadian routine clinical practice P. O'Connor (Toronto, Canada)

Reduced risk of disability progression in patients with MS treated with early vsdelayed teriflunomide 14 mg

P. O'Connor (Toronto, Canada)

Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity

T. Spelman (Parkville, Australia)

Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate inrelapsing MS

T. Spelman (Parkville, Australia)

Risk of early relapse following switch to oral agents for multiple sclerosis T. Spelman (Parkville, Australia)

Switching from other oral DMTs to fingolimod: Canadian real world experience F. Grand'Maison (Greenfield Park, Canada)

Vitamin D enhances interferon-beta-1b response in multiple sclerosis A.T. Reder (Chicago, United States)

Optical coherence tomography and ophthalmological findings in patients with CIStreated with interferon beta-1b: 11-year follow-up in BENEFIT (BENEFIT 11)

S.C. Lukas (Zurich, Switzerland)

Daclizumab HYP provided clinically meaningful benefits on cognitive outcomes versusintramuscular interferon beta-1a over 2 years: results from the DECIDE study

R.H.B. Benedict (Buffalo, United States)

Pregnancy experience: preclinical data and pregnancy outcomes in the daclizumabhigh-yield process clinical program

R. Gold (Bochum, Germany)

Efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: post-hocanalysis of the phase 3 DEFINE and CONFIRM studies according to baseline cognitivefunction


Efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: post-hocanalysis of the phase 3 DEFINE and CONFIRM studies according to baseline disability


Initial experience with teriflunomide in a real-world clinical setting P. Duquette (Montréal, Canada)

Efficacy and tolerability of teriflunomide in a real-world clinical setting P. Duquette (Montréal, Canada)

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability H. Zéphir (Lille, France)

Page 36 / 114


Anti-mu CD52 treatment induces CD39+ regulatory cells in the GALT and suppressesinflammatory cytokine expression within the CNS of EAE mice

A.B. Pant (Hanover, United States)

An open-label add-on trial of cetirizine for neuromyelitis optica: baseline data andpreliminary results

I. Katz Sand (New York, United States)

Effects of laquinimod on microglia and monocytes following traumatic brain injury A. Katsumoto (Cleveland, United States)

Six-year follow-up of delayed-release dimethyl fumarate in RRMS: integrated clinicalefficacy data from the DEFINE, CONFIRM, and ENDORSE studies

M. Hutchinson (Dublin, Ireland)

Long-term follow-up of the safety of delayed-release dimethyl fumarate in RRMS:interim results from the ENDORSE extension study

C. Pozzilli (Rome, Italy)

Predicting response to fingolimod in patients with relapsing-remitting multiplesclerosis


Long-term effect of delayed-release dimethyl fumarate on total disability burden inDEFINE, CONFIRM, and ENDORSE: area under the curve analysis of changes frombaseline in expanded disability status scale scores

J. Lechner-Scott (Callaghan, Australia)

Lesion characteristics differentiating asymptomatic natalizumab-associated PML fromnew MS lesions

M.T. Wijburg (Amsterdam, Netherlands)

Therapeutic treatment with ATX-MS-1467 reduces T1-weighted gadolinium leakagevolume in a preclinical model of multiple sclerosis

T. Dellovade (Billerica, United States)

Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the11-year follow-up of BENEFIT (BENEFIT 11)

F. Foley (New York, United States)

Survival in multiple sclerosis: a prospective cohort study T. Ducruet (Montréal, Canada)

Incidence, severity, duration, and treatment of cutaneous adverse events in theDECIDE study of daclizumab HYP versus intramuscular interferon beta-1a in patientswith relapsing-remitting multiple sclerosis

L. Kircik (New York, United States)

MT-1303, a novel sphingosine 1-phosphate (S1P) receptor modulator, has lesspotential for bradycardia than fingolimod

K. Sugahara (Yokohama, Japan)

Long-term safety of alemtuzumab in relapsing-remitting multiple sclerosis: pregnancyand infection data from a cohort of patients on open label studies in Cambridge, UK

C.L. McCarthy (Cambridge, United Kingdom)

Page 37 / 114


Safety and tolerability of daclizumab HYP in patients with relapsing-remittingmultiple sclerosis: an integrated analysis of six clinical studies

G. Giovannoni (London, United Kingdom)

Benefits on brain MRI lesion activity with daclizumab HYP compared withintramuscular interferon beta-1a are maintained through 144 weeks' treatment:results from the DECIDE study

D.L. Arnold (Montréal, Canada)

Reduction in brain volume loss in patients receiving daclizumab HYP versusintramuscular interferon beta-1a: results of the DECIDE study


Association between no evidence of disease activity (NEDA) and long-term clinicalefficacy of delayed-release dimethyl fumarate (DMF) in patients with relapsing-remitting multiple sclerosis from the phase 3 study, ENDORSE

E. Havrdová (Prague, Czech Republic)

Increased nuclear Nrf2 expression after fumarate treatment for multiple sclerosis andpsoriasis

I. Metz (Göttingen, Germany)

Efficacy of daclizumab HYP vs intramuscular interferon beta-1a on disabilityprogression across patient demographic and disease activity subgroups in DECIDE

S. Cohan (Portland, United States)

Real-world clinical outcomes in relapsing-remitting multiple sclerosis patients whoswitch from natalizumab to delayed-release dimethyl fumarate: a multicenter,retrospective, observational study (STRATEGY)

S. Cohan (Portland, United States)

Improvements in patient-reported outcomes with teriflunomide: week 24 interimresults from the US cohort of the Teri-PRO phase 4 study

P.K. Coyle (Stony Brook, United States)

Longer-term follow-up of the efficacy of delayed-release dimethyl fumarate in newlydiagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, andENDORSE

J. Marantz (Cambridge, United States)

Six-year follow-up of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM and ENDORSE

R. Zhang (Cambridge, United States)

Autologous haematopoietic stem cell transplantation with reduced-intensityconditioning for aggressive multiple sclerosis: the Polish experience

L. Szczechowski (Katowice, Poland)

Long-term therapy with interleukin-6-receptor blockade in highly active neuromyelitisoptica spectrum disorder

M. Ringelstein (Düsseldorf, Germany)

Efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis inreal world clinical practice

R. Totaro (L'Aquila, Italy)

Page 38 / 114


Hepatic disorders due to teriflunomide in multiple sclerosis treatment. Impact andmanagement in clinical practice


A myeloid directed immune modulator, MIS416, modulates homeostatic CNSleucocyte trafficking - implications for neuro-inflammation

G. Webster (Auckland, New Zealand)

Costimulatory blockade with abatacept (CTLA4-Ig) in relapsing-remitting multiplesclerosis: results from the ACCLAIM trial

S.J. Khoury (Boston, United States)

The effect of disease modifying therapies on brain atrophy in patients with clinicallyisolated syndrome: a systematic review and meta-analysis

G. Tsivgoulis (Athens, Greece)

The concept of no evidence of disease activity in multiple sclerosis after autologoushematopoietic stem cell transplantation - assessing outcome parameters across trials

A. Wundes (Seattle, United States)

Effects of exercise on disease progression and cognition in the marmoset EAE model K.A. Phillips (San Antonio, United States)

Siponimod - direct CNS effects of an immunomodulatory drug? S.G. Meuth (Muenster, Germany)

Melanocortin 4 receptors on oligodendrocytes and oligodendrocyte precursors signalACTH protection from in vitro death induced by mechanisms involved in cell damagein multiple sclerosis

R.P. Lisak (Detroit, United States)

Sodium channel blockade with phenytoin has a neuroprotective effect on the ganglioncell complex after acute optic neuritis

R. Raftopoulos (London, United Kingdom)

Fingolimod reduces deep grey matter and regional volume loss in the brain of RRMSpatients: a post-hoc analysis of FREEDOMS and FREEDOMS II data

T. Sprenger (Basel, Switzerland)

ABT-555, a human anti-RGMa monoclonal antibody promotes axon regeneration andneuroprotection in multiple sclerosis models

B.K. Mueller (Ludwigshafen, Germany)

A thyromimetic drug accelerates remyelination in vivo: a small molecule approach topromoting repair in multiple sclerosis

D. Bourdette (Portland, United States)

Overexpression of Olig2 promotes differentiation of neural stem cells intooligodendrocytes only in non-inflammatory conditions

A.M. Malvandi (Milan, Italy)

Diffusion tensor imaging effects of mesenchymal stem cell transplantation in multiplesclerosis

D. Ontaneda (Cleveland, United States)

Page 39 / 114


Should brain atrophy be incorporated to patterns of response to therapy in MS? G.M.A. Figueira (Rio de Janeiro, Brazil)

US patient perspectives on the multiple sclerosis treatment experience: results of aUS web-based survey

P. Wicks (Cambridge, United States)

Long-term use of glatiramer acetate in MS: possible predictors of the differences intreatment effect after 10-15 years of therapy

A. Boyko (Moscow, Russian Federation)

Long-term effect of disease-modifying drugs on disability progression in multiplesclerosis: a meta-analysis

A. Signori (Genova, Italy)

Detection and management of immune thrombocytopenia in alemtuzumab-treatedpatients in the multiple sclerosis clinical development program

A. Cuker (Philadelphia, United States)

Long-term safety and effectiveness of fingolimod: 7 year data from the LONGTERMSstudy

J.A. Cohen (Cleveland, United States)

Update - real life use of natalizumab and fingolimod in Austria: benefit-risk data fromthe Austrian multiple sclerosis treatment registry

M. Guger (Linz, Austria)

36 months PANGAEA: a 5-year non-interventional study of safety, efficacy andpharmacoeconomic data for fingolimod patients in daily clinical practice

T. Ziemssen (Dresden, Germany)

Treatment satisfaction with injectable disease-modifying therapy in patients withisolated demyelinating syndrome or relapsing-remitting multiple sclerosis

O. Fernández (Málaga, Spain)

Lessons from clinical practice: lymphocyte and leukocyte count on innovative MStreatments

K. Thomas (Dresden, Germany)

Acute humoral and cellular effects during the first alemtuzumab infusion week inactive multiple sclerosis (MS) patients

K. Thomas (Dresden, Germany)

Baseline characteristics and interim analysis results of TRANSITION: a 2-yearobservational study evaluating the safety profile of patients with multiple sclerosiswho switched from natalizumab to fingolimod

H. Butzkueven (Melbourne, Australia)

Erythroblastaemia in natalizumab-treated patients with multiple sclerosis S. La Gioia (Bergamo, Italy)

The IMSE 2 study: a Swedish nationwide pharmaco-epidemiological and genetic studyfocused on long-term safety and efficacy of fingolimod

S. Johansson (Stockholm, Sweden)

Page 40 / 114


A Swedish nationwide pharmaco-epidemiological and genetic study of the long-termsafety and efficacy of natalizumab

S. Johansson (Stockholm, Sweden)

A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of dimethyl fumarate

L. Forsberg (Stockholm, Sweden)

Real life experience with interruption of natalizumab treatment C.S. Simonsen (Drammen, Norway)

Impact of fingolimod on headache course in a multicenter MS population E. Binello (Turin, Italy)

Long-term effectiveness and safety of natalizumab in a Portuguese cohort I. Correia (Coimbra, Portugal)

Interferon-β therapy and risk of thrombocytopenia in multiple sclerosis patients T. Koudriavtseva (Rome, Italy)

An interim analysis of monthly surveillance 3T MRI in MS patients switching from longterm natalizumab to teriflunomide in a prospective study

K.R. Edwards (Latham, United States)

Characterization of absolute lymphocyte count profiles in MS patients treated withdelayed-release dimethyl fumarate: considerations for patient management

R.J. Fox (Cleveland, United States)

Relapse management in RRMS: real-world characteristics of steroid-treated patients R.J. Fox (Cleveland, United States)

Quantitative comparison of MS patient-reported injection site reactions and flu-likesymptoms with non-pegylated and pegylated subcutaneous interferon beta drugs inNARCOMS

G. Wang (Birmingham, United States)

Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancyoutcomes from clinical trials and postmarketing experience

J. Li (Cambridge, United States)

Modeling probability of cases of dimethyl fumarate-associated PML with normallymphocytes

R. Carruthers (Vancouver, Canada)

Lymphopenia in patients on dimethyl fumarate (DMF): data from the providencemultiple sclerosis center

K.E. Smoot (Portland, United States)

Pregnancy outcomes after exposure to fingolimod and in the general population Y. Geissbühler (Basel, Switzerland)

Diagnostically challenging PML: case of a small unifocal lesion with mild radiologicalprogression and CSF negative for JCV DNA and antibodies

M.H. Hyland (Rochester, United States)

Page 41 / 114


Risk of cancer in multiple sclerosis patients who developed high concentrations ofneutralizing antibodies against interferon-beta

N. Koch-Henriksen (Aarhus, Denmark)

Comparative analysis of oral disease-modifying therapies after natalizumabwithdrawal in patients with multiple sclerosis

N. Hadhoum (Lille, France)

Variability of John Cunningham virus (JCV) index in multiple sclerosis patients treatedwith natalizumab in routine clinical practice

N. Arndt (Chicago, United States)

Longitudinal anti-JCV antibody titres increase with natalizumab treatment J. Raffel (London, United Kingdom)

Post-natalizumab relapses and MRI activity do not predict long-term disabilityoutcomes

J. Raffel (London, United Kingdom)

Severe relapses and rebound activity after natalizumab discontinuation in MSpatients with more than five years of treatment with stable disease course

J. Fagius (Uppsala, Sweden)

Dynamics of Th17 cells during and after cessation of natalizumab therapy B. Wildemann (Heidelberg, Germany)

Disease activity after natalizumab discontinuation: a retrospective study from twoItalian MS centers

M. Lo Re (Palermo, Italy)

Natalizumab treatment is associated with increased anti-JCV antibody seroconversion T. Schneider-Hohendorf (Muenster, Germany)

The long-term impact of natalizumab on multiple sclerosis: to continue or to stop? F. Sangalli (Milano, Italy)

Persistent lymphopenia after routine clinical use of dimethyl fumarate for relapsingremitting multiple sclerosis

N.J. MacDougall (Glasgow, United Kingdom)

Efficacy of fingolimod on NEDA-4 in pooled FREEDOMS and FREEDOMS II studies bysubgroups of baseline characteristics

M.S. Freedman (Ottawa, Canada)

Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiplesclerosis using a composite measure of disability: integrated analysis of the phase 3DEFINE and CONFIRM studies

A. Bar-Or (Montreal, Canada)

Correlation of brain volume and physical measures with cognitive function usingbaseline data from the anti-LINGO-1 SYNERGY trial in multiple sclerosis

D. Cadavid (Cambridge, United States)

Sema4A as a biomarker for personalized therapy of multiple sclerosis T. Koda (Osaka, Japan)

Page 42 / 114


A lesion topography-based approach to refine the value of new active lesions inpredicting response to interferon beta in multiple sclerosis


Real-world effectiveness of natalizumab and fingolimod compared with injectabledrugs in non-responders and in treatment-naïve patients with multiple sclerosis


Ambulatory motor fatigue in MS assessed by wearable inertial sensor metrics duringthe six minute walk

H.J. Witchel (Brighton, United Kingdom)

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - resultsof the placebo-controlled, double-blind, phase III ORATORIO study

X. Montalban (Barcelona, Spain)

Immunomodulatory therapy slows accumulation of disability in moderately advancedmultiple sclerosis

T. Kalincik (Melbourne, Australia)

Increasing levels of disability on objective measures of ambulation and upperextremity function are associated with increasing levels of patient-reportedimpairment in secondary progressive multiple sclerosis patients: baseline data fromASCEND

D. Steiner (Cambridge, United States)

Improvement in relapse outcomes following switch from subcutaneous interferonbeta-1a to alemtuzumab: CARE-MS II extension study

B. Kieseier (Düsseldorf, Germany)

Off-label rituximab in patients with secondary progressive multiple sclerosis Y. Naegelin (Basel, Switzerland)

Comparative gene expression profiling between Glatopa? and Copaxone® J. D’Alessandro (Cambridge, United States)

Use of multiple, high resolution, orthogonal assays for demonstration of biologicaland immunological equivalence of Glatopa? and Copaxone®

J. D’Alessandro (Cambridge, United States)

Progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate N.M. Dammeier (Tuebingen, Germany)

The state of MS: treatment goals and challenges M. Tintoré (Barcelona, Spain)

Persistence and adherence to immunomodulators varies between Canadian provinces C. Evans (Saskatoon, Canada)

The impact of adherence to immunomodulators on hospitalisations in multiplesclerosis

C. Evans (Saskatoon, Canada)

Page 43 / 114


Comparing dimethyl fumarate efficacy and tolerability among Caucasian-, African-and Hispanic-American MS patients

L. Zhovtis Ryerson (New York, United States)

Pharmacokinetics, safety and tolerability of single-dose siponimod (BAF312) insubjects with renal impairment versus matched healthy controls

A. Gardin (Basel, Switzerland)

Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis(SPMS): baseline characteristics of the EXPAND study population


Effect of laquinimod, a novel immunomodulator in development for treatment ofmultiple sclerosis, on cardiac repolarization in healthy subjects: a thorough QT/QTcstudy

A. Elgart (Netanya, Israel)

Inmunomodulator skin reactions: do anthropometric characteristics and lifestyleinfluence?

M. Rus-Hidalgo (Seville, Spain)

Fingolimod efficacy in second-line treatment for RRMS: treatment outcome isindependent from previous MRI or clinical activity

M. Merschhemke (Basel, Switzerland)

Factors associated with continuation of treatment with IFN ß-1a givensubcutaneously three times a week: a US retrospective cohort study

M. Sabidó-Espin (Darmstadt, Germany)

Disease-modifying therapy improved depression symptoms in multiple sclerosispatients: the POSIDONIA study

E. Montanari (Fidenza, Italy)

Enhanced migration of CD56bright NK cells across hCMEC/D3 in interferon-beta-1atreated multiple sclerosis patients

A. Harrer (Salzburg, Austria)

Differences in patient characteristics, disease-modifying treatment utilization, andrelapse by race/ethnicity in Texas medicaid patients with multiple sclerosis

J.J. Ko (East Hanover, United States)

Omega-3, Omega-6 PUFA and γ-Tocopherol in multiple sclerosis: PLP10 interventionefficacy and red blood cells' membrane lipids composition

I.S. Patrikios (Nicosia, Cyprus)

Cost-effectiveness of First-line disease-modifying treatments for relapsing-remittingMS

E. Soini (Kuopio, Finland)

Pharmacokinetics of a CNS-penetrating, putative remyelinating human monoclonalantibody, rHIgM22, in a Phase 1 clinical trial in patients with stable multiple sclerosis(MS)

A. Eisen (Ardsley, United States)

Page 44 / 114


Equimolar mixture of 50% oxygen and nitrous oxide inhalation reduces pain duringlumbar puncture: a randomized control trial

M.A. Sia (Clermont Ferrand, France)

Therapeutic software for the treatment of fatigue, depression and anxiety in multiplesclerosis

M. Weiss (Hamburg, Germany)

Prolonged-release fampridine treatment improved patient-reported impact ofmultiple sclerosis: item-level analysis of the MSIS-29

C. Gasperini (Rome, Italy)

The effect of different assistive devices on gait and walking in persons with multiplesclerosis-related walking difficulty

D.A. Barone (Stratford, United States)

Objective and subjective impact of dalfampridine on ambulation in multiple sclerosis S. Klineova (New York, United States)

THC:CBD oromucosal spray in multiple sclerosis spasticity: end of treatment,frequency, reasons and moments

J. Koehler (Berg, Germany)

Effectiveness of THC:CBD oromucosal spray in multiple sclerosis spasticity. First datafrom a large observational study in Italy

M. Trojano (Bari, Italy)

TRPV1 and TRPA1 activators reduce muscle cramping. Potential new treatment for MSsymptoms

B.W. Hegarty (Boston, United States)

Use of patient case scenarios to assess current practice patterns of MS relapseassessment and treatment among MS specialists in the United States

A. Javed (Chicago, United States)

A double blind clinical trial of the effect of coenzyme Q10 on oxidative stress,depression and fatigue in multiple sclerosis patients

F. Seifar (Tabriz, Iran, Islamic Republic of)

Longterm discapacity progression in MS patients treated with fampridine F.A. Rodriguez-Leal (Dresden, Germany)

PR-Fampridine improves walking and quality of life in people with severe MS-relatedwalking impairment

R. Ewe (London, United Kingdom)

High-dose intravenous methylprednisolone induced hepatotoxicity in multiplesclerosis patients: three case reports

M. Hidalgo de la Cruz (Madrid, Spain)

Differences in use and perceptions on effectiveness of marijuana for MS: a survey ofNARCOMS participants

S.S. Cofield (Birmingham, United States)

Page 45 / 114


Remotely-supervised cognitive remediation is feasible and effective: results of a pilotstudy

L.E. Charvet (Stony Brook, United States)

Using techniques of positive psychology as an intervention to address the challengesof living with MS: an examination of the National MS Society's Everyday Matters:living your Best Life Program

K. Koch (Denver, United States)

A revolutionary new way of looking at the link between quality of life (QoL) andmultiple sclerosis (MS) progression

R. Devy (Saumur, France)

The relationship between beliefs about illness causes and well-being among personswith multiple sclerosis and their caregivers

M. Falautano (Milano, Italy)

Impact of walking impairment on healthcare resource utilisation in multiple sclerosispatients: an updated analysis from 2015

Y. Liu (Cambridge, United States)

Daclizumab HYP reduced psychological impact of multiple sclerosis versusintramuscular interferon beta-1a in the DECIDE trial

B. Turner (London, United Kingdom)

Relapse rates and quality of life among patients receiving disease modifying therapyfor multiple sclerosis

S. Naoshy (Cambridge, United States)

Suboptimal disability measurement in multiple sclerosis clinical trials: limitations ofexisting patient-reported outcomes measures

S. Naoshy (Cambridge, United States)

Work, fatigue and cognition: a correlational analysis using the QUIPSEP, a cognitiveergonomic questionnaire for work holding in multiple sclerosis patients

G. Delrue (Liège, Belgium)

The impact of urinary dysfunction in multiple sclerosis: rasch analysis of the SF-Qualiveen

K. Milinis (Liverpool, United Kingdom)

Study of subclinical oculomotor disturbances by video oculography in patients withclinically isolated syndromes

A. Ferraro (Montpellier, France)

Difference in recovery from optic neuritis between neuromyelitis optica and multiplesclerosis patients

H. Masuda (Chiba, Japan)

Failure of smooth pursuit as a marker of early multiple sclerosis N.S. Lizak (Melbourne, Australia)

The Pulfrich Phenomenon: a signature of visual system pathophysiology in multiplesclerosis

R. Agarwal (Dallas, United States)

Page 46 / 114


Retinal oximetry: a novel visual biomarker of retinal metabolic dysfunction in MS S.C. Beh (Dallas, United States)

Neuromyelitis optica spectrum disorders in Algeria M. Bouzar (Tizi-Ouzou, Algeria)

Dyschromatopsia in multiple sclerosis points to retinal ganglion cell damage E.H. Martinez-Lapiscina (Barcelona, Spain)

20/40 or better visual acuity after optic neuritis: not as good as we once thought! R.C. Nolan (New York, United States)

CSF biomarker levels of inflammation and degeneration in relapsing MS followingswitch to fingolimod from other disease modifying therapies

M. Axelsson (Gothenburg, Sweden)

Platelet-derived genes are altered in MS patients M. Axelsson (Gothenburg, Sweden)

Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treatedwith natalizumab or mitoxantrone

M. Axelsson (Gothenburg, Sweden)

Can optic nerve MTR and OCT distinguish between multiple sclerosis andneuromyelitis optica?

L. Magnolay (London, United Kingdom)

Combination of YKL-40 and GFAP in CSF predicts disability progression in relapsing-remitting forms of multiple sclerosis

M. Mañé-Martínez (Tarragona, Spain)

Glial and neuronal markers in cerebrospinal fluid in different multiple sclerosis types M. Mañé-Martínez (Tarragona, Spain)

Autoantibodies to myelin-oligodendrocyte glycoprotein antibodies in a smallproportion of adult multiple sclerosis patients

T. Kümpfel (München, Germany)

Multiple sclerosis clinical characteristics in molecularly-defined patient populations A. Enayetallah (Cambridge, United States)

Molecular markers predicting JCV-antibody switch in natalizumab treated multiplesclerosis patients

A. Achiron (Tel Hashomer, Israel)

Clinically suspected neuromyelitis optica associated to anti-MOG antibodies L.M.O. de Paula Salles (Sao Paulo, Brazil)

Analysis of lymphocytic DNA damage in early multiple sclerosis by automated gamma-H2AX and 53BP1 foci detection

L. Rasche (Berlin, Germany)

Cerebrospinal fluid kynurenines in multiple sclerosis: relation to disease course andneurocognitive symptoms

S. Ståhl (Solna, Sweden)

Page 47 / 114


Cerebrospinal fluid lactic dehydrogenation enzyme levels in acute attacks ofinflammatory demyelinating diseases

S. Nishiyama (Sendai, Japan)

From genetic variations to plasma cytokine receptor levels during MS treatment S.K. Bedri (Stockholm, Sweden)

Relationships between CSF biomarkers of inflammation and degeneration in RRMSare also found in healthy controls

L. Novakova (Gothenburg, Sweden)

The urine proteome profile is different in neuromyelitis optica compared to multiplesclerosis

H.H. Nielsen (Odense C, Denmark)

Cerebrospinal fluid and serum levels of interleukin-6, interleukin-8, interleukin-10,beta-2-microglobulin and orosomucoid at the time of first clinical symptoms in MSpatients

Z. Matejčíková (Olomouc, Czech Republic)

Galectin 8 autoantibodies are associated with relapsing remitting phenotype ofmultiple sclerosis and with higher disability scores

E. Ciampi (Santiago, Chile)

Serum neurofilament light chain levels are associated with brain atrophy in early MS -analysis from the randomized controlled phase II trial of riluzole in early MS

S. Gnanapavan (London, United Kingdom)

Cerebrospinal fluid/serum CXCL13 ratio: an early prognostic marker of conversion toclinically definite multiple sclerosis

I. Dujmovic (Belgrade, Serbia)

Predicting optimal response to B-cell depletion with rituximab in multiple sclerosisusing biomarkers

E. Alvarez (Aurora, United States)

Specificity of serum and cerebrospinal fluid chitinase-3 like protein 1 (CHI3L1) formultiple sclerosis diagnosis

E. Thouvenot (Nîmes, France)

Adipokines in multiple sclerosis and clinically isolated syndrome: a follow-up study S. Hagman (Tampere, Finland)

The link between thalamic volume and cognition in multiple sclerosis is mediated bypremorbid intelligence

J.F. Sumowski (West Orange, United States)

Corpus callosum structural changes associated with Kawashima Nintendo BrainTraining in patients with multiple sclerosis

L. De Giglio (Rome, Italy)

Proposal for a new measure of cognitive fatigability derived from Symbol DigitModalities Test: the Information Processing Speed Deceleration Index (IPSDI)

L. De Giglio (Rome, Italy)

Page 48 / 114


Cognitive rehabilitation in MS. Evidence for neuroplasticity. A fMRI study J. Campbell (Brighton, United Kingdom)

The utility of BICAMS in detecting cognitive impairment in the outpatient clinic.Associations with employment and quality of life measures

J. Campbell (Brighton, United Kingdom)

Functional connectivity and frequency-specific variability of cognitive networks inprimary-progressive MS

M. Inglese (New York, United States)

Association of cognitive impairment with optical coherence tomography and magneticresonance imaging changes in multiple sclerosis patients

N. Giedraitiene (Vilnius, Lithuania)

Hippocampal microstructural damage and memory impairment in clinically isolatedsyndrome

V. Planche (Bordeaux, France)

Structural MRI substrates of cognitive impairment in neuromyelitis optica Y. Liu (Beijing, China)

White matter tract abnormalities are associated with cognitive dysfunction insecondary progressive multiple sclerosis

K.A. Meijer (Amsterdam, Netherlands)

Cerebellar sub-structures in cognitive impairment: volumetric and microstructuralanalyses at different stages of multiple sclerosis

A. Moroso (Bordeaux, France)

An improved computerized symbol digit modalities test: introducing distracters V.P. Patel (Toronto, Canada)

The sound lateralization test demonstrates slowed processing speed in MS patientswith minimal to mild disability and shows no learning effects in multiple testingsessions over a 1-year period

J. Bacon (New York, United States)

Cognitive evolution in Tysabri treated multiple sclerosis patients F. Jacques (Gatineau, Canada)

Poster Sessions, Poster Exhibition15:45 - 17:00 e-Poster Session 1

LOMS vs. other diseases: the consequence of ¨to be or not to be¨ M.C. Curbelo (CABA, Argentina)

Asymptomatic spinal cord lesions in patients with clinically isolated syndrome M. Prieto León (Sevilla, Spain)

Epidemiology of neuromyelitis optica at the Instituto Neurológico de Colombia in aten-year period: a retrospective analysis

I.C. Restrepo (Medellín, Colombia)

Page 49 / 114


Neuromyelitis optica spectrum disorders and polyautoimmunity A.S. Correia (Oxford, United Kingdom)

Targeting AQP4 in neuromyelitis optica spectrum disorders in clinical practice.Comparison of different assays

C. Tortorella (Bari, Italy)

Neuromyelitis optica and anti-aquaporin 4 status in Brazilian patients: is it reallyrelevant?

V.R. Guedes (Niteroi, Brazil)

Bilateral optic neuritis in the context of Crohn's disease, aggravated by infliximab R. Robles (Girona, Spain)

Neuromyelitis optica clinical manifestations in a Brazilian population M.F. Xavier (Niteroi, Brazil)

Highly active MS in a 13-year-old young girl: is Alemtuzumab therapy a reasonableoption?

D.L. Dive (Esneux, Belgium)

Clinical and laboratory features of pediatric MS progression E. Skripchenko (St.Petersburg, Russian Federation)

JCV seroprevalence in paediatric multiple sclerosis patients in Poland M. Bilska (Warsaw, Poland)

Vitamin D deficiency and vitamin D receptor polymorphisms as the enviromental riskfactors for paediatric multiple sclerosis in Poland

M. Bilska (Warsaw, Poland)

Demographic and clinical aspects of pediatric and adolescent multiple sclerosis inGreece: lower presence of pediatric prevalence, primary progressive typepresentation and expanded disability status scale (EDSS) progression rate

S. Katsavos (Athens, Greece)

Prevalence and HLA class II associations with neuromyelitis optica (NMO) among theMuslims Arabs in Israel

L. Brill (Jerusalem, Israel)

Epidemiological characteristics of multiple sclerosis in the town of Kielce (centralPoland ) - ten years of prospective observation (2003 -2012)

A. Potemkowski (Szczecin, Poland)

Familial autoimmunity and polyautoimmunity among Turkish cypriot multiplesclerosis patients

S. Usar Incirli (Nicosia, Cyprus)

Month of birth as a risk of multiple sclerosis C. Oreja-Guevara (Madrid, Spain)

Association of primary pulmonary fibrosis and multiple sclerosis: a report of 2 cases W. Sheremata (Miami, United States)

Page 50 / 114


Multiple sclerosis prevalence in northern Black Sea Region, Karabük,Turkey Ü. Türk Börü (Istanbul, Turkey)

Lower socioeconomic status and increased risk for disability in multiple sclerosis J.F. Sumowski (West Orange, United States)

SymptoMScreen: a novel tool for rapidly assessing MS symptom severity in 11domains

R. Green (New York, United States)

Multiple sclerosis & sleep disorders: sleep disordered breathing - apnea hypopneaindex non-REM versus REM in a community cohort of people with multiple sclerosiswho report fatigue - more than just a bad night sleep


Multiple sclerosis, quality of life and EDSS: a walking scale with no quality of life M. Gudesblatt (Patchogue, United States)

Multiple sclerosis and fatigue: motor skills are independently associated withsubjective sense of patient reported fatigue


The relationship between depression, anxiety and cognition over the course ofmultiple sclerosis

S.M. Rubin (Evanston, United States)

The impact of fampridine on fatigue, cognitive function, mood and quality of life M. Baruca (Ljubljana, Slovenia)

Validation of the MS performance test walking and balance tests: preliminary results S. Rao (Cleveland, United States)

Developing the Guy's Neurological Scale (GNDS) in 28 languages B. Sharrack (Sheffield, United Kingdom)

Correlation of the VEMP score and ambulation in clinically isolated syndrome L. Crnošija (Zagreb, Croatia)

Current MS relapse assessment practices determined by a modified Delphi process E. Havrdová (Prague, Czech Republic)

Baroreceptor sensitivity by the sequence technique is retained in early-treated butnot late-treated multiple sclerosis - a non-invasive autonomic function analysis

E. Barin (Sydney, Australia)

Evaluation of manual skills / hand function and their impact on EDSS in multiplesclerosis

M. Oztekin (Ankara, Turkey)

Natural and treated multiple sclerosis course: a historical model on benefits andcosts

G. Iuliano (Salerno, Italy)

Page 51 / 114


Treatment patterns and costs among patients with multiple sclerosis treated withprolonged-release fampridine in Germany

A. Lee (Cambridge, United States)

Differences in work productivity activity impairment in RRMS patients initiated onoral DMF or platform therapies in Europe and the US

R. Iyer (Cambridge, United States)

Neural cell adhesion molecules in acute optic neuritis: relation to clinical andparaclinical findings

J.L. Frederiksen (Copenhagen, Denmark)

The impact of detoxifying and repair gene polymorphisms and the levels of serum rosin the susceptibility to multiple sclerosis: a hospitalbased case-control study

G. Orhan (Ankara, Turkey)

Capparis ovate ameliorates experimental allergic encephalomyelitis model of multiplesclerosis in C57BL/6 mice

A. Sen (Denizli, Turkey)

Treatment with Nabiximols induces short-term and long-term transcriptional changesat peripheral level in patients with multiple sclerosis

F. Martinelli Boneschi (Milan, Italy)

Resequencing of the genes proposed to be associated to multiple sclerosis in theGWAS 2011 (Nature) in Basque-MS families and the microRNAs inside these loci

I. Osorio-Querejeta (San Sebastian, Spain)

HLA-G 3' untranslated region polymorphisms are associated with neuromyelitis optica R.B. Souza (Botucatu, Brazil)

Whole transcript profile after intravenous methylprednisolone administration inpatients with remittent-recurrent multiple sclerosis

L.A. López-Fernández (Madrid, Spain)

Genomic host factors for developing PML N. Breuil (Toulouse, France)

Genetic markers of multiple sclerosis susceptibility have no effect on diseaseoutcome

D. Vecchio (Novara, Italy)

Anti-JCV antibodies in a Spanish multiple sclerosis cohort M.I. Dominguez-Mozo (Madrid, Spain)

The CSF JCV antibody index for diagnosis of asymptomatic progressive multifocalleukoencephalopathy

C. Warnke (Duesseldorf, Germany)

EBV and Mycobacterium avium subsp. paratuberculosis peptides induce a diffuseimmune response against myelin basic protein and human interferon regulatoryfactor 5 in MS patients

J. Frau (Cagliari, Italy)

Page 52 / 114


Human fat microvascular pericytes ameliorate experimental autoimmuneencephalomyelitis

P. Dore-Duffy (Detroit, United States)

Improved probabilistic segmentation of white matter lesions in multiple sclerosis E. Lommers (Liege, Belgium)

Neurovascular reactivity in patients with clinically isolated syndrome N. Uzuner (Eskisehir, Turkey)

A toolbox for segmenting multiple sclerosis lesions using T1w and FLAIR images X. Llado (Girona, Spain)

Evaluating the relationship between brain volume and patient reported outcomesusing clinical and imaging parameters collected in the routine care of MS patients

J.M. Honce (Aurora, United States)

Quantitative proton MR spectroscopy of lesion evolution in relapsing-remittingmultiple sclerosis

I. Kirov (New York, United States)

White matter integrity during fingolimod therapy as determined by diffusion tensormagnetic resonance imaging

K.E. Sakaie (Cleveland, United States)

Use of quantitative susceptibility mapping (QSM) in progressive multifocalleukoencephalopathy

C. Carra-Dalliere (Montpellier, France)

A French observational study about treatment failure under fingolimod in 91 multiplesclerosis patients

C. Carra-Dalliere (Montpellier, France)

INSPIRATION-MRI: standardized acquisition and centralized quantitative reading ofMRI scans of RRMS patients in German daily clinical practice

A. Gass (Mannheim, Germany)

Heterogeneity of susceptibility mapping of cortical lesions in MS M. Castellaro (Padova, Italy)

Brainstem dysfunction protects against syncope in multiple sclerosis M. Habek (Zagreb, Croatia)

Correlation of VEMP score and upper limb dysfunction in clinically isolated syndrome I. Adamec (Zagreb, Croatia)

Frequency spectrum pattern of postural oscillatory movement in multiple sclerosisusing an accelerometer: a pilot study

I. Stetkarova (Prague, Czech Republic)

Neuroinflammation, cortical excitability and epileptogenesis in patients with multiplesclerosis: does a link exist?

M. Albanese (Rome, Italy)

Page 53 / 114


Fingolimod favors the migration of T cells toward the CNS without interfering withtheir anti-viral properties

A. Mathias (Epalinges, Switzerland)

Alemtuzumab therapy in active multiple sklerosis: retrospective analysis of analternative regimen

P. von Wussow (Hannover, Germany)

Induction of type II (M2) monocytes/macrophages in patients receiving Gilenya B.T. Lund (Los Angeles, United States)

Longterm follow-up of patients treated with mitoxantrone A.C. Daigle (Providence, United States)

Comparative tolerability and efficacy of fingolimod and dimethyl fumarate in clinicalpractice with 12-month follow-up

C.M. Hersh (Cleveland, United States)

Pharmacokinetics, pharmacodynamics and tolerability of an innovative pegylatedinterferon beta-1a BCD-054 in healthy volunteers

M. Nikolskaia (Saint-Petersburg, Russian Federation)

Evolution of therapeutic practices in real world A. Fromont (Dijon, France)

MT-1303, a novel sphingosine 1-phosphate (S1P) receptor modulator, amelioratesexperimental autoimmune encephalomyelitis (EAE) in mice

H. Kataoka (Yokohama, Japan)

Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiplesclerosis in prior interferon users with low clinical disease activity: integratedanalysis of the phase 3 DEFINE and CONFIRM studies

O. Fernández (Málaga, Spain)

Comparison of physicochemical, biological and genomic characteristics of differentlymanufactured glatiramoids to ensure MS patient safety

A. Komlosh (Netanya, Israel)

Pre-clinical studies and evaluation of treatment need of glatiramer acetate depot N. Bleich-Kimelman (Ness Ziona, Israel)

Experimental autoimmune encephalomyelitis induced by passive transfer ofpolymerase 1 silent lymphatic node cells: verification of a novel therapeutic approachin multiple sclerosis

M. Gurevich (Ramat-Gan, Israel)

Clincial experience with fingolimod for relapsing-remitting multiple sclerosis inAsturias and Cantabria (SPAIN). An independent, retrospective multicenter clinicalstudy

A. Oterino (Santander, Spain)

Severe bradycardia: an unreported adverse event of alemtuzumab treatment E. Nerrant (Nîmes, France)

Page 54 / 114


Natalizumab: passage into breast milk and neonatal blood U. Hainke (Dresden, Germany)

Spanish Registry of patients with multiple sclerosis treated with fingolimod (GILENYARegistry): safety and effectiveness after three years of registry


Voxel-wise magnetization transfer imaging study of effects of fingolimod (Gilenya®)on remyelination and demyelination in patients with relapsing forms of multiplesclerosis


Fingolimod (FTY720, Gilenya) inhibits brain atrophy and enhances CNS-derived BDNFexpression during a pre-clinical model of chronic neuroinflammation

P. Smith (Basel, Switzerland)

Improvement of EDSS in a subset of Japanese MS patients treated with fingolimod: apossible association with remyelination

J. Nakahara (Tokyo, Japan)

Effect of FTY720 treatment on oligodendrocyte progenitor cell migration following afocal demyelinating injury

E.E. Kelland (Los Angeles, United States)

Relationships among treatment decision making, multiple sclerosis-related symptomsand disease severity: findings from a US web-based patient preference survey


How many injections did you miss last month? A simple question to predict Interferonβ-1a adherence in multiple sclerosis

M. Moccia (Napoli, Italy)

PANGAEA: the average German fingolimod patient. Demographics and baselinecharacteristics from a 5 year non-interventional study of RRMS patients treated withfingolimod

C. Cornelissen (Nuremberg, Germany)

Efficacy and safety of natalizumab treatment for relapsing-remitting multiplesclerosis: interim results of the TYSABRI® Observational Programme in Canada

F. Jacques (Gatineau, Canada)

Adherence to interferon-beta treatment in patients with relapsing-remitting form ofmultiple sclerosis in Serbian district Sumadija

G. Toncev (Kragujevac, Serbia)

Comparison of the humoral and cellular varicella-zoster virus (VZV) immunity duringfingolimod (FTY) treatment of MS patients

S. Matko (Dresden, Germany)

The Delphi method on peginterferon beta-1 injection site reactions and managementstrategies in the relapsing-remitting multiple sclerosis ALLOW study

D. Huang (Akron, United States)

Evolution of anti-JCV antibodies over 3 years of follow-up M. Cambron (Lille, France)

Page 55 / 114


Interim analysis of the START study - extensive electrocardiographic monitoringconfirms the good cardiac safety profile of fingolimod

V. Limmroth (Köln, Germany)

Teriflunomide-induced fatal toxic epidermal necrolysis in a patient with multiplesclerosis

F. Derouiche (Mulhouse, France)

Ischemic stroke with spontaneous multiple cervical artery dissections in a 40-y oldwoman during a first course of alemtuzumab: cause or coincidence?

F. Durand-Dubief (Bron Cedex - Lyon, France)

Real-world fingolimod first-dose effects in patients with pre-existing hypertension,pre-existing cardiac conditions and in those receiving selective serotonin-reuptakeinhibitors

C. LaGanke (Cullman, United States)

Rituximab suppresses disease activity after natalizumab withdrawal: an exploratorystudy

S. Malucchi (Orbassano, Italy)

Health related quality of life in MS is associated with annual household income M.W. Koch (Calgary, Canada)

Assessing the construct validity of BESTest in people with multiple sclerosis C. Irkec (Ankara, Turkey)

Evalution of the relationship between postural imbalance and ataxia with disability inpatients with multiple sclerosis

C. Irkec (Ankara, Turkey)

Predictors of response to fingolimod treatment in an Italian monocentric cohort ofmultiple sclerosis patients

F. Esposito (Milan, Italy)

Early oxidation state for predicting long term response to first-line disease modifyingtherapies in MS

J.L. Ruiz Peña (Sevilla, Spain)

Covariate analysis using item response theory modelling of expanded disabilitystatus scale (EDSS): a case study of cladribine tablets

A. Novakovic (Uppsala, Sweden)

N-MOmentum — study design for a placebo-controlled study of MEDI-551 inneuromyelitis optica

B.A. Cree (San Francisco, United States)

A prospective study evaluating the efficacy and safety of autologous MSC cellsobtained from adipose tissue in the treatment of MS

A. Stępień (Warsaw, Poland)

Efficacy and safety of the combination therapy with rituximab and mycophenolatemofetil in three cases of neuromyelitis optica

P. Bochniak (Grudziadz, Poland)

Page 56 / 114


Repository corticotropin injection relapse treatment in patients with multiplesclerosis and diabetes

C.F. Kutz (Colorado Springs, United States)

Adherence to treatment with fingolimod after switching from interferon beta amongpatients with multiple sclerosis

D. Golan (Haifa, Israel)

Influence of optimized anti-spastic pre-treatment on the efficacy and tolerability ofTHC:CBD oromucosal spray in multiple sclerosis spasticity patients. A post-hoc RCTdata analyses

M. Haupts (Isselburg-Anholt, Germany)

Current practice patterns of MS relapse management among MS specialists in theUnited States: survey results of the MS relapse practice patterns project

O. Khan (Detroit, United States)

Measuring sustained response in a small cohort of fampridine-PR treated personswith multiple sclerosis

S. Jordan (Dublin, Ireland)

Fampridine in clinical practice - experience in a Portuguese center G. Cação (Porto, Portugal)

DIMMI SI - a randomized controlled trial on integrated imaginative distention in MS: aselfmanaged tool to cope with fatigue, stress and insomnia in MS persons. Firstresults

A. Sgoifo (Milano, Italy)

Evaluation of mirabegron tolerability and efficacy in usual clinical practice at anurban MS center

B. Brucker (New York City, United States)

Quality of life (QoL) assessment in multiple sclerosis (MS) patients undergoingautologous hematopoietic stem cell transplantation (AHSCT)

D. Fedorenko (Moscow, Russian Federation)

Quality of life in multiple sclerosis: comparison with Systemic Lupus Erythematosus inan Argentinean population

E. Carnero Contentti (Buenos Aires, Argentina)

Preliminary results of a German non-interventional study over 12 months to evaluatethe relationships between physical activity and course of disease and patient-reported outcomes in multiple sclerosis patients treated with interferon ß-1b

J. Koehler (Berg, Germany)

Doctor´s and patient´s perceptions of quality of life in Argentinean multiple sclerosispatients

M.C. Ysrraelit (Buenos Aires, Argentina)

A comparison of adults with MS and healthy controls on self-esteem, self-efficacy,mood and quality of life

M. Messmer Uccelli (Genoa, Italy)

Impact of sense of coherence on quality of life in Slovenian multiple sclerosis patients B. Stern (Maribor, Slovenia)

Page 57 / 114


Intrathecal synthesis of immunoglobulin free light chains in clinically isolatedsyndrome predicts conversion to multiple sclerosis and disability level in two yearsfollow-up

G. Makshakov (Saint-Petersburg, Russian Federation)

Increased expression of miR-130b-5p in B cells and its modulation by Glatirameracetate in multiple sclerosis

K.E. Balashov (New Brunswick, United States)

Uric acid as a marker of response to treatment in relapsing-remitting multiplesclerosis

I. Azkune Calle (Galdakao, Spain)

The association between plasma chitotriosidase concentration and the diseaseactivity in patients with MS

R. Abolfazli (Tehran, Iran, Islamic Republic of)

Existence and significance of antibody against the inward rectifying potassiumchannel KIR4.1 in patients with multiple sclerosis in western part of Turkey

E. İdiman (Izmir, Turkey)

Serum prolactin levels in multiple sclerosis, neuromyelitis optica and clinicallyisolated syndrome patients

E. Tuzun (Istanbul, Turkey)

Hot Topic Sessions, Hall A17:00 - 17:45 Hot Topic 3 Early multiple sclerosis

ChairsM.P. Amato (Florence, Italy)J. Hillert (Stockholm, Sweden)

17:00 - 17:15 Brain compensatory mechanisms and cognition in early multiple sclerosis B. Audoin (Marseille, France)

17:15 - 17:30 Big MS data contribution in early MS M. Trojano (Bari, Italy)

17:30 - 17:45 Baseline CSF NfL levels in CIS and their association with mid-term brain volumechanges: a step towards predicting the extent of axonal loss?

G. Arrambide (Barcelona, Spain)

Hot Topic Sessions, Hall B17:00 - 17:45 Hot Topic 2 MS care 3.0

ChairsS. Vukusic (Bron, France)T. Ziemssen (Dresden, Germany)

Page 58 / 114


17:00 - 17:15 Tools to improve shared-decision making A. Solari (Milan, Italy)

17:15 - 17:30 Telerehabilitation in MS M. Mäurer (Bad Mergentheim, Germany)

17:30 - 17:45 Online fatigue management program for patients with multiple sclerosis - arandomized controlled trial

J. Poettgen (Hamburg, Germany)

Hot Topic Sessions, Hall C17:00 - 17:45 Hot Topic 1 New players in MS immunopathogenesis

ChairsH.-P. Hartung (Düsseldorf, Germany)A. Prat (Montreal, Canada)

17:00 - 17:15 Regulatory cell populations S. Issazadeh-Navikas (Copenhagen, Denmark)

17:15 - 17:30 NK cells in multiple sclerosis: on the border of innate and adaptive immunity M. López-Botet (Barcelona, Spain)

17:30 - 17:45 DICAM: a novel molecular effector in neuroinflammation S. Ghannam (Montreal, Canada)

Satellite Symposia, Hall B18:00 - 19:00 Satellite Symposium: THC:CBD daily practice evidence in MS

spasticity management: the moment of large databases

Almirall S.A.

ChairsM. Trojano (Bari, Italy)

18:00 - 18:15 THC:CBD in daily practice: UK, Germany and Spain available data O. Fernández (Málaga, Spain)

18:15 - 18:30 New THC:CBD observational study data: resistent MS spasticity and associatedsymptoms evolution


18:30 - 18:45 Health Authorities data collection: AIFA web registry, figures after 1.5 years. F. Patti (Catania, Italy)

18:45 - 19:00 Q&A, conclusions and closure M. Trojano (Bari, Italy)

Page 59 / 114


Satellite Symposia, Hall A19:15 - 20:15 Satellite Symposium: Breaking down the walls in Multiple Sclerosis?

Teva Pharmaceuticals Europe

19:15 - 19:20 New challenges in MS

19:20 - 19:35 Working out the challenges faced by MS patients versus neurologists

19:35 - 19:50 Bringing new therapies to people with MS: The case of glatiramer acetate injection 40mg tiw

19:50 - 20:05 Glatiramer acetate 40 mg tiw: The real life experience

20:05 - 20:15 Take home messages

Page 60 / 114


Friday, 09 October 2015

Satellite Symposia, Hall B08:00 - 09:00 Satellite Symposium: Shifting Perspectives: Neuromyelitis Optica

Spectrum Disorder (NMOSD) Pathogenesis, Diagnosis, andTreatment

Alexion Pharmaceuticals Inc.

ChairsD.M. Wingerchuk (Scottsdale, United States)

08:00 - 08:05 Welcome and Introductions D.M. Wingerchuk (Scottsdale, United States)

08:05 - 08:20 NMOSD: Current and Future Research in Understanding Pathology and Mechanism ofDisease

A. Verkman (San Francisco, United States)

08:20 - 08:35 NMOSD: Current Status and Future Directions in Diagnosis and Prognosis D.M. Wingerchuk (Scottsdale, United States)

08:35 - 08:50 Therapeutic Approaches in NMOSD J. Palace (Oxford, United Kingdom)

08:50 - 09:00 Q&A - Full Panel Discussion

Free Communications, Hall A09:15 - 10:15 Free Communications Platform presentations

ChairsR.J. Fox (Cleveland, United States)A.E. Miller (New York, United States)

09:15 - 09:27 Alemtuzumab slows brain volume loss over 5 years in patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years:CARE MS I and II extension study


09:27 - 09:39 Durable efficacy of Aaemtuzumab on clinical outcomes over 5 years in treatment-naive patients with active relapsing-remitting multiple sclerosis with most patientsnot receiving treatment for 4 years: CARE-MS I extension study


09:39 - 09:51 MRI measures and disability progression in PPMS: analysis of the PROMiSe clinicaltrial dataset

M.W. Koch (Calgary, Canada)

09:51 - 10:03 Microglial activation correlates with disease progression in multiple sclerosis E. Rissanen (Turku, Finland)

Page 61 / 114


10:03 - 10:15 Post-mortem validation of MRI cortical volume measurements in MS R. Klaver (Amsterdam, Netherlands)

Free Communications, Hall B09:15 - 10:15 Free Communications Platform presentations

ChairsP. Duquette (Montréal, Canada)L. Ramió-Torrentà (Girona, Spain)

09:15 - 09:27 The effect of rhythmic cued motor imagery on walking, fatigue and quality of life inpeople with multiple sclerosis

B. Seebacher (Eastbourne, United Kingdom)

09:27 - 09:39 The effect of spaced presentation on recall and understanding of medication riskinformation in MS

D. Langdon (Egham, United Kingdom)

09:39 - 09:51 Vulnerability of dentate gyrus to microglial activation leads to early memoryimpairment in a model of multiple sclerosis

V. Planche (Bordeaux, France)

09:51 - 10:03 Treatment outcomes with rituximab in 100 patients with neuromyelitis optica:influence of FCGR3A polymorphism on the therapeutic response to rituximab

H.J. Kim (Goyang, Korea, Republic of)

10:03 - 10:15 Cognitive impairment differs between neuromyelitis optica spectrum disorder andmultiple sclerosis

S.-H. Kim (Goyang, Korea, Republic of)

Free Communications, Hall C09:15 - 10:15 Free Communications Platform presentations

ChairsF. Selleberg (Copenhagen, Denmark)K. Selmaj (Lodz, Poland)

09:15 - 09:27 Visual information processing speed and the damage to posterior visual pathway inmultiple sclerosis

I. Gabilondo (Bilbao, Spain)

09:27 - 09:39 Exploring the role of mtDNA variation in multiple sclerosis in a large cohort ofdiscordant monozygotic twins

L.A. Gerdes (München, Germany)

09:39 - 09:51 During MS attacks diverse populations of B cells migrate from the periphery to theCNS compartment

H.-C. von Büdingen (San Francisco, United States)

Page 62 / 114


09:51 - 10:03 Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervoussystem

J. Zhang (Detroit, United States)

10:03 - 10:15 Anti-LINGO-1 monoclonal antibody BIIB033 improves optic nerve latency in acuteoptic neuritis: primary efficacy analysis of the RENEW study

O. Aktas (Düsseldorf, Germany)

Parallel Sessions, Hall A10:45 - 12:15 Parallel Session 7 Will MS be prevented?

ChairsJ.C. Álvarez-Cermeño (Madrid, Spain)G. Edan (Rennes, France)

10:45 - 11:05 Environmental factors J. Correale (Buenos Aires, Argentina)

11:05 - 11:25 Modulating microbiota: friend or foe? R. Hohlfeld (Munich, Germany)

11:25 - 11:37 Polyunsaturated fatty acids and the risk of multiple sclerosis K. Bjørnevik (Bergen, Norway)

11:37 - 11:49 Onset of comorbidities prior to multiple sclerosis - a nationwide study in Denmark A. Thormann (Copenhagen, Denmark)

11:49 - 12:01 Common genetic contributions of MS risk are found in hispanic Americans with MS L. Amezcua (Los Angeles, United States)

12:01 - 12:13 Evidence of preclinical disease activity - a prospective study on cognitive and physicalperformance prior to first symptom of multiple sclerosis

M. Cortese (Bergen, Norway)

Parallel Sessions, Hall B10:45 - 12:15 Parallel Session 8 MS Clinical phenotypes

ChairsR. Arroyo González (Madrid, Spain)F. Lublin (New York, United States)

10:45 - 11:05 Pros and Cons of the new classification M. Hutchinson (Dublin, Ireland)

11:05 - 11:25 Predicting MS extremes: benign and aggressive M. Tintoré (Barcelona, Spain)

11:25 - 11:37 A significant decrease in the diagnosis of primary progressive multiple sclerosis: acohort study


Page 63 / 114


11:37 - 11:49 Incidence of radiologically isolated syndrome: a population-based study Y. Forslin (Stockholm, Sweden)

11:49 - 12:01 Long term course of apparently benign multiple sclerosis I. Ionescu (Bron, France)

12:01 - 12:13 Novel multiple sclerosis phenotypes influence disability outcomes Y.-C. Lee (Sydney, Australia)

Parallel Sessions, Hall C10:45 - 12:15 Parallel Session 9 MR outcomes in rehabilitation clinical trials

ChairsN. De Stefano (Siena, Italy)I. Penner (Düsseldorf, Germany)

10:45 - 11:05 Measuring brain function in MS P. Matthews (London, United Kingdom)

11:05 - 11:25 MR monitoring of cognitive rehabilitation M. Rocca (Milan, Italy)

11:25 - 11:37 A novel network-based cognitive rehabilitation approach in patients with relapsing-remitting multiple sclerosis and mild cognitive impairment

M. Mitolo (Venice, Italy)

11:37 - 11:49 Measuring resting-state changes in multiple sclerosis patients after aneurorehabilitation program. A feasibility study using classical block-designfunctional magnetic resonance studies

D. Pareto (Barcelona, Spain)

11:49 - 12:01 Effects of gait training on brain plasticity in multiple sclerosis: a functional MRI study N. Bergsland (Milan, Italy)

12:01 - 12:13 Changes in cerebellar functional connectivity after a training with a videogamebalance board in patients with multiple sclerosis

F. Tona (Rome, Italy)

Page 64 / 114


Satellite Symposia, Hall B12:45 - 13:45 Satellite Symposium: MS developments: Transitioning evidence into

clinical practice

Biogen International

An exploration of the factors that drive treatment decisions in MS and how to incorporate currentand future real-world evidence into patient care.

ChairsH.-P. Hartung (Düsseldorf, Germany)X. Montalban (Barcelona, Spain)

Chair's introduction H.-P. Hartung (Düsseldorf, Germany) X. Montalban (Barcelona, Spain)

Weighing-up the evidence with new therapies and new benefits

How can real-world evidence benefit clinical practice? X. Montalban (Barcelona, Spain)

Is real-world evidence any good? H. Butzkueven (Melbourne, Australia)

Closing discussion, audience Q&A

Parallel Sessions, Hall A14:00 - 15:30 Parallel Session 10 Update on therapies

ChairsA. Boyko (Moscow, Russian Federation)C. Tur (London, United Kingdom)

14:00 - 14:20 Treatment algorithms in 2015 O. Fernández (Málaga, Spain)

14:20 - 14:40 Unmet needs in 2015 G. Giovannoni (London, United Kingdom)

14:40 - 14:52 Efficacy and safety of ocrelizumab in relapsing multiple sclerosis - results of theinterferon-beta-1a-controlled, double-blind, Phase III OPERA I and II studies

S.L. Hauser (San Francisco, United States)

14:52 - 15:04 Comparative efficacyof fingolimod versus natalizumab in multiple sclerosis: aprospective multicenter observational study

D.A. Laplaud (Nantes, France)

15:04 - 15:16 A comparison of MS disease activity between patients treated with natalizumab andfingolimod

N. Koch-Henriksen (Aarhus, Denmark)

Page 65 / 114


15:16 - 15:28 Long term outcomes after autologous hematopoietic stem cell transplantation fortreatment of MS

P.A. Muraro (London, United Kingdom)

Parallel Sessions, Hall B14:00 - 15:30 Parallel Session 11 Diagnosis and differential diagnosis: moving

forward

ChairsJ. Geurts (Amsterdam, Netherlands)A. Saiz (Barcelona, Spain)

14:00 - 14:20 Value of cortical lesions in the diagnosis of MS M. Filippi (Milano, Italy)

14:20 - 14:40 Value of autoantibodies in the diagnosis and differential diagnosis of demyelinatingdiseases

M.I. Leite (Oxford, United Kingdom)

14:40 - 14:52 Should we include lesions in the symptomatic region in dissemination in space inpatients with clinically isolated syndromes?

W.J. Brownlee (London, United Kingdom)

14:52 - 15:04 A single symptomatic lesion can determine disease course: a subgroup analysis of1000 patients with clinically isolated syndrome (CIS)

M. Tintoré (Barcelona, Spain)

15:04 - 15:16 The “central vessel sign” on 3T FLAIR* MRI differentiates multiple sclerosis frommigraine

A.J. Solomon (Burlington, United States)

15:16 - 15:28 Defining a clinical, radiological and pathological signature of CLIPPERS (chroniclymphocytic inflammation with pontine perivascular enhancement responsive tosteroids)

W.O. Tobin (Rochester, United States)

Parallel Sessions, Hall C14:00 - 15:30 Parallel Session 12 CNS cells in neurodegeneration

ChairsM. Kerschensteiner (Munich, Germany)R. Liblau (Toulouse, France)

14:00 - 14:20 Altering the crosstalk of the immune and nervous system towards repair F. Zipp (Mainz, Germany)

14:20 - 14:40 Altering the CNS microenvironment during neurodegeneration to promoteremyelination

V.W. Yong (Calgary, Canada)

Page 66 / 114


14:40 - 14:52 Iron rings around plaques of multiple sclerosis patients S. Hametner (Vienna, Austria)

14:52 - 15:04 In vitro Model of multiple sclerosis patient-specific motor neurons from urinary renalepithelial cells using induced pluripotent stem cells

B. Gisevius (Bochum, Germany)

15:04 - 15:16 Increased ongoing axonal injury in spinal normal-appearing white matter in multiplesclerosis as compared to neuromyelitis optica

C. Wegner (Goettingen, Germany)

15:16 - 15:28 Extensive loss of astrocytic monocarboxylate transporter 4 in active lesions ofmultiple sclerosis and neuromyelitis optica

K. Masaki (Fukuoka, Japan)

Poster Sessions, Poster Exhibition15:30 - 17:00 Poster Session 2

Characteristics of a French prospective cohort of 233 clinically isolated syndromepatients and predictive factors of conversion to multiple sclerosis

E. Thouvenot (Nîmes, France)

STAR-MS study: single test to ARrive at MS diagnosis. A prospective, investigatorblinded pilot study, assessing the accuracy of a single 3 Tesla MRI scan in predictingmultiple sclerosis in cases of diagnostic uncertainty: study protocol

A.P. Samaraweera (Nottingham, United Kingdom)

CLIPPERS as a differential diagnosis to multiple sclerosis: evidence from pathologyand 7T MRI

M. Blaabjerg (Odense, Denmark)

Use of multiple biomarkers to improve the prediction of multiple sclerosis in patientswith clinically isolated syndromes

V. Martinelli (Milan, Italy)

Antibody to myelin oligodendrocyte glycoprotein in adults with inflammatorydemyelinating disease of the CNS

S.-M. Kim (Seoul, Korea, Republic of)

Gender effect in the seropositive neuromyelitis optica S.-M. Kim (Seoul, Korea, Republic of)

Development of aquaporin4 antibody binding inhibitor: a preliminary data S.-M. Kim (Seoul, Korea, Republic of)

Glycyrrhizic acid might reduce the NMO-IgG induced cell death by inhibition of thecomplement activation

S.-M. Kim (Seoul, Korea, Republic of)

Novel multiple sclerosis phenotypes are associated with differences in cognitivedisability

A. Fontes-Villalba (Sydney, Australia)

Page 67 / 114


Neuromyelitis optica spectrum disorders: comparison of clinical and MRIcharacteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands

E.D. van Pelt (Rotterdam, Netherlands)

Seasonal variation of acute exacerbations in neuromyelitis optica spectrum disorder W. Kim (Seoul, Korea, Republic of)

Treatment of neuromyelitis optica with rituximab: further insights on efficacy, safetyand dosing regimen from 73 Italian patients

P. Annovazzi (Gallarate, Italy)

Aquaporin-4-autoimmunity and association to systemic lupus erythematosus. Apredominantly population-based study

N. Asgari (Odense, Denmark)

Adult- versus pediatric-onset acute disseminated encephalomyelitis: is there adifference? A retrospective, multi-center cohort study

D.L. Koelman (Boston, United States)

Prognostic factors in a cohort of neuromyelitis optica and neuromyelitis opticaspectrum disorders

A. Orviz-García (Madrid, Spain)

Gastrointestinal tolerability of dimethyl fumarate improves with a four-week titrationin multiple sclerosis

A. Orviz-García (Madrid, Spain)

Neuromyelitis optica spectrum disorders: brain lesions in Venezuelans patients I. Soto (Maracaibo, Bolivarian Republic of Venezuela)

NMO severity is associated with the presence of AQP4-ab L. Campanella (Rio de Janeiro, Brazil)

Comparison of revised 2014 NMO diagnostic criteria vs. 2006 criteria in a pediatricdemyelinating cohort

W. Meador (Birmingham, United States)

Bladder problems in paediatric patients with multiple sclerosis in the early diseasephase

Y.Y.M. Wong (Rotterdam, Netherlands)

Decreased gamma-band oscillations in visual cortex in pediatric MS A.T. Waldman (Philadelphia, United States)

Dissemination in space involving the spinal cord and optic nerves: improvingpredictors for children with relapsing disease in a high NMO-risk, low MS-risk region

T. Thomas (Singapore, Singapore)

Baseline IQ is a robust predictor of 5-year change in SDMT performance in pediatricMS: results from a combination of Canadian and Italian cohorts

N. Akbar (Toronto, Canada)

Alterations in functional and structural connectivity in pediatric-onset multiplesclerosis

N. Akbar (Toronto, Canada)

Page 68 / 114


Assessing exposure to secondhand smoke in pediatric patients with demyelinatingdisease

A.M. Lavery (Philadelphia, United States)

Low levels of participation in vigorous physical activity in youth with multiplesclerosis and the associations with fatigue and depression

S.A. Grover (Toronto, Canada)

Rituximab in paediatric MS J. Salzer (Umeå, Sweden)

Higher incidence of lesions involving the cortex detected in pediatric-onset multiplesclerosis using multimodal MRI

J. Maranzano (Montreal, Canada)

Decreased quality of life in parents of children with MS irrespective of diseaseactivity

J. O'Mahony (Toronto, Canada)

The apoptotic markers in adolescents with remitting relapsing multiple sclerosis O. Bykova (Moscow, Russian Federation)

Latitude significantly predicts an earlier age of disease onset in multiple sclerosis C. Tao (Hobart, Australia)

Is it possible to predict benign multiple sclerosis? A. Sartori (Trieste, Italy)

Time to treatment after acute optic neuritis in patients with neuromyelitis optica andits spectrum disorders predicts visual outcome

S. Siritho (Bangkok, Thailand)

Disability in relapsing-remitting multiple sclerosis patients in Rio de Janeiro - Brazil:influence of clinical and demographic factors

G.A. Cruz dos Santos (Rio de Janeiro, Brazil)

Mortality in a population-based MS cohort K.E. Harding (Cardiff, United Kingdom)

The risk to reach EDSS of 6 and different immunointerventions I. Ilicic (Berlin, Germany)

The Swiss multiple sclerosis cohort study: a prospective nationwide investigation ofdisease evolution and the effects of new disease modifying drugs

G. Disanto (Lugano, Switzerland)

Sex ratio trends over time in multiple sclerosis patients from Argentina J.I. Rojas (Buenos Aires, Argentina)

Corpus callosum index to measure brain volume loss in clinical practice in MS patients J.I. Rojas (Buenos Aires, Argentina)

Clinical and neuroimaging characteristics in a sample of patients with familialmultiple sclerosis: a Hellenic retrospective cohort study

S. Katsavos (Athens, Greece)

Page 69 / 114


Are pregnancies prior to MS onset protective against subsequent disease severity? K. Ribbons (Newcastle, Australia)

Risk of osteoporotic fractures in multiple sclerosis population in southwest Finland J. Åivo (Turku, Finland)

Stable incidence, gender ratio and no direct latitudinal gradient in the incidence andprevalence of MS in Ontario, Canada

D.L. Rotstein (Toronto, Canada)

Prevalence of tumefactive demyelinating lesions in multiple sclerosis R. Totaro (L'Aquila, Italy)

Upper respiratory infections and MRI activity in relapsing-remitting MS O. Andersen (Gothenburg, Sweden)

Reduction of cancer risk in multiple sclerosis, despite use of disease-modifyingtherapies

M. Perie (Clermont Ferrand, France)

Systematic assessment and characterization of chronic pain in multiple sclerosispatients: preliminary results


Social media and recruitment in the NARCOMS registry C. Crowe (Birmingham, United States)

Recovery from first relapse in the CombiRx trial S.S. Cofield (Birmingham, United States)

Characteristics of continued tecfidera Use in the NARCOMS registry S.S. Cofield (Birmingham, United States)

Functional system involvement and confirmation of EDSS progression in CombiRx S.S. Cofield (Birmingham, United States)

Familial forms of multiple sclerosis in Brazilian patients: is HLA-DR2 involved insusceptibility to the disease?

M.S. Bernardes (Rio de Janeiro, Brazil)

Increased prevalence of multiple sclerosis (MS) in islands of the Aegean Sea andCrete

A.I. Kaliontzoglou (Rhodes, Greece)

The diagnosis of multiple sclerosis: pinpointing the concept of “no betterexplanation”

M. Calabrese (Verona, Italy)

Temporal lobe damage is linked to epilepsy in multiple sclerosis patients M. Calabrese (Verona, Italy)

Prevalence of multiple sclerosis in 2012 from the French health insurance data T. Moreau (Dijon, France)

Page 70 / 114


Disability improvement with alemtuzumab is associated with durable improvement onfunctional assessment in multiple sclerosis scores over 4 years in CARE-MS II patientswith RRMS though most were treatment-free after year 1

T. Moreau (Dijon, France)

Anti-JCV antibody levels (index) in the population of Polish patients with multiplesclerosis (multicenter study in patients treated with immunomodulating orimmunosuppressive drugs and naïve patients)

R. Bonek (Grudziądz, Poland)

The prevalence of John Cunningham virus antibody in the population of Polishpatients with multiple sclerosis (multicenter study in patients treated withimmunomodulating or immunosuppressive drugs and naïve patients)

R. Bonek (Grudziądz, Poland)

Autoimmune hepatitis and multiple sclerosis: an occasional association G. Cação (Porto, Portugal)

Incidence of multiple sclerosis in the Republic of Ireland: an observational population-based study

K. O'Connell (Dublin, Ireland)

Cognition in a newly diagnosed MS patient cohort K. O'Connell (Dublin, Ireland)

Characterizing sun exposure behaviours in early life using latent variable analyses:the EnvIMS study

S. Magalhaes (Montreal, Canada)

Multiple sclerosis and risk of completed and attempted suicide - a national cohortstudy

P. Brenner (Stockholm, Sweden)

Age has an effect on disability independent of age at onset of symptoms and diseaseduration

S. Alla (Christchurch, New Zealand)

Employment among persons with multiple sclerosis in New Zealand S. Alla (Christchurch, New Zealand)

Increasing prevalence of multiple sclerosis in tuscany: a study based on validatedadministrative data

D. Bezzini (Siena, Italy)

Handling MS patients in the ED: clinical decision making and current practice H. Abboud (Cleveland, United States)

Vitamin D and the development and evolution of permanent black holes amongpatients with clinically isolated syndrome

K.C. Fitzgerald (Boston, United States)

Hispanics enriched for non-European derived genetic ancestry are at increased risk ofyounger age of onset and optic neuritis

L. Amezcua (Los Angeles, United States)

Page 71 / 114


Risk of cerebral vascular complications in multiple sclerosis: analysis of thenationwide inpatient sample

S.M. Belliston (Kansas City, United States)

The effect of assisted reproductive techniques on relapse rate in women withmultiple sclerosis

A. Gullestrup (Copenhagen, Denmark)

The impact of age, gender, and geographic region on the prevalence of commoncomorbidities in patients with MS in a large US administrative claims database from2006-2012

J.C. Locklear (Rockland, United States)

An evaluation of adherence between patients with multiple sclerosis newly initiatingtreatment with a self-injectable or an oral disease-modifying drug

J.C. Locklear (Rockland, United States)

Earlier menarche is associated with earlier symptom onset in a clinical cohort of 544women with MS

R. Bove (Brookline, United States)

Effects of oral hormonal contraceptives on the clinical course of relapsing-remittingmultiple sclerosis

R. Hernandez Clares (Murcia, Spain)

Pregnancy in women with multiple sclerosis in Portugal - results of the national cross-sectional PORT-MS study

J. Ferreira (Lisboa, Portugal)

Rare symptoms and attack types in the course of multiple sclerosis: a retrospectivestudy in a large population with multiple sclerosis

B. Kaymakamzade (Nicosia, Cyprus)

Gait abnormalities are present in multiple sclerosis even in patients with EDSS 0-1.5 K. Novotna (Prague, Czech Republic)

A 6-month, multicenter, randomized, controlled study to evaluate the effect ofphysical training on fatigue in patients with relapsing-remitting multiple sclerosistreated with Fingolimod (Gilenya®) - first results of the PACE study

M. Mäurer (Bad Mergentheim, Germany)

The MS relapse phone as part of a new clinical pathway A. Skår (Bergen, Norway)

Understanding how people with MS get tired while walking S. Piérard (Liège, Belgium)

High intensity training may reverse the fiber type specific decline in myogenic stemcells in multiple sclerosis patients

I. Wens (Diepenbeek, Belgium)

Prevalence of neuropathic pain in early multiple sclerosis H. Heitmann (Munich, Germany)

Page 72 / 114


Changes in configuration of gait temporal joint patterns in PPMS patients: networkand random forest analysis

I. González-Suárez (Madrid, Spain)

Epilepsy among patients with multiple sclerosis E. Benjaminsen (Bodø, Norway)

Defining a score based on gait analysis for the longitudinal follow-up of MS patients S. Azrour (Liège, Belgium)

Prediction of expanded disability status scale subscores of motor dysfunction inmultiple sclerosis using depth-sensing computer vision

M. D'Souza (Basel, Switzerland)

Visualizing ubiquitously sensed measures of motor ability in multiple sclerosis forclinical use

J. Dorn (Basel, Switzerland)

Stability and prognostic utility of patient-derived MS severity score (P-MSSS) amongMS clinic patients

I. Kister (New York, United States)

Longitudinal ultra-high field MRI study of brain lesions in neuromyelitis optica I. Kister (New York, United States)

Harnessing real-time patient data to improve clinical outcomes and research: themultiple sclerosis partners advancing technology and healthcare solutions (MSPATHS) initiative

E.M. Mowry (Baltimore, United States)

Baseline MSSS is not better than EDSS at predicting ambulatory disability R. Gross (New York, United States)

Exploratory analysis of multiple sclerosis disability progression unrelated to relapses L. Kappos (Basel, Switzerland)

Teriflunomide efficacy on annualized relapse rate and expanded disability statusscale scores: 2.5-year follow-up in the TOWER extension study in patients withrelapsing MS


Results of MOMENTUM, a randomised, double-blind, placebo-controlled, phase 2 trialwith MT-1303, a novel selective sphingosine 1-phosphate receptor 1 (S1P1)modulator, in relapsing-remitting MS


25-foot walking test as predictor of proprioceptive training efficacy in multiplesclerosis patients

B. Zakrzewska-Pniewska (Warsaw, Poland)

The multiple sclerosis Well-Being Map? - a visual tool to support patientcommunication with their care team in Korea

J. Oh (Seoul, Korea, Republic of)

Page 73 / 114


A longitudinal study using whole brain, neocortical and subcortical atrophy rates andpatient reported outcomes (PROs). Interim analysis

A. Miravalle (Aurora, United States)

A systematic appraoch for the evaluation of neurogenic bladder in MS patients A. Miravalle (Aurora, United States)

Measures of falls risk in persons with multiple sclerosis: a comparative study of theTimed Up-and-Go and Timed Up-and-Go cognitive tests

M.A. Ciol (Seattle, United States)

Brain atrophy in multiple sclerosis patients measured by a web based automatedsiena version (NeuroResearch)


Skin adverse events occurring during treatment with new oral drugs for multiplesclerosis


Genome-wide pharmacogenomic study of response to cannabinoids in MS spasticitypatients


Daily activity and its association with gait impairment and fear of falling in patientswith multiple sclerosis

T. Krüger (Berlin, Germany)

The effects of different cognitive and motor tasks on the dual task cost of walking inmultiple sclerosis: a case-control study

C. Leone (Catania, Italy)

“Function Watch” - a real time, graphical composite representation of MS patients´health status as a decision support tool in daily clinical practice

L. Stawiarz (Stockholm, Sweden)

Experiences with a self developed accelerometer in multiple sclerosis L. Racz (Debrecen, Hungary)

Clinical and economic outcomes in MS patients treated with DMTs (SWITCH study):Canadian real-world experience


The rate of retirement due to multiple sclerosis related disability has decreased inFinland since introduction of disease modifying therapy

H. Kuusisto (Hämeenlinna, Finland)

Earnings and financial compensation from social security systems correlate stronglywith disability for multiple sclerosis patients

A. Kavaliunas (Stockholm, Sweden)

Development of a composite, administrative claims-based measure of diseaseseverity among patients with multiple sclerosis receiving disease-modifying drugtherapy

A.L. Phillips (Rockland, United States)

Page 74 / 114


Cost-effectiveness of 44 mcg subcutaneous interferon beta-1a (scIFNβ1a) and 30 mcgintramuscular interferon beta-1a (imIFNβ1a) using clinical endpoints of diseaseactivity


Factors associated with early disease-modifying drug (DMD) treatment initiation innewly diagnosed patients with multiple sclerosis (MS)


Multiple sclerosis: analysis of predicted medication adherence behavior by moriskymedication adherence scale (MMAS-8) and the relationship to patient derived EDSS(PDSS) and multiple sclerosis impact scale (MSIS-29) and quality of life (QoL)


Clostridium perfringens epsilon toxin induced blood brain barrier permeability:human relevance and molecular mechanisms

J.R. Linden (New York, United States)

Early disease stage in MOG35-55-induced EAE is associated with induction of theextrinsic apoptotic pathway in neurons

J.M. Orian (Melbourne, Australia)

Novel in vivo immunoglobulin G-driven model of multiple sclerosis K.R. Blauth (Aurora, United States)

Cortical atrophy predicts neuronal loss in MS: a post mortem study using unbiasedsampling

D. Carassiti (London, United Kingdom)

The influence of HLA-DRB1*15 on motor cortical neurodegeneration in multiplesclerosis

R.L. Yates (Oxford, United Kingdom)

Distinct energy utilization properties of human oligodendrocytes and oligodendrocyteprogenitor cells (OPCs) as determinants of their susceptibility to injury in multiplesclerosis

M. Rone (Montreal, Canada)

High HDL levels suppress blood brain barrier injury following the first demyelinatingevent

K. Fellows (Buffalo, United States)

Astrocyte injury and secondary demyelination induced by intracerebral injection ofAQP4-IgG and complement in mouse brain

Y. Takai (Sendai, Japan)

Increased production of pro-inflammatory cytokines and chemokines in the cerebralleptomeninges of MS cases with more severe cortical pathology

C. Cruciani (London, United Kingdom)

Elevated levels of S100B impair oligodendrogenesis A. Fernandes (Lisbon, Portugal)

Increased cortical lesion load and CSF cytokines in oligoclonal band positive MSpatients

G. Farina (Verona, Italy)

Page 75 / 114


Reduced tissue perfusion in MS lesions evident at time of acute inflammatory activity S.A. Gauthier (New York, United States)

The role of temperature deregulation in neurodegeneration in multiple sclerosis D. Bourdette (Portland, United States)

RNA-induced silencing complex (RISC) determined miRNA abnormalities inautoimmune demyelination

P. Lewkowicz (Lodz, Poland)

Chronic meningeal production of TNF and interferon-γ can drive cortical grey matterpathology

R.E. James (London, United Kingdom)

Interleukin 5 mediates disease protection associated with parasite infestation in EAE S. Hodgkinson (Strathfield, Australia)

Natural CD4+CD25+T regulatory cells (nTreg) cultured with antigen and Th2cytokines, suppress induction of EAE

S. Hodgkinson (Strathfield, Australia)

The development of a novel demyelination zebrafish model to be used for high-throughput drug screening of pro-myelinating compounds in multiple sclerosis

A. McGown (Sheffield, United Kingdom)

HSP70 overexpression in oligodendrocytes exacerbate demyelination and inhibitsremyelination

A. Jurewicz (Lodz, Poland)

Effects of in vivo chronic fingolimod on impaired presynaptic functions inexperimental autoimmune encephalomyelitis EAE mice at different stages of disease

A. Pittaluga (Genova, Italy)

Evaluation of cannabidiol and mesenchymal stem cells in adoptively transferredexperimental autoimmune encephalomyelitis. A comparative study

C. González-García (Majadahonda / Madrid, Spain)

Neuromyelitis optica IgG in the cerebrospinal fluid induces astrocytopathy in opticnerve

K.K. Soelberg (Vejle, Denmark)

Human herpesvirus 6 accelerates clinical and radiological disease in a nonhumanprimate model of multiple sclerosis

E. Leibovitch (Bethesda, United States)

Amantadine ameliorates gait deficits and disease severity in an animal model ofmultiple sclerosis

J. Nguyen (Emeryville, United States)

Oleanolic acid protects against optic nerve degeneration and retinal ganglion cellsloss in an experimental model of multiple sclerosis

M.L. Nieto (Valladolid, Spain)

Page 76 / 114


Transforming growth factor-β1-producing B-cells limit the severity of autoimmuneneuroinflammation by exerting regulatory functions

N. Molnarfi (Geneva, Switzerland)

Human aquaporin 4 auto-antibody alters blood brain barrier permeability A. Cobo-Calvo (Barcelona, Spain)

Adhesion molecule dynamics after natalizumab withdrawal in T-lymphocytessubpopulations

A. Cobo-Calvo (Barcelona, Spain)

Genetic load in eleven distantly related individuals from an MS high risk area K. Imrell (Stockholm, Sweden)

NOX genes - genetic markers for severe multiple sclerosis? A. Gyllenberg (Stockholm, Sweden)

A weighted genetic risk score distinguish MS patients from healthy individuals butdoes not correlate with MS disease activity

H. Bach Søndergaard (Copenhagen, Denmark)

Exome sequencing in multiple sclerosis patients with benign and aggressive diseasecourses

N. Fissolo (Barcelona, Spain)

Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a newbiomarker of disease activity

M. Clerico (Torino, Italy)

Search of causal variants in risk genes for multiple sclerosis by means of DNA-sequencing

E. Gil (Barcelona, Spain)

Global methylation in multiple sclerosis patients. Correlation with pathogenesis andtherapeutic response to IFNbeta

M.J. Pinto-Medel (Málaga, Spain)

A genetic variant associates with intrathecal immunoglobulin status and multiplesclerosis susceptibility

G. Izquierdo (Sevilla, Spain)

GWAS on relapse outcomes in CombiRx trial H. Tiwari (Birmingham, United States)

Association of genetic variants to multiple sclerosis by performing whole exomesequencing in a high prevalence family

G. Mattei (Rome, Italy)

Increased neutralization capacity of TNF-α in sera of relapsing remitting multiplesclerosis patients is not related to soluble TNF-α receptors or anti-TNF-α autoantibodylevels

A. Karni (Tel Aviv, Israel)

Page 77 / 114


Expanded T-cell clonotype sequences showed specificity relatedness in the peripheralblood of MS patients by phylogenetic tree analysis

A. De Paula Alves Sousa (Bethesda, United States)

The Gut-Brain CD39+ T regulatory cell Axis: role of the microbiota and gut associatedlymphoid tissue in regulating inflammatory CNS demyelination

L. Kasper (Hanover, United States)

Antiviral B-cells can activate demyelinating T-cells N.S. Sanderson (Basel, Switzerland)

Proinflammatory ALCAM+ B-cells migrate faster across blood meningeal barrier L. Michel (Montréal, Canada)

Placental mesenchymal stem cells (pMSCs) modulate the differentiation and functionsof macrophages in multiple sclerosis patients

M. Al Jumah (Riyadh, Saudi Arabia)

The association between IgM and IgG antibodies against cardiolipin, β2-glycoprotein Iand Domain I of β2-glycoprotein I with disease profile in patients with multiplesclerosis

N. Filippidou (Nicosia, Cyprus)

Clinical and histopathological amieloration of experimental autoimmuneencephalomyelitis by AAV vectors expressing soluble IL23 receptor

C. Espejo (Barcelona, Spain)

Characterization of local T-cell responses in multiple sclerosis patients G.M. Verjans (Rotterdam, Netherlands)

Natural killer cell redistribution during short-term treatment with fingolimod inmultiple sclerosis

A. Harrer (Salzburg, Austria)

The novel role of integrin alpha8 in mediating CD4+ T lymphocyte migration acrossthe CNS vasculature in multiple sclerosis

E.M. Gowing (Montreal, Canada)

Gene expression analysis of immune infiltrates isolated by laser microdissection fromthe multiple sclerosis brain

C. Veroni (Rome, Italy)

CD8+CD45RClow regulatory T-cells are functionally altered in multiple sclerosis B. Nicol (Nantes, France)

TCF-1 regulates T-cell response in multiple sclerosis M.A. Mazzola (Boston, United States)

Increase in JC virus antibody levels during pregnancy in MS patients S. Atula (Helsinki, Finland)

The role of norepinephrine in regulating interactions of the immune and nervoussystem in multiple sclerosis

M. Melnikov (Moscow, Russian Federation)

Page 78 / 114


Study of intracellular cytokine production in CSF of MS patients classified accordingto oligoclonal IgM band status

C. Picón (Madrid, Spain)

Blood coagulation factor XII drives adaptive immunity during neuroinflammation viamodulation of dendritic cells

S. Pankratz (Münster, Germany)

EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) gene expressionis down-regulated in multiple sclerosis patients

S. Malhotra (Barcelona, Spain)

NLRP3 (Nod-like receptor family, pyrin domain containing 3) inflammasome isincreased in patients with primary progressive multiple sclerosis

S. Malhotra (Barcelona, Spain)

Interleukin-24, produced by both TH lymphocytes and astrocytes, decreases bloodbrain barrier function

B. Broux (Diepenbeek, Belgium)

The effect of IL-27 signaling on miRNA expression in myeloid dendritic cells inmultiple sclerosis

R. Raheja (Boston, United States)

Broad screening for anti-neuronal and anti-glial autoantibodies in patients withpathologically classified multiple sclerosis

S. Jarius (Heidelberg, Germany)

The influence of microbiota on the adaptive immune response in MS T.F. Runia (San Francisco, United States)

Intrathecal transplantation of neural stem/progenitor cells modulates the CNS-confined autoimmune response of experimental autoimmune encephalomyelitis

D. De Feo (Milan, Italy)

EBV genotypes and response to high-dose interferon-beta in multiple sclerosis R. Mechelli (Rome, Italy)

Search of biomarkers for PML risk in multiple sclerosis patients receiving natalizumab M. Comabella (Barcelona, Spain)

Protein-based biomarker predicts conversion from clinically isolated syndrome tomultiple sclerosis

M. Comabella (Barcelona, Spain)

Search of biomarkers for multiple sclerosis by RNA, microRNA, and exome sequencingapproaches

M. Comabella (Barcelona, Spain)

The association between human endogenous retroviruses and multiple sclerosis: asystematic review and meta-analysis

E. Morandi (Nottingham, United Kingdom)

Tobacco smoking and severity of neuromyelitis optica L. Kremer (Strasbourg, France)

Page 79 / 114


Commensal gut flora in MS: spatial organization and composition K. Baum (Hennigsdorf, Germany)

Adiponectin and not leptin is associated with genetic susceptibility to multiplesclerosis

E. Kantorová (Martin, Slovakia)

Is there any relation between Gilbert syndrome and multiple sclerosis? M. Sharifian Dorche (Shiraz, Iran, Islamic Republic of)

Set-up of a smoking cessation program for MS patients: results after 1 year S. Otero-Romero (Barcelona, Spain)

Sunshine, sea, and season of birth: MS incidence in Wales R.M. Middleton (Swansea, United Kingdom)

Ambient air pollution boosts multiple sclerosis activity through up-regulation ofadhesion molecules and chemokine receptors on circulating lymphocytes

A. Cortese (Pavia, Italy)

Role of B-cells in primary progressive multiple sclerosis: elevated intrathecal IgGproduction at disease onset predicts aggressive disease course

A. Abdelhak (Ulm, Germany)

Two determinants of late disability progression in multiple sclerosis: earlyinflammatory disease and old age in damaged brain


Disability outcome and sample size considerations for PPMS clinical trial efficiency M.D. Davis (Frazer, United States)

A robust activation of complement in cortical grey matter lesions of progressive MS O.W. Howell (Swansea, United Kingdom)

Combinatorial antibody phage display libraries constructed from B-cells infiltratingbrain tissue of people with progressive multiple sclerosis

C. Maggiore (London, United Kingdom)

Fatigue predicts conversion to secondary progressive disease phenotype in relapsing-remitting multiple sclerosis patients

M. Cavallari (Boston, United States)

Progressive multiple sclerosis: the beneficial effects of multimodal complex therapy M. Haupts (Isselburg-Anholt, Germany)

Ermin as a marker of remyelination in MS I. Ahmad (Bergen, Norway)

Systemically administered exosomes mediate recovery in the Theiler's MourineEcephalomyelitis virus animal model of multiple sclerosis

M. Fernández-Fournier (Madrid, Spain)

Page 80 / 114


Differential viability, distribution and therapeutic efficacy of transplanted neuralstem cells in the acute and chronic disease phases of experimental autoimmuneencephalomyelitis

A. Merlini (Milan, Italy)

Fingolimod every-other-day as a possible strategy to overcome fingolimod-inducedsevere lymphopenia in MS patients

A. Merlini (Milan, Italy)

Vulnerability of oligodendrocyte precursor cells to death is modulated by keyprostaglandins

N.G. Carlson (Salt Lake City, United States)

Neural correlates of cognitive variation in patients with clinically isolated syndrome F.M. Boonstra (Melbourne, Australia)

Grey matter atrophy and physical and cognitive function in very early MS: alongitudinal study

B. Nourbakhsh (San Francisco, United States)

Analysis of normal appearing white matter in multiple sclerosis using myelin waterimaging: a preliminary report

I.H. Jeong (Goyang-si, Korea, Republic of)

Comparison of myelin water fraction values in periventricular white matter lesionsbetween multiple sclerosis and neuromyelitis optica spectrum disorder: a preliminaryreport


Quantitative sterol signatures of cerebrospinal fluid in multiple sclerosis andneuromyelitis optica spectrum disorder


A novel MRI pipeline for assessing multiple sclerosis lesion evolution in the opticradiation

C. Wang (Sydney, Australia)

Imaging perivenular distribution can differentiate MS from CNS vasculitis L. Vuolo (Florence, Italy)

Perivenular white matter lesions on SWI at 3-T MRI as a diagnostic sign todifferentiate multiple sclerosis from neuromyelitis optica

R. Cortese (London, United Kingdom)

Longitudinal MRI study to measure cervical cord atrophy in multiple sclerosis patients F.X. Aymerich (Barcelona, Spain)

Iron deposit within focal lesions in patients with clinically isolated syndrome F.X. Aymerich (Barcelona, Spain)

Association between iron deposit within focal lesions and radiological/clinicalmeasurements in patients with clinically isolated syndrome

F.X. Aymerich (Barcelona, Spain)

Page 81 / 114


Iron deposits within new T2 lesions in patients with clinically isolated syndrome F.X. Aymerich (Barcelona, Spain)

High-resolution T1-relaxation time mapping displays subtle, but clinically relevant,gray matter damage in long-standing multiple sclerosis

M.D. Steenwijk (Amsterdam, Netherlands)

Tissue damage within normal-appearing white-matter in early MS: quantification bythe ratio of T1/T2-weighted MR image intensities

M. Mühlau (Munich, Germany)

Periventricular gradient in thalamic abnormalities in MS: a magnetisation transferratio imaging study

M. Pardini (Genoa, Italy)

Distribution of cerebellar white matter magnetisation transfer ratio abnormalities inmultiple sclerosis


Isolated cognitive relapses and informant-based evaluation of cognitive performancein MS


The cortical damage among MS patients with frequent early relapses A. Scalfari (London, United Kingdom)

Assessing individual lesion myelination and its change over time C. Köhler (Dresden, Germany)

Positron emission tomography imaging in multiple sclerosis highlights a diffuseinflammatory response in brain that appears normal on conventional magneticresonance imaging

G. Datta (London, United Kingdom)

Imaging of Rituximab-Zirconium-89 uptake with PET scans in active relapsing-remitting MS patients

M.H. Hagens (Amsterdam, Netherlands)

The effect of lesions on automated deep gray matter segmentation N. Bergsland (Milan, Italy)

Assessing the relationship between white matter lesion accumulation and graymatter atrophy development: a serial 10-year voxel-based morphometry and lesionprobability mapping follow-up study of early relapsing-remitting MS patients

N. Bergsland (Milan, Italy)

Localized atrophy of the thalamus is related to changes in cognitive processing speedin MS patients

N. Bergsland (Milan, Italy)

Spinal cord gray matter atrophy in early multiple sclerosis R. Schlaeger (Basel, Switzerland)

Page 82 / 114


Monitoring tools in MS: quantitative, semi-quantitative and ordinal evoked potentialscores

R. Schlaeger (Basel, Switzerland)

Brain MRI assessment in clinical practice: descriptive analysis of a cohort of MSpatients at Hospital Federal da Lagoa - Rio de Janeiro (Brazil)

M.P. Alvarenga (Rio de Janeiro, Brazil)

Diagnosing multiple sclerosis using the central vein sign. What is the agreementbetween a blinded rater and the final diagnosis using T2* weighted sequences at 3TMRI?

M. Clarke (Nottingham, United Kingdom)

Using diffusion MRI to study demyelination in deep gray matter in animal model ofmultiple sclerosis

S. Wergeland (Bergen, Norway)

Cerebellar functional connectivity alterations and their association with balancedeficit in multiple sclerosis

F. Tona (Rome, Italy)

Multivariate combination of quantitative T2* and T1 at 7T MRI detects in vivo subpialdemyelination in the early stages of MS

G. Mangeat (Montreal, Canada)

Motor practice effect on functional connectivity is modulated in time by interferonbeta treatment in multiple sclerosis

N. Petsas (Rome, Italy)

Validation of automated versus manual T2 lesion segmentation applied on FLAIR- andDIR-sequences

C. Egger (Zurich, Switzerland)

Cortical myelin mapping in MS using the T1w/T2w ratio R. Righart (Munich, Germany)

Assessment of whole brain blood flow changes in multiple sclerosis: phase contrastMRI versus ASL

Y. Ge (New York City, United States)

Spontaneous remyelination in MS improves clinical prognosis and protects fromneuro-axonal degeneration

B. Bodini (Paris, France)

Energy dysregulation and neuro-axonal dysfunction in MS measured in-vivo withdiffusion-weighed spectroscopy

B. Bodini (Paris, France)

Influence of focal gray matter and white matter lesions on normal-appearing tissuesin multiple sclerosis

A. Pitiot (Nottingham, United Kingdom)

Regional grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-basedmorphometry studies using a novel coordinate-based method

C.R. Tench (Nottingham, United Kingdom)

Page 83 / 114


Neurite orientation dispersion and density imaging (NODDI) at ultra high gradientstrength reveals axon pathology in multiple sclerosis

J.D. Bireley (Charlestown, United States)

Spinal cord lesions and relationship to spinal cord atrophy and disability in multiplesclerosis

N. Seraji-Bozorgzad (Detroit, United States)

Estimation of inflammatory microscopic tissue injury after cessation of fingolimod ornatalizumab in patients with multiple sclerosis

N. Seraji-Bozogzad (Detroit, United States)

Effect of smoking cessation on brain volume in patients with multiple sclerosis N. Seraji-Bozogzad (Detroit, United States)

Intra- and interscanner variability of magnetic resonance imaging based volumetry inmultiple sclerosis

V. Biberacher (München, Germany)

Demonstration of hypometabolic cortical areas in clinically isolated syndromes: a 3T18F-FDG PET/MRI study

D. Poggiali (Padova, Italy)

Hippocampal inflammation and depression in multiple sclerosis: integrating evidencefrom TSPO PET and resting state fMRI

A. Colasanti (London, United Kingdom)

Value of cortical and corpus callosum lesions in the diagnosis of MS: inter-raterreliability first


Spinal cord MRI and its role in monitoring disease progression: prognostic value atthe time of a clinically isolated syndrome


Spinal cord microstructural alterations and grey matter atrophy in RMS E. Datta (San Francisco, United States)

Deep gray matter segmentation from 1.5T vs. 3T MRI in normal controls and patientswith multiple sclerosis

R. Chu (Boston, United States)

Improving measurement errors in the assessment of GM and WM volume changesusing a new sienax procedure

M. Battaglini (Siena, Italy)

Gray matter volume changes in patients with multiple sclerosis: contribution ofmeasurements using two independent methods, voxel-basel morphometry and source-based morphometry

M. Dufek (Brno, Czech Republic)

Anterograde trans-synaptic degeneration after optic neuritis: earlier optic nerveatrophy predicts later optic radiation damage

C. Tur (London, United Kingdom)

Page 84 / 114


Motor fatigue scores correlate with task-related activity in cerebellum during a non-fatiguing precision grip task

O. Svolgaard (Hvidovre, Denmark)

Regional and tissue-type based assessment of Gaussian and non-Gaussian diffusionMRI indices in three subtypes of multiple sclerosis using diffusional kurtosis imaging

P. Lee (Kansas City, United States)

Predicting conversion to clinically definite multiple sclerosis using machine learningon the basis of cerebral grey matter segmentations

K. Bendfeldt (Basel, Switzerland)

A composite scale using MRI-defined cerebral lesions and atrophy to assess thetherapeutic effect of glatiramer acetate in multiple sclerosis

S. Tauhid (Boston, United States)

MRI Bookend perfusion discriminates cognitively intact and impaired patients withRRMS

R. Aviv (Toronto, Canada)

Increased accuracy and reproducibility of MS lesion volume quantification by usingpublicly available BrainSeg3D image analysis software

Ž. Lesjak (Ljubljana, Slovenia)

Brain contrast enhancement in neuromyelitis optica: its relation to acute attacks andclinical disease severity

G. Orman (Baltimore, United States)

Longitudinal evolution of neuromyelitis optica brain lesions on MRI and correlation todisability scores

G. Orman (Baltimore, United States)

Improved lesion detection rates with high sensitivity gadolinium enhanced magneticresonance imaging protocols translate into increased statistical power for clinicaltrials in MS

R.A. Brown (Montreal, Canada)

Increase in magnetic susceptibility after MS lesion formation and potential diagnosticutility

Y. Zhang (New York City, United States)

Serum microRNAs are related to brain MRI lesions and atrophy in patients withmultiple sclerosis

R. Gandhi (Boston, United States)

Circulating microRNAs (miRNAs) serve as a biomarker for diagnosis, disease stage,prognosis, treatment response and disability in multiple sclerosis

R. Gandhi (Boston, United States)

Walking performance is associated with the integrity of cognitive motor networkstructures in relapsing-remitting MS

J.-P. Stellmann (Hamburg, Germany)

Resistance training increases cortical thickness in RRMS - results of a pilot RCT J.-P. Stellmann (Hamburg, Germany)

Page 85 / 114


MRI characteristics of short myelitis lesions in NMO-IgG-positive neuromyelitis opticaspectrum disorders

J.Y. Jin (Seoul, Korea, Republic of)

Associations of global and regional white matter lesion load with anxiety and fatiguein multiple sclerosis

M. Palotai (Boston, United States)

Cerebrospinal fluid gadolinium concentration in multiple sclerosis M.A. Pawlak (Poznan, Poland)

Reduced perfusion in white matter lesions in multiple sclerosis P. Sowa (Oslo, Norway)

Role of retinal nerve fibre layer thinning in monitoring multiple sclerosis M. Pisa (Milan, Italy)

Structural functional relationship in the visual system in multiple sclerosis P. Tewarie (Amsterdam, Netherlands)

Evidence of functional retinal impairment in the absence of sustained structuraldamage following MS-related optic neuritis

J.V. Hanson (Zurich, Switzerland)

Disease modifying therapy in relapsing remitting multiple sclerosis reduces innernuclear layer volumes as measured by optical coherence tomography

B. Knier (München, Germany)

Afferent visual system damage in MOG-antibody seropositive opticospinalinflammatory disease

H.G. Zimmermann (Berlin, Germany)

Optic coherence tomography (OCT) and visual evoked potentials (VEPs): which ismore sensitive to detect visual pathway abnormalities in NMO spectrum disorders(NMOSDs)?

H. Jang (Seoul, Korea, Republic of)

Retinal structure injury and CSF humoral response in multiple sclerosis J. Chorostecki (Detroit, United States)

Individual retinal layer thinning over time in multiple sclerosis: what is optic neuritishiding?

J. Chorostecki (Detroit, United States)

Brain metabolites and retinal nerve fibre layer thickness and their relation todisability in multiple sclerosis: a longitudinal high-field proton magnetic resonancespectroscopy and optical coherence tomography study

Ö. Yaldizli (London, United Kingdom)

Effect of age and MS disease duration on RNFL C. Fjeldstad (Oklahoma City, United States)

Relationship between OCT measures and brain cortical lesions in primary-progressiveMS

C. Cordano (Genova, Italy)

Page 86 / 114


The yield of serial spectral-domain OCT testing in multiple sclerosis M.J. Morrow (Torrance, United States)

Disease modifying therapies modulate retinal layer atrophy in multiple sclerosis: alongitudinal study

O. Al-Louzi (Baltimore, United States)

Visual evoked potentials versus optical coherence tomography: which is more usefulin neuromyelitis optica spectrum disorder?

N.-H. Kim (Goyangsi, Korea, Republic of)

Longitudinal performance of multi-modal evoked potentials as a biomarker ofdisability in primary progressive multiple sclerosis

L.J.W. Canham (Bristol, United Kingdom)

Longitudinal analysis of topographic VEP in relapsing-remitting patients with multiplesclerosis

M. Hardmeier (Basel, Switzerland)

Evoked potentials - an old tool as a predictor of benign multiple sclerosis R. Samões (Porto, Portugal)

Corticospinal reserve measured with the H-coil predicts walking impairment but notfatigability in progressive multiple sclerosis patients

A. Nuara (Milan, Italy)

Ocular motor markers of progressive cognitive decline in MS J. Fielding (Clayton, Australia)

Depression, sleep and coping predict subjective but not objective fatigue in MS M. Hu (Cardiff, United Kingdom)

Cognitive impairment in multiple sclerosis: the role of fine abilities assesment D. Passafiume (L'Aquila, Italy)

The role of processing speed in multiple sclerosis cognitive impairment O. Rilo (Bilbao, Spain)

Cross-cultural adaptation and psychometric properties of the brief internationalcognitive assessment for multiple sclerosis (BICAMS) in Brazilian context

C.T. Spedo (Ribeirão Preto, Brazil)

Cognition in early and late stages of multiple sclerosis and its correlation to MRI A. Kunkel (Teupitz, Germany)

The life orientation test-revised in multiple sclerosis C.R. Wicks (Leeds, United Kingdom)

Slowness of information processing in multiple sclerosis: disentangling the relativecontribution of MS and depression

G. Lubrini (Madrid, Spain)

Impact of psychological factors on job retention in multiple sclerosis K. Ward (Leeds, United Kingdom)

Page 87 / 114


A simple measure of cognitive reserve predicts cognitive performance in a largegroup of MS patients

A. Gallo (Naples, Italy)

Relation between cognitive function and physical activity in multiple sclerosispatients treated with interferon beta-1b - the CogniPlus study

B. Brochet (Bordeaux Cedex, France)

Proposed cut scores for tests of the brief international cognitive assessment ofmultiple sclerosis (BICAMS)

M. Beier (Seattle, United States)

Effect of teriflunomide on relapses associated with disability worsening: results fromthe TEMSO and TOWER studies

P. O'Connor (Toronto, Canada)

The oral immunomodulator laquinimod affects experimental autoimmuneencephalomyelitis via the aryl hydrocarbon receptor

J. Berg (Bochum, Germany)

Teriflunomide mechanism of action: linking species' sensitivities to pregnancyoutcomes

L. Davenport (Bridgewater, United States)

Compliance and discontinuation rates with Gilenya® and other disease-modifyingtherapies: Canadian real-world experience

P. Duquette (Montréal, Canada)

Treatment patterns and efficacy in multiple sclerosis in a real life setting: aprospective cohort study

P. Duquette (Montréal, Canada)

Efficacy of teriflunomide treatment in achieving no evidence of disease activity over aperiod of 6 months to 2 years in the TEMSO study

A. Chan (Bochum, Germany)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML M.T. Wijburg (Amsterdam, Netherlands)

Natalizumab-associated PML in Dutch MS patients M.T. Wijburg (Amsterdam, Netherlands)

Safety and efficacy of transitioning to teriflunomide in patients switching from otherdisease-modifying therapies, including natalizumab

K.R. Edwards (Latham, United States)

Comparative effectiveness using a matching-adjusted indirect comparison betweendelayed-release dimethyl fumarate and fingolimod for the treatment of relapsing-remitting multiple sclerosis


Teriflunomide slows down brain volume loss in RMS: a SIENA analysis of the TEMSOMRI dataset

E.-W. Radue (Basel, Switzerland)

Page 88 / 114


Efficacy of teriflunomide in MS patients with a primary presentation of optic neuritis:a subgroup analysis from the phase 3 TOPIC study

A.E. Miller (New York, United States)

Cognitive impairment rebound in multiple sclerosis patients after natalizumabdiscontinuation

P. Iaffaldano (Bari, Italy)

Computer-assisted rehabilitation of attention in patients with multiple sclerosisincreases functional activity in the left prefrontal cortex

P. Iaffaldano (Bari, Italy)

Characterizing the impact of teriflunomide on adaptive immune cell subsets,repertoire and function in patients with relapsing-remitting MS: TERI-DYNAMIC


Characteristics of leukocyte recovery following treatment with humanized anti-CD52(alemtuzumab/Lemtrada) in multiple sclerosis

B.T. Lund (Los Angeles, United States)

Early reconstitution of the peripheral immune repertoire following withdrawal offingolimod therapy

M. Ghadiri (Montreal, Canada)

Efficacy of teriflunomide treatment in achieving no evidence of disease activity in theTEMSO long-term extension study

J.S. Wolinsky (Houston, United States)

Teriflunomide efficacy in subsets of patients with relapsing MS: results from TEMSOand TOWER studies


Teriflunomide safety in a subsets of patients with relapsing MS: results from theTEMSO and TOWER studies


Comparison of fingolimod and dimethyl fumarate in the treatment of multiplesclerosis: one year experience

B.L. Vollmer (Aurora, United States)

IL-6 signal blockade therapy may suppress plasmablast-mediated pathology inrelapsing-remitting multiple sclerosis

M. Nakamura (Tokyo, Japan)

Switching from branded to generic glatiramer acetate: two-year clinical data from theGATE trial further support the continued efficacy and tolerability of genericglatiramer acetate


Durable improvement in clinical outcomes with alemtuzumab following switch fromsubcutaneous interferon beta-1a in patients with active RRMS: three-year follow-upof the CARE-MS II extension study


Page 89 / 114


Altered lymphocyte function in MS patients treated with immunomodulatory orimmunosuppressive drugs

C. Malmeström (Gothenburg, Sweden)

Prospective, multicenter study of monthly pulsed methylprednisolone treatment inpatients with primary progressive multiple sclerosis: clinical and magnetic resonanceimaging results

S. Ozakbas (Izmir, Turkey)

Cognitive dysfunction in patients with multiple sclerosis treated with first linedisease modifying therapy

S. Ozakbas (Izmir, Turkey)

Therapeutic management in the real life setting of Italian MS centers: when, why andhow we switch therapy

G.T. Maniscalco (Naples, Italy)

IFNb enhances immunoregulatory features of mesenchymal stem cells A. Uccelli (Genova, Italy)

MESEMS: a randomized, double blind placebo-controlled cross-over study to evaluatesafety and efficacy of intravenous administration of autologous mesenchymal stemcells in patients with multiple sclerosis

A. Uccelli (Genova, Italy)

The effect of interferon beta 1a and polyphenolic extracts on autophagy, apoptosisand oxidative stress in patients with multiple sclerosis: an in vitro study

M. Ruggieri (Bari, Italy)

Sigma - 1 receptor agonists: new drug-candidates targeting neurological and immuneaspects of MS

B. Oxombre Vanteghem (Lille Cedex, France)

Natalizumab versus fingolimod in RRMS patients non-responder to first-linetherapies: a 2 years, bicenter, retrospective, intention-to-treat cohort study

D. Baroncini (Gallarate, Italy)

Adaptive and innate immune cell phenotypes in the blood of fingolimod-treated MS-patients

J.L. Talbot (Copenhagen, Denmark)

Assessing the efficacy, tolerability, and safety of rituximab for the treatment ofmultiple sclerosis: experience in 313 patients at a large academic center

E. Alvarez (Aurora, United States)

Characterization of vatelizumab, a novel antibody that binds VLA-2 W.M. Siders (Framingham, United States)

Efficacy of delayed-release dimethyl fumarate vs glatiramer acetate on a novelcomposite outcome measure of inflammatory disease activity: post-hoc analysis ofthe CONFIRM study

M. Kremenchutzky (London, Canada)

A novel mechanism of action for teriflunomide by the induction ofimmunosuppressive gut CD39+FoxP3+Tregs in mice

L. Kasper (Hanover, United States)

Page 90 / 114


Fingolimod treatment induces changes in NK and T-helper cell subpopulations and inT-cell co-stimulation markers

F. Largey (Zurich, Switzerland)

Antigen-selective reduction of intrathecal synthesis of antiviral antibodies duringnatalizumab treatment of MS patients


Formation of JCV- and BKV-cross-reactive antibodies during natalizumab-associatedprogressive multifocal leukoencephalopathy


Lack of evidence for T-cell expression of siglec-10 and suppressive interaction withsoluble CD52

L. Azzopardi (Cambridge, United Kingdom)

Alemtuzumab use in neuromyelitis optica spectrum disorders - a brief case series L. Azzopardi (Cambridge, United Kingdom)

Key regulatory function of vitamin D for response to glucocorticosteroids in multiplesclerosis

R. Hoepner (Bochum, Germany)

Glatiramer acetate in patients with autoimmune diseases predominantly affecting themyelon


Influence of ethyl hydrogen fumarate vs. dimethylfumarate on the development oflymphopenia


Targeting innate immune cells as a novel therapeutic approach for multiple sclerosis A. Edling (Framingham, United States)

The bile acid receptor FXR controls CNS autoimmunity in an IL-10-dependent fashion M. Herold (Münster, Germany)

Delayed onset and reduced disease severity of spontaneous CNS autoimmunity byconjugated linoleic acid-rich diet

M. Herold (Münster, Germany)

Sodium chloride promotes pro-inflammatory macrophage polarization therebyaggravating CNS autoimmunity

M. Herold (Münster, Germany)

T helper subsets changes in alemtuzumab multiple sclerosis treated patients: therecovery of immune system capacity as a possible indicator to treatment

S.F. De Mercanti (Torino, Italy)

Sustained low rate of brain volume loss with long-term delayed-release dimethylfumarate treatment in relapsing-remitting multiple sclerosis patients: results fromthe ENDORSE study

D. Miller (London, United Kingdom)

Page 91 / 114


Efficacy and safety of delayed-release dimethyl fumarate in relapsing-remittingmultiple sclerosis patients with cardiovascular disease: integrated analysis of thephase 3 DEFINE and CONFIRM studies


Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MSpatients

M.P. Wattjes (Amsterdam, Netherlands)

MR imaging characteristics of early PML-IRIS in natalizumab-treated MS patients M.P. Wattjes (Amsterdam, Netherlands)

Safety, tolerability and pharmacodynamic characterization of vatelizumab, amonoclonal antibody targeting very-late-antigen (VLA)-2: a randomized, double-blind,placebo-controlled phase 1 study

I.A. Antonijevic (Cambridge, United States)

Superior efficacy and tolerability of rituximab as compared to fingolimod for MSpatients switching from natalizumab due to positive JC virus serology

F. Piehl (Stockholm, Sweden)

Preliminary results of a phase 2 trial of autologous mesenchymal cell therapy in MS(STREAMS)

R. Ali (London, United Kingdom)

Switching from natalizumab to fingolimod: recurrence of disease activity is closelyrelated to duration of wash out and alpha-4 integrin desaturation - a prospectivestudy in RRMS

Y. Naegelin (Basel, Switzerland)

Fumaric acid esters do not reduce T-cell adhesiveness of inflamed human brainmicrovascular endothelium

A. Haarmann (Würzburg, Germany)

Postpartum relapse rate in multiple sclerosis and intravenous immunoglobulines inthe postpartum period

S. Raunegger (Berlin, Germany)

Estimation of brain volume loss with multiple imputation of missing values in theplacebo-controlled FREEDOMS trials of fingolimod

G. Cutter (Birmingham, United States)

Switching from subcutaneous interferon beta-1a to alemtuzumab further decreasesnew lesion activity and slows brain volume loss in treatment-naive patients withactive relapsing-remitting multiple sclerosis: CARE-MS I extension study

A. Rovira (Barcelona, Spain)

Laquinimod reduces CNS pathology and demyelination induced by B lymphocytesfrom multiple sclerosis patients in a novel brain slice model of MS


Laquinimod is protective to oligodendrocytes during lysolecithin-induceddemyelination in a murine brain slice model


Page 92 / 114


Adult bone marrow mesenchymal stem cells suppress the inflammation-inducedincrease of Ccl2 and Ccl5 mRNA levels in vitro and in vivo and promote reparativeresponses by astrocytes in vitro

A. Voulgari-Kokota (Genoa, Italy)

Progression to disability milestones in multiple sclerosis with long-term natalizumabtreatment


No evidence of an increased risk for malignancy associated with natalizumab therapyin 9 years of postmarketing surveillance

C. Carrillo-Infante (Cambridge, United States)

Durable improvement in clinical outcomes with alemtuzumab following switch fromsubcutaneous interferon beta-1a in treatment-naive patients with active RRMS: three-year follow-up of the CARE-MS I extension study

H.-P. Hartung (Düsseldorf, Germany)

First dose time effects of fingolimod on the autonomic nervous system T. Ziemssen (Dresden, Germany)

TREAT-MS: design and baseline characteristics of a noninterventional study toestablish effectiveness, quality of life, cognition, health-related, and work capacitydata on alemtuzumab in multiple sclerosis patients in Germany

T. Ziemssen (Dresden, Germany)

Peginterferon beta-1a dosed every 2 weeks maintained efficacy over 3 years inpatients with relapsing-remitting multiple sclerosis

S.D. Newsome (Baltimore, United States)

Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS I with the majority of patients treatment-free for 4 years


Durable efficacy of alemtuzumab on clinical outcomes over 5 years in CARE-MS II withmost patients free from treatment for 4 years

E.J. Fox (Round Rock, United States)

Fingolimod first-dose effects in patients with RRMS concomitantly receiving SSRIs onday 1: pooled analysis of the real-world phase 4 PREFERMS and EPOC studies

E.J. Fox (Round Rock, United States)

Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS II with most patients free from treatment for 4 years

A. Traboulsee (Vancouver, Canada)

Durable improvement in expanded disability status scale functional systems scoresover 4 years with alemtuzumab despite a majority of patients not receiving treatmentsince year 1

G. Giovannoni (London, United Kingdom)

Efficacy and safety of fingolimod in relapsing-remitting multiple sclerosis: resultsfrom a retrospective French cohort

E. Nerrant (Nîmes, France)

Page 93 / 114


Durable efficacy of alemtuzumab in CARE-MS II patients with highly active relapsing-remitting multiple sclerosis: 4-year outcomes

S. Krieger (New York, United States)

Increased relapses in patients switching from natalizumab to dimethylfumarate,fingolimod and teriflunomide

N. Vu (Nashville, United States)

Rituximab in multiple sclerosis, a long term safety and efficacy study P. Islam-Jakobsson (Umeå, Sweden)

Predictive value of EDSS worsening and relapse/active T2 lesions on outcomes amongpatients receiving IFN β-1a SC tiw for RRMS: post hoc analyses of PRISMS data over 4years

M. Cascione (Tampa, United States)

The evolution of the anti-JCV antibody index value post-natalizumab: switching tofingolimod or dimethyl fumarate

L. Bellengier (Lille, France)

JCV (John Cunningham virus) index: follow-up of a French cohort S. Mathais (Clermont-Ferrand, France)

Novel oral MS treatments: one-year real-life experience with 128 patients treatedwith dimethyl-fumarate

T. Sejbaek (Odense, Denmark)

Long-term follow-up of cognition by monthly symbol digit modalities test in multiplesclerosis patients treated with natalizumab

T. Sejbaek (Odense, Denmark)

Exploring the clinical course of hair thinning associated with teriflunomide: an updateto the teriflunomide real-world case series

L. Hendin Travis (Phoenix, United States)

ALLOW - a phase 3b trial characterising flu-like symptoms in patients transitioning topegylated interferon beta-1a: interim analysis of all patients

R.T. Naismith (St Louis, United States)

Reduced risk of relapses in the switch between natalizumab and fingolimod in 91patients

Y.D. Fragoso (Santos, Brazil)

Detection of thyroid malignancies in alemtuzumab-treated patients in the multiplesclerosis clinical development program

B. Lecumberri (Madrid, Spain)

A functional scale for progressive multifocal leukoencephalopathy: the NIH PML scale G. von Geldern (Seattle, United States)

The importance of low JC virus copy numbers in CSF in the diagnosis of progressivemultifocal leukoencephalopathy in MS patients

G. von Geldern (Seattle, United States)

Page 94 / 114


Real world experience of lymphopenia in MS patients treated with dimethyl fumarate G. von Geldern (Seattle, United States)

Pregnancy outcomes in patients with active RRMS who received alemtuzumab in theclinical development program

A. Achiron (Tel Hashomer, Israel)

Disparities and challenges to oral disease modifying MS therapies and the potentialof individualized patient coaching

B. Schmid (Ismaning, Germany)

Alemtuzumab related Listeria infections - a growing concern? S. Ohm (Berlin, Germany)

Peripheral lymphocyte subsets and JCV antibody index in MS patients treated withnatalizumab: a longitudinal analysis

A. Carotenuto (Naples, Italy)

The pharmacogenetics of interferon beta induced liver injury in multiple sclerosis K. Kowalec (Vancouver, Canada)

Progressive multifocal leukoencephalopathy presenting with posterior fossaradiological features in the context of natalizumab therapy in relapsing-remittingmultiple sclerosis

R. Nicholas (London, United Kingdom)

Longitudinal analyses of anti-JCV antibody index as risk assessment for progressivemultifocal leukoencephalopathy

A. Salmen (Bochum, Germany)

Lessons learned from eighteen non-fatal outcomes in natalizumab-associated PML: anevolving therapeutic approach in settings of varied presentations

D. Stefoski (Chicago, United States)

Predicting treatment response to teriflunomide in the TEMSO study using themodified Rio score

M.P. Sormani (Genoa, Italy)

Alemtuzumab improves disability outcomes versus subcutaneous interferon beta-1ain CARE-MS I and II patients with active relapsing multiple sclerosis using the novelSAD-plus endpoint

X. Montalban (Barcelona, Spain)

Fampridine in multiple sclerosis patients: activity on upper limb function evaluatedby kinematic analysis

C. Solaro (Genova, Italy)

Dalfampridine positive sensory and painful side effects C. Solaro (Genova, Italy)

Gait improvement in multiple sclerosis patients treated with fingolimod S. Eichau (Sevilla, Spain)

Page 95 / 114


Antibodies against interferon beta and natalizumab in European multiple sclerosispatients

J. Link (Stockholm, Sweden)

Disease activity on individual components of “no evidence of disease activity”(NEDA-4) in young adult patients with relapsing-remitting multiple sclerosis

J. Gärtner (Göttingen, Germany)

Relevance of time 25 foot walk test to assess the effectiveness of dalfampridine C. Donzé (Lomme, France)

Cross-reactivity of anti-interferon beta antibodies against different interferons betaand interference of their presence in the JAK-STAT signalling pathway in multiplesclerosis patients

I. Hurtado-Guerrero (Malaga, Spain)

Baseline MxA expression as a biomarker of treatment response in multiple sclerosispatients treated with interferon β

E. Matas (L'Hospitalet de Llobregat, Spain)

The regulatory/activated CD4+ T-cell ratio in peripheral blood predict response tofingolimod in multiple sclerosis patients

L.M. Villar Guimerans (Madrid, Spain)

Lymphocyte subsets changes as biomarker of therapeutic response in Fingolimodtreated relapsing MS

M. D'Onghia (Bari, Italy)

Predictive value of early MRI measures for long-term disease activity in patients withrelapsing-remitting multiple sclerosis receiving IFN β-1a SC tiw or IFN β-1a IM qw:post hoc analyses of the EVIDENCE study

P.K. Coyle (Stony Brook, United States)

Demonstration of equivalence between Glatopa? and Copaxone® J. Anderson (Cambridge, United States)

Plasmapheresis as relapse treatment in relapse remitting multiple sclerosis: singlecentre experience

P. Kleinova (Praha, Czech Republic)

MS Italian patients manifesting natalizumab-related PML between 2009 and 2014.Report of the Italian group for MS-PML study

N. De Rossi (Brescia, Italy)

COMPARE: a phase 1 pharmacokinetic study of subcutaneous peginterferon beta-1avs subcutaneous interferon beta-1a over 2 weeks in healthy subjects

B. Werneburg (Cambridge, United States)

Evaluation of the impact of an electronic diary on adherence to long-term interferon-beta-1b therapy

M. Hecker (Rostock, Germany)

Statistical comparison of adverse events for glatiramer acetate 20mg vs 40mg for thetreatment of relapsing-remitting multiple sclerosis

F.J. Zagmutt (Boulder, United States)

Page 96 / 114


Comprehension of confidence intervals in audio-visual patient information materialsfor people with multiple sclerosis (COCO-MS): a web-based randomised controlledtrial

C. Heesen (Hamburg, Germany)

Sustained reduction in disability with alemtuzumab is associated with durable quality-of-life improvement on SF-36 over 4 years in CARE-MS II patients with RRMS thoughmost were treatment-free after year 1

R. Arroyo González (Madrid, Spain)

Switching from initial first-line agents to other disease modifying therapies: anobservational study

E. Le Page (Rennes, France)

Tailored case-based approach is successful in improving the use of disease-modifyingtherapies in multiple sclerosis

T.F. Finnegan (New York, United States)

Alemtuzumab infusion management: the British Columbia experience N. Bogle (Vancouver, Canada)

Belief characteristics towards medication adherence in relapsing-remitting multiplesclerosis

M.B. Glusman (Kansas City, United States)

Patient-provider relationships and autonomy support in multiple sclerosis M.B. Glusman (Kansas City, United States)

Shared decision making and disease modifying treatment history in NARCOMS A.R. Salter (Birmingham, United States)

Rituximab treatment of MS: a single centre retrospective observational study F. Holm (Gothenburg, Sweden)

Mymsmagazin.com - effect of multimedial digital teaching for German speaking MSpatients

A. Raji (Hamburg, Germany)

Multi-center, randomized, double-blinded assessment of Tecfidera® in extending thetime to a first attack in radiologically isolated syndrome (RIS) (ARISE)

D.T. Okuda (Dallas, United States)

Depressive state and chronic fatigue in neuromyelitis optica I. Nakashima (Sendai, Japan)

Effects of prolonged-release fampridine on leg muscle activity during treadmillwalking in individuals with multiple sclerosis (FAMPKIN)

L. Lörincz (Zurich, Switzerland)

Long-term effects of fampridine on walking ability in patients with multiple sclerosis:a double-blind, placebo-controlled, monocenteric phase II study (FAMPKIN-EXT)

C. Meyer (Zurich, Switzerland)

Page 97 / 114


The impact of peripheral nerve field stimulation on treatment of facial painsyndromes including trigeminal neuropathy attributed to multiple sclerosis

J.C. Eisele (Dresden, Germany)

Compound functional improvement after treatment with nabiximol in multiplesclerosis

G. Coghe (Cagliari, Italy)

A final report of an observational post-marketing safety registry of patients primarilyfrom the United Kingdom who have been prescribed an oromucosal spray containingΔ9-tetrahydrocannabinol and cannabidiol (THC:CBD)

T. Etges (Cambridge, United Kingdom)

Using a wrist worn motion sensor to identify and quantify upper limb tremor inpeople with multiple sclerosis

S. Teufl (Glasgow, United Kingdom)

Evaluating the effect of enhanced physical activity and energy management onfatigue in patients suffering from multiple sclerosis: the MS TeleCoach study

G. Van Gassen (Wilrijk, Belgium)

Efficacy of fampridine modified-release on ambulation in neuromyelitis optica: a pilotstudy

K.P. Mutch (Liverpool, United Kingdom)

Multicenter, prospective, observational study aimed at evaluating SAtivex efFEcts(effectiveness and tolerability) in a large population of Italian multiple sclerosispatients: SA.FE. study

F. Patti (Catania, Italy)

THC:CBD oromucosal spray as an add-on therapy in a large population of Italianmultiple sclerosis patients (SA.FE. study)


THC:CBD discontinuation in a large population of Italian multiple sclerosis patients(SA.FE. study)


Effects of fampridine in MS patients with walking disability on gait parameters F.A. Rodriguez-Leal (Dresden, Germany)

Is fatigue associated with impaired walking in patients with multiple sclerosis? U. Dalgas (Aarhus, Denmark)

Effects of internet-based exercise (e-training) on fatigue and other patient reportedbehavioural outcomes (PRO) in patients with relapsing-remitting multiple sclerosis(RRMS)

N. Jäckel (Offenburg, Germany)

Treatment of balance problems with Nintendo Wii-Fit games in multiple sclerosispatients: a pilot study

Y. Zenginler (Istanbul, Turkey)

It's all about personality: its impact on health, coping, psychological well-being andquality of life

L. Strober (West Orange, United States)

Page 98 / 114


An assessment of felt-stigma in multiple sclerosis R.J. Mills (Preston, United Kingdom)

Rasch analysis of the Herth Hope Index in multiple sclerosis R.J. Mills (Preston, United Kingdom)

Neurological Coping Index-MS: a short positive coping scale for multiple sclerosis R.J. Mills (Preston, United Kingdom)

Quality of life improvements in patients with active relapsing-remitting multiplesclerosis are not impacted by acute infections after receiving alemtuzumab in CARE-MS II

P. Vermersch (Lille, France)

Health-related quality of life in individuals with multiple sclerosis and validation of amethod to map MSIS-29 on EQ-5D

O. Ernstsson (Stockholm, Sweden)

Measuring the impact of multiple sclerosis: enhancing the MSIS-29's performance S. Cano (Plymouth, United Kingdom)

Coping strategies used by people with multiple sclerosis D. Holland (Liverpool, United Kingdom)

Treatment satisfaction and side effect experience with fingolimod and dimethylfumarate for multiple sclerosis: findings from an online patient cohort


Worry and self-esteem in multiple sclerosis E. Zitnik (Liverpool, United Kingdom)

Narrative-medicine approach to multiple sclerosis patients, description of a tool tointegrate clinical data and patients experiences and emotions

S. Baldini (Gallarate (VA), Italy)

Quality of life for patients with multiple sclerosis treated with autologoushaematopoietic stem cell transplantation (AHSCT)

M. Smilowski (Katowice, Poland)

Impact of psychological variables on the quality of life of multiple sclerosis patients L. Fàbregas (Salt, Spain)

Insomnia in low to mild disability multiple sclerosis patients is not an independentfactor for low quality of life

M. Mendonça (Lisbon, Portugal)

Visual field impairment as a marker of diffuse damage in multiple sclerosis E.H. Martinez-Lapiscina (Barcelona, Spain)

Molecular imaging of In vivo human retina by Raman spectroscopy: basis and MS andhealthy voluntaries profile

E.H. Martinez-Lapiscina (Barcelona, Spain)

Hyperacute steroid therapy in patients with recurrent optic neuritis E.Y. Osinga (Amsterdam, Netherlands)

Page 99 / 114


What are the differences determined by optic coherence tomography andneuroopthalmological parameters in optic neuritis due to neuromyelitis optica andmultiple sclerosis?

F. Idiman (Izmir, Turkey)

The association between multiple sclerosis and uveitis T.G. Olsen (Glostrup, Denmark)

Neuromyelitis optica spectrum disorder can be distinguished at onset of optic neuritisby combining brain and optic nerve MRI

D.S. Buch (Paris, France)

Role of Aquaporin 4 antibodies in the first optic neuritis: a retrospective study inArgentina

E. Carnero Contentti (Buenos Aires, Argentina)

Chronic relapsing inflammatory optic neuropathy (CRION) clinical characteristics andtreatment response

Y. Rito (Mexico, Mexico)

Increased cerebrospinal fluid immunoglobulin free light chain levels in relation tolesion load and cortical thinning of multiple sclerosis patients

M.M. Voortman (Graz, Austria)

Circulating MicroRNAs as biomarkers in chronic progressive multiple sclerosis J. Vistbakka (Tampere, Finland)

Higher concentrations of mtDNA in CSF of SPMS and PPMS patients C.E. Leurs (Amsterdam, Netherlands)

Extracellular vesicles cargo as a novel biomarker in multiple sclerosis M. Sáenz-Cuesta (San Sebastián, Spain)

Impact of cerebrospinal fluid lipocalin-2 on brain iron accumulation and clinicalprogression in multiple sclerosis

M. Khalil (Graz, Austria)

Circulating miR-150 in cerebrospinal fluid is a novel biomarker for multiple sclerosis M. Jagodic (Stockholm, Sweden)

Exosomal RNA signature in multiple sclerosis patients I. Selmaj (Lodz, Poland)

Evaluation of postulant predictive and prognostic biomarkers in multiple sclerosis:Fetuin-A, S100B and GFAP

A. Altintas (Istanbul, Turkey)

Chitinase 3-like 1 is associated with the response to interferon-beta in multiplesclerosis patients

C. Matute (Barcelona, Spain)

Elevation of serum Sema4A in neuromyelitis optica spectrum disorder (NMOsd) T. Okuno (Suita, Japan)

Page 100 / 114


pharmacokinetics and pharmacodimamics of rituximab in NMOSD and RRSM treatedpatients

A. Sala (Orbassano, Italy)

Using TMA methodology to Investigate differential expression of the complementpathway in MS grey matter lesions

S. Loveless (Cardiff, United Kingdom)

Combined CSF and MRI longitudinal study of grey matter damage in multiple sclerosismay allow prediction and monitoring of disease progression

R. Magliozzi (Rome, Italy)

Retrospective and prospective studies of the CD62L as a predictive marker of PMLrisk in NTZ-treated MS patients

B. Pignolet (Toulouse, France)

Plasmapheresis sessions do not alter sensitivity of standardized cell basedimmunofluorescence assay for anti-AQP4 antibody detection in neuromyelitis opticapatients

R.B. Souza (Botucatu, Brazil)

Markers of long-term disability in RRMS patients treated with interferon beta J. Río (Barcelona, Spain)

Serum NfL levels in early relapsing remitting MS are increased and correlate with CSFand MRI measures

J. Kuhle (Basel, Switzerland)

Cerebral antioxidant glutathione (GSH) in major subtypes of multiple sclerosis:relations with MRI measures and clinical status

I.-Y. Choi (Kansas City, United States)

Differential associations of intrathecally produced immunoglubulin (Ig)G and IgM withradiological findings in early multiple sclerosis

J. Oechtering (Berlin, Germany)

Global metabolomics identifies perturbation of multiple metabolic pathways inmultiple sclerosis patients

P. Bhargava (Baltimore, United States)

Role of the C-terminal fragment of osteopontin in multiple sclerosis C. Comi (Novara, Italy)

Different patterns of gray and white matter microstructural abnormalities areassociated to PASAT and SDMT performances in relapsing remitting multiple sclerosis


Selective cognitive impairment is correlated with regional corpus callosum index in acohort of relapsing remitting multiple sclerosis patients in Chile

M. Vasquez (Santiago, Chile)

Structural connectivity and cognitive performance in multiple sclerosis S. Llufriu (Barcelona, Spain)

Page 101 / 114


Deep gray matter volume and cognitive functions in clinically isolated syndrome J. Laczó (Prague, Czech Republic)

Cerebral atrophy and cognitive reserve in multiple sclerosis: a MRI study G. Fenu (Cagliari, Italy)

Association between memory impairment and hippocampus in patients with clinicallyisolated syndrome

E. Hyncicova (Prague, Czech Republic)

eMotionS: emotional memory impairment and amygdala activation in multiplesclerosis

H.E. Hulst (Amsterdam, Netherlands)

Region-based structural MRI measures offer better specificity in correlation withcognitive performance in patients with secondary progressive multiple sclerosis

P. Adany (Kansas City, United States)

Evolution of cognitive impairment during the first 10 years of RRMS D. Wybrecht (Marseille Cedex, France)

Reduced cerebral blood flow in cognitively impaired relapsing-remitting multiplesclerosis patients

S.-P. Hojjat (Toronto, Canada)

Abnormal structural network in correlation with cognitive impairment inneuromyelitis optica spectrum disorder

E.B. Cho (Seoul, Korea, Republic of)

Disentangling the information processing deficit in multiple sclerosis: insights from aparameter-based approach

M. Fischer (Wermsdorf, Germany)

Cognitive impairment according to detection of cerebellar involvement by oculomotortesting in early multiple sclerosis

A. Moroso (Bordeaux, France)

Correlation between cognitive impairment and behavioral symptoms in relapsingremitting multiple sclerosis patients

M. López-Góngora (Barcelona, Spain)

Altered alpha brain oscillations related with alerting and orienting impairment inrelapsing remitting multiple sclerosis patients

A. Galvao-Carmona (Sevilla, Spain)

Poster Sessions, Poster Exhibition15:30 - 17:00 e-Poster Session 2

Geriatric forms of multiple sclerosis (MS) about an algerian cohort S. Daoudi (Tizi Ouzou, Algeria)

Page 102 / 114


False positivity of anti aquaporin-4 antibodies in patients treated with natalizumab:report of 2 cases

M. Cohen (Nice, France)

Efficacy of recurrence prevention by tacrolimus in patients with Aquaporin-4 antibodypositive neuromyelitis optica

M. Kojima (Kawagoe-shi, Japan)

Characterization of NMO spectrum disorders in an Italian cohort of patients M. Radaelli (Milan, Italy)

Clinical characteristics of disabling onset attacks in patients with neuromyelitisoptica spectrum disorders

J.M. Seok (Seoul, Korea, Republic of)

A conversion of “radiological isolated syndrome”into multiple sclerosis afterhormonal stimulation

C. Blanc (Dijon, France)

Efficacy and safety of tocilizumab for the treatment of refractory neuromyelitis optica G. Dalla Costa (Milan, Italy)

Long-term follow-up of initially benign multiple sclerosis patients: results from theSwedish multiple sclerosis register


Demographic and clinical profile among multiple sclerosis patients in Egypt H.S. Shehata (Cairo, Egypt)

Vitamin D and disability in multiple sclerosis patients N. Niedziela (Zabrze, Poland)

Disease activity in primary progressive multiple sclerosis A. Vural (Ankara, Turkey)

Impact of immunomodulatory treatment on disability progression in relapsingremitting multiple sclerosis

L. Bau (L'Hospitalet de Llobregat, Spain)

Comorbidity and polytherapy in multiple sclerosis E. Costa Arpín (Santiago de Compostela, Spain)

Characteristics of familial multiple sclerosis in New Zealand: a country-widepopulation based study

S. Alla (Christchurch, New Zealand)

Characteristics, causes of admission and short-term mortality of multiple sclerosispatients at the neurological intensive care unit

A. Karamyan (Salzburg, Austria)

Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm basedon Health Information Systems

V. Nociti (Rome, Italy)

Page 103 / 114


Prevalence of cognitive impairment among Hungarian patients with relapsing-remitting multiple sclerosis and clinically isolated syndrome

D. Sandi (Szeged, Hungary)

The impact of cognitive impairment on multiple sclerosis patients' quality of life D. Sandi (Szeged, Hungary)

Prevalence of multiple sclerosis in Iceland - a population based study Ó.J. Elíasdóttir (Reykjavík, Iceland)

Multiple sclerosis in Debrecen between 1998-2014: what have we learnt from adatabase?

L. Racz (Debrecen, Hungary)

Epidural analgesia is not associated with an increased risk of post-partum relapses inwomen with multiple sclerosis activity during pregnancy

C. Lavie (Lyon, France)

Does multiple sclerosis influence women´s fertility? K. Fink (Solna, Sweden)

Effect of relapse phenotype on the accumulation of disability in relapsing-remittingmultiple sclerosis

T. Kalincik (Melbourne, Australia)

Medium and long term efficacy of nabiximols for the treatment of multiple sclerosisrelated spasticity: an Italian monocentric study

L. Ferrè (Milan, Italy)

Longitudinal findings in subjective and objective olfactometry in patients withmultiple sclerosis

F. Schmidt (Berlin, Germany)

The relationship between cognitive impairments and independence levels in activitiesof daily living in patients with multiple sclerosis

E. Tarakci (Istanbul, Turkey)

Demographics and characteristics of multiple sclerosis-related hypothermia M. Toledano (Rochester, United States)

Multiple sclerosis, EDSS, fear of falling: a walking scale with no thought of falling M. Gudesblatt (Patchogue, United States)

RIG could be a therapeutic option to reduce the risk of swallowing problems in MSpatients: preliminary results of a multidisciplinary approach

M. Malentacchi (Orbassano, Italy)

Interdigitating performance outcomes and patient reported outcomes to produce alinear hierarchical unidimensional measure of global physical disability in MS

S. Hum (Montreal, Canada)

Endothelial damage in multiple sclerosis patients compared to a systemicinflammatory disorder as rheumatoid arthritis. A case-control study with an activegroup

V.G. Quintanilla (Santander, Spain)

Page 104 / 114


A Proposal for a risk score for long-term progression of multiple sclerosis C.C.F. Vasconcelos (Rio de Janeiro, Brazil)

Utilizing partners MS Center database for efficient identification of subjects forresearch studies and improved monitoring of patients during routine clinical care

A. Polgar (Boston, United States)

Are we minimizing the patients´ risk for headache? - a lumbar puncture practicequestionnaire study among European neurologists

C. Rajda (Szeged, Hungary)

The disability level and the use of corticosteroids may be related to bone loss inwomen with multiple sclerosis

C.T. Guerreiro (Ribeirão Preto, Brazil)

Netrin-1: a new player in multiple sclerosis pathogenesis? P. Mulero (Valladolid, Spain)

Evaluation of cerebral perfusion with transcranial Doppler and near-infraredspectroscopy in patients with multiple sclerosis

M. D'haeseleer (Brussels, Belgium)

Cyclic phosphatidic acid treatment suppress demyelination and motor dysfunction ina cuprizone-induced multiple sclerosis mouse model

K. Yoshikawa (Iruma, Japan)

Modified mesenchymal stem cells: a novel cellular therapy paradigm for thetreatment of multiple sclerosis

I. Kassis (Jerusalem, Israel)

Human placental mesenchymal stem cells (pMSCs) modulate theimmunopathogenesis process in experimental autoimmune encephalomyelitis (EAE)

M.H. Abumaree (Riyadh, Saudi Arabia)

Concomitant multiple sclerosis and another autoimmune disease: does the clinicalcourse change?

A. Naser Moghadasi (Tehran, Iran, Islamic Republic of)

Adaptive NK-cell response to cytomegalovirus and disability progression in multiplesclerosis

J.E. Martinez Rodriguez (Barcelona, Spain)

Oxysterol-EBI2 interaction and human lymphocytes: an attractive story A. Clottu (Geneva, Switzerland)

Assessment of T-cell lineage-specific transcription factors and cytokines expression inmultiple slcerosis and neuro-behçet disease patients

M. Kchaou (Tunis, Tunisia)

Oligoclonal IgM bands in the cerebrospinal fluid of patients with clinically isolatedsyndrome, multiple sclerosis and neuromyelitis optica

E. İdiman (Izmir, Turkey)

Page 105 / 114


CEACAM1 expression is altered on B-cell subsets of natalizumab-treated RRMSpatients

D.M. Rovituso (Würzburg, Germany)

MOG-antibody seropositivity is not necessarily associated with favourable structuraland functional outcomes in bilateral optic neuritis

S.C. Lukas (Zurich, Switzerland)

Risk factors for multiple sclerosis and associations with anti-EBV antibody titers T.H. Mouhieddine (Beirut, Lebanon)

Smoking exposure and multiple sclerosis in Sardinia L. Lorefice (Cagliari, Italy)

Pregnancy exposures and risk for paediatric onset MS J.S. Graves (San Francisco, United States)

The geographic distribution of pediatric MS in the US A.M. Lavery (Philadelphia, United States)

Does air pollution influence risk of relapse in multiple sclerosis? E. Leray (Rennes, France)

Differential screening-selected gene aberrative in neuroblastoma (DAN) is increasedin the CSF of patients with RR-MS and may be induced by therapy with Interferon-β

A. Karni (Tel Aviv, Israel)

Febuxostat, a xanthine oxidase inhibitor, ameliorates animal model of progressivemultiple sclerosis by improving mitochondrial function

Y. Nakatsuji (Suita, Japan)

Expanded disability status scale is not correlated with gait abnormalities in patientswith primary progressive multiple sclerosis


Primary progressive multiple sclerosis patients use walking pattern adaptationrevealing by instrumented gait analysis: a hierarchical clustering approach


Fampyra also improves manual skills and information processing speed in PPMSpatients


Gadolinium-DTPA enhancing lesions on MRI in patients with acute optic neuritis - acomparison of findings in patients with and without enhancement

J.L. Frederiksen (Copenhagen, Denmark)

Magnetization transfer ratio as an endophenotype in multiple sclerosis K. Hilven (Leuven, Belgium)

Brain and spinal cord MRI findings in primary progressive vs. relapsing-remittingmultiple sclerosis

A. Dastagir (Boston, United States)

Page 106 / 114


Crossectional quantified 3T MRI global and regional brain atrophy in MS patientswithout DMT (natural course) for clinical routine and trials

G. Winkler (Hamburg, Germany)

Changes in brain water content and volume during the first 6 months of multiplesclerosis high dose interferon beta-1a and beta-1b therapy

S.M. Meyers (Vancouver, Canada)

Cortical and deep gray matter involvement in multiple sclerosis; correlation of clinicaland cognitive diasability with DTI magnetic resonance imaging findings

H. Efendi (Kocaeli, Turkey)

Short T1 inversion recovery and T2 weighted sequences comparing and correlationwith clinical findings of multiple sclerosis spinal cord lesions

M. Terzi (Samsun, Turkey)

Connectoms from DTI based probabilistic tractography are associated with walkingand real-life physical activity in PPMS

J.-P. Stellmann (Hamburg, Germany)

Nerve root enhancement differentiates spinal neurosarcoid from NMO P. Deng (New York, United States)

Sensitivity and predictive role of OCT and VEP in multiple sclerosis G. Di Maggio (Milano, Italy)

Correlation of T25FW and RNFL in a prospective large MS cohort C. Fjeldstad (Oklahoma City, United States)

Anxiety and depressive symptoms are associated with worse performance onobjective cognitive tests in MS

S.A. Morrow (London, Canada)

Single center pilot study of the effects of fingolimod (gilenya) on cognitive function inrelapsing multiple sclerosis patients across first 12 months of treatment

P. Repovic (Seattle, United States)

Montreal cognitive assessment (MOCA) as screening tool of cognitive impairment inmultiple sclerosis

J.I. Rojas (Buenos Aires, Argentina)

Vitamin D and cognitive performance A. Aparicio-Mingueza (Pamplona, Spain)

Eosinophilia in patients treated with disease modifying therapies T. Mihalova (Manchester, United Kingdom)

No evidence of disease activity (NEDA): effect of fingolimod in a Galician series L. Ramos Rúa (Vigo, Spain)

Early reduction of CD19+ B-cells following treatment initiation with dimethylfumarate in multiple sclerosis patients

F. Luessi (Mainz, Germany)

Page 107 / 114


Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: the Chietiexperience

M. di Ioia (Chieti, Italy)

Fingolimod in a monocentric cohort of 123 patients with relapsing-remitting multiplesclerosis: impact on relapses and disability

E. Maillart (Paris, France)

GZ402668, a next-generation anti-CD52 antibody, binds to a unique epitope onhuman CD52 and displays decreased cytokine release

W.M. Siders (Framingham, United States)

High-dose intravenous methotrexate (HDMTX) with leucovorin rescue (LR) for thetreatment of acute inflammatory demyelinating central nervous system (CNS)syndromes

S.C. Beh (Dallas, United States)

Does multiple sclerosis treatment influence quality of sleep? E. Mielczarek (Łódź, Poland)

Differential expression of miRNA and mRNA expression in astrocytes followingtreatment with laquinimod

A. Vaknin-Dembinsky (Jerusalem, Israel)

Safety and efficacy of fingolimod in clinical practice: the experience of an academiccenter in the Middle East

M.M. Zeineddine (Beirut, Lebanon)

Multiple sclerosis: implications of higher S100B levels in demyelination and gliareactivity

A. Barateiro (Lisbon, Portugal)

Early clinical efficacy of fingolimod compared with interferon-beta-1a in relapsingmultiple sclerosis

D. Ontaneda (Cleveland, United States)

MK2 is required for Glatiramer acetate mediated C17.2 neuronal cell proliferation L. Mittal (Giessen, Germany)

A randomised, double-blind, placebo-controlled, multicentre trial to evaluate thesafety and efficacy of eculizumab in patients with relapsing neuromyelitis optica: thePREVENT study

D.M. Wingerchuk (Scottsdale, United States)

Intravenous methylprednisolone as add-on therapy to glatiramer acetate fortreatment of relapsing-remitting multiple sclerosis: a multicenter, double-masked,prospective study

B. Piri Çinar (Giresun, Turkey)

EMPIRE: a randomized, placebo-controlled study assessing Efficacy, safety and doseresponse of vatelizumab in Patients with Relapsing-remitting MS


Efficacy of delayed-release dimethyl fumarate in young adults with RRMS: anintegrated analysis of DEFINE and CONFIRM

T. Soman (Cambridge, United States)

Page 108 / 114


Long-term safety of teriflunomide: 2.5-year follow-up in the TOWER extension studyin patients with relapsing MS


Safety profile of dalfampridine extended release in multiple sclerosis: 5-year post-marketing experience in the United States

M. Jara (Ardsley, United States)

Natalizumab for relapsing-remitting multiple sclerosis: interim data from the IrelandTysabri Observational Program (iTOP)

C. Mcguigan (Dublin, Ireland)

1st year of experience with dimethyl fumarate in the largest prescribing centre inEurope

P.J. Gallagher (Glasgow, United Kingdom)

Long-term efficacy, safety, tolerability and quality of life with fingolimod treatment inpatients with multiple sclerosis in real-world settings in France: VIRGILE study design

B. Allaf (Rueil-Malmaison Cedex, Paris, France)

MSDS3D - a platform to guide complex management of MS treatment R. Kern (Dresden, Germany)

Monitoring interferon beta treatment response with magnetic resonancespectroscopy in relapsing remitting multiple sclerosis

M.F. Yetkin (Kayseri, Turkey)

Switching from natalizumab to fingolimod with no washout. Results of a pilotexplorative study

D. Seppi (Padova, Italy)

Patient characteristics and compliance with alemtuzumab infusion schedule andpremedication regimen: EMERALD study

S. Vukusic (Bron, France)

Patient and physician reported injection site reactions and mitigation strategies withinjectable disease modifying therapies

T. Livingston (Weston, United States)

Suspicion of a late immune reconstitution inflammatory syndrome due to a possibleprogressive multifocal leucoencephalopathy, but without formal demonstration of theinfection

A. Melin (Liège, Belgium)

Natalizumab prescribing for multiple sclerosis in Northern Ireland S.E. Hughes (Belfast, United Kingdom)

Safety profile of autologous haematopoietic stem cell transplantation followingnatalizumab therapy in aggressive forms of multiple sclerosis

A. Mariottini (Florence, Italy)

Early experience of 150 multiple sclerosis patients treated with alemtuzumab in asingle provider United States center

C. LaGanke (Cullman, United States)

Page 109 / 114


Effectiveness in the follow-up of the patients managed in alSacEP, the health networkfor multiple sclerosis in Alsace (France)

T. Riquier (Paris, France)

SPRINT-MS/NN 102 phase II trial of ibudilast in progressive MS: baselinecharacteristics


Research trends in therapeutics for progressive forms of multiple sclerosis: a reviewof trials in progress and future prospects

A. Shirani (Dallas, United States)

Real world relapse rates of glatiramer acetate patients switching to fingolimod orinterferon beta-1a versus remaining on glatiramer acetate

V. Herrera (East Hanover, United States)

Experience with fingolimod in clinical practice: clinical and MRI data G. Kosehasanogullari (Usak, Turkey)

Natalizumab modifies the changes in melatonin and oxidative damage stress levelspresents in patients with relapsing-remitting multiple sclerosis

M. Aguilar-Luque (Cordoba, Spain)

History of fracture or sprain: new risk factors of falls in people with multiple sclerosis M.-A. Guyot (Lomme, France)

Success of an educational intervention on optimizing the management of multiplesclerosis

T.F. Finnegan (New York, United States)

Lack of association between pulse steroid therapy and bone mineral density inpatients with multiple sclerosis

C. Boz (Trabzon, Turkey)

E-doctor and MSers, the challenges of distance J. Steinberg (Buenos Aires, Argentina)

Quality of life of multiple sclerosis patients in Argentina M.P. Fiol (Buenos Aires, Argentina)

Burden of disease and it's relationship with subjective life quality and rolefunctioning in adult multiple sclerosis patients

E. Sukockiene (Kaunas, Lithuania)

Mii-vitaliSe - Development of a physiotherapist-supported Nintendo Wii? interventionto encourage people with multiple sclerosis to become more active in the home

S. Thomas (Bournemouth, United Kingdom)

The importance of a self-regulation program to promote physical activity, to reducefatigue and perception of disease severity in people with multiple sclerosis

L. Pedro (Lisbon, Portugal)

The effects of fatigue on balance and quality of life in patients with multiple sclerosis A. Ozdincler (Istanbul, Turkey)

Page 110 / 114


Occurrence of anti natalizumab antibodies in patients with therapeutic inefficacy oradverse reactions during the treatment with natalizumab

B. Oliver-Martos (Málaga, Spain)

Pro-inflammatory biomarkers predictive of poor response to Interferon beta1a inmultiple sclerosis

R. Lanzillo (Naples, Italy)

TLC-MALDI-Imaging approach for lipidomics studies in cerebrospinal fluid reveals lowlevels of sphingomyelin in multiple sclerosis patients

D. Pieragostino (Chieti, Italy)

Increased endothelin-1 serum levels in patients with multiple sclerosis R. Lanzillo (Naples, Italy)

Anti-glycolipid antibodies in multiple sclerosis M. Ivanova (Moscow, Russian Federation)

Hot Topic Sessions, Hall A17:00 - 17:45 Hot Topic 6 Innovative therapeutic strategies

ChairsB. Hemmer (Munich, Germany)B. Trapp (Cleveland, United States)

17:00 - 17:15 Targets to promote remyelination C. Lubetzki (Paris, France)

17:15 - 17:30 Specific immune interventions R. Martin (Zurich, Switzerland)

17:30 - 17:45 Tocilizumab as an invaluable disease-modifying drug in neuromyelitis optica M. Araki (Tokyo, Japan)

Hot Topic Sessions, Hall B17:00 - 17:45 Hot Topic 4 Brain and spinal cord atrophy

ChairsM.S. Freedman (Ottawa, Canada)J.S. Wolinsky (Houston, United States)

17:00 - 17:15 As a primary endpoint in clinical trials D.L. Arnold (Montréal, Canada)

17:15 - 17:30 In monitoring individuals in clinical practice F. Barkhof (Amsterdam, Netherlands)

17:30 - 17:45 Spinal cord gray matter atrophy - a biomarker for MS progression R. Schlaeger (Basel, Switzerland)

Page 111 / 114


Hot Topic Sessions, Hall C17:00 - 17:45 Hot Topic 5 Incidence, prevalence and phenotypes of demyelinating

diseases outside Europe and NA

ChairsD. Miller (London, United Kingdom)X. Montalban (Barcelona, Spain)

17:00 - 17:07 Asia K. Fujihara (Sendai, Japan)

17:07 - 17:14 Middle East B. Yamout (Beirut, Lebanon)

17:14 - 17:21 Iran M.A. Sahraian (Tehran, Iran, Islamic Republic of)

17:21 - 17:28 Latin America E. Cristiano (Buenos Aires, Argentina)

17:28 - 17:35 Australia / NZ B. Taylor (Hobart, Australia)

17:35 - 17:45 Wrap-up A. Siva (Istanbul, Turkey)


F. Hoffmann-La Roche Ltd


18:00 - 18:05 Chair's welcome X. Montalban (Barcelona, Spain)

18:05 - 18:15 The role of B cells in MS T. Vollmer (Aurora, United States)

18:15 - 18:40 Opportunities with CD20+ B cell targeted therapy S.L. Hauser (San Francisco, United States) L. Kappos (Basel, Switzerland)

18:40 - 18:50 Panel discussion: Evolving treatment options and strategies G. Giovannoni (London, United Kingdom)

18:50 - 19:00 Audience Q&A and close J.S. Wolinsky (Houston, United States) X. Montalban (Barcelona, Spain)

Page 112 / 114



Page 113 / 114


Saturday, 10 October 2015

Satellite Symposia, Hall B07:15 - 08:15 Satellite Symposium

Parallel Sessions, Hall B08:30 - 10:00 Parallel Session 13 Late Breaking News

ChairsW. Brück (Göttingen, Germany)J. Río (Barcelona, Spain)

Presentation 1

Presentation 2

Presentation 3

Presentation 4

Presentation 5

Presentation 6

Presentation 7

Plenary Sessions, Hall B10:30 - 12:30 Plenary Session 2 Closing Session ECTRIMS Highlights & Awards


10:30 - 10:50 Charcot Lecture G. Comi (Milan, Italy)

10:50 - 11:10 ECTRIMS Highlights: Clinical research J. Sastre-Garriga (Barcelona, Spain)

11:10 - 11:30 ECTRIMS Highlights: Basic research H. Wiendl (Münster, Germany)

11:30 - 12:25 Presentation of selected poster awards and awards for best oral presentations byyoung researchers as well as the MSIF award

X. Montalban (Barcelona, Spain) O. Ciccarelli (London, United Kingdom)

12:25 - 12:30 Welcome to London

Powered by TCPDF (www.tcpdf.org)

Page 114 / 114

http://www.tcpdf.org

Health & Medicine

Programme ectrims2015